0001493152-22-015363.txt : 20220527 0001493152-22-015363.hdr.sgml : 20220527 20220527162400 ACCESSION NUMBER: 0001493152-22-015363 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ehave, Inc. CENTRAL INDEX KEY: 0001653606 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING SERVICES [7371] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 000-56146 FILM NUMBER: 22977933 BUSINESS ADDRESS: STREET 1: 2020 WINSTON PARK DRIVE STREET 2: SUITE 201 CITY: OAKVILLE STATE: A6 ZIP: L6H 6X7 BUSINESS PHONE: (647) 490-5122 MAIL ADDRESS: STREET 1: 2020 WINSTON PARK DRIVE STREET 2: SUITE 201 CITY: OAKVILLE STATE: A6 ZIP: L6H 6X7 FORMER COMPANY: FORMER CONFORMED NAME: ehave, Inc. DATE OF NAME CHANGE: 20160104 FORMER COMPANY: FORMER CONFORMED NAME: ehāve, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: 2304101 Ontario Inc. DATE OF NAME CHANGE: 20150921 20-F 1 form20-f.htm
0001653606 false FY Unlimited Unlimited 0001653606 2021-01-01 2021-12-31 0001653606 2021-12-31 0001653606 2020-12-31 0001653606 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember 2019-12-31 0001653606 EHVVF:EquityPayableMember 2019-12-31 0001653606 us-gaap:RetainedEarningsMember 2019-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001653606 EHVVF:TotalEquityMember 2019-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2019-12-31 0001653606 2019-12-31 0001653606 us-gaap:CommonStockMember 2020-12-31 0001653606 EHVVF:EquityPayableMember 2020-12-31 0001653606 us-gaap:RetainedEarningsMember 2020-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001653606 EHVVF:TotalEquityMember 2020-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2020-12-31 0001653606 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001653606 EHVVF:EquityPayableMember 2020-01-01 2020-12-31 0001653606 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001653606 EHVVF:TotalEquityMember 2020-01-01 2020-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001653606 EHVVF:EquityPayableMember 2021-01-01 2021-12-31 0001653606 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001653606 EHVVF:TotalEquityMember 2021-01-01 2021-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001653606 us-gaap:CommonStockMember 2021-12-31 0001653606 EHVVF:EquityPayableMember 2021-12-31 0001653606 us-gaap:RetainedEarningsMember 2021-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001653606 EHVVF:TotalEquityMember 2021-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2021-12-31 0001653606 EHVVF:MycotopiaTherapiesIncMember 2021-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalEquipmentMember 2021-01-01 2021-12-31 0001653606 EHVVF:MedicalEquipmentMember 2021-12-31 0001653606 EHVVF:MedicalEquipmentMember 2020-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteThreeMember 2020-12-31 0001653606 EHVVF:RelatedPartyMember 2020-08-03 2020-08-04 0001653606 EHVVF:DirectorsMember 2020-08-03 2020-08-04 0001653606 EHVVF:ExecutiveConsultingAgreementMember EHVVF:BenjaminKaplanMember 2021-01-01 2021-01-02 0001653606 EHVVF:ExecutiveConsultingAgreementMember 2021-01-01 2021-12-31 0001653606 EHVVF:ExecutiveConsultingAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:ExecutiveConsultingAgreementMember EHVVF:BenjaminKaplanMember 2019-06-23 2019-06-24 0001653606 EHVVF:ExecutiveConsultingAgreementMember EHVVF:BenjaminKaplanMember 2020-04-16 0001653606 EHVVF:BenjaminKaplanMember 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember 2020-01-01 2020-12-31 0001653606 EHVVF:ExecutiveConsultingAgreementMember EHVVF:BenjaminKaplanMember srt:MinimumMember 2020-01-01 2020-12-31 0001653606 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001653606 us-gaap:ServiceMember 2020-01-01 2020-01-02 0001653606 EHVVF:ChiefTechonologyOfficerMember 2021-01-01 2021-12-31 0001653606 EHVVF:ChiefTechonologyOfficerMember 2020-01-01 2020-12-31 0001653606 EHVVF:BonusOneMember 2021-12-31 0001653606 EHVVF:MilestonesOneMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusTwoMember 2021-12-31 0001653606 EHVVF:MilestonesTwoMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusThreeMember 2021-12-31 0001653606 EHVVF:MilestonesThreeMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusFourMember 2021-12-31 0001653606 EHVVF:MilestonesFourMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusFiveMember 2021-12-31 0001653606 EHVVF:MilestonesFiveMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesOneMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesTwoMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesThreeMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFourMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFiveMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001653606 EHVVF:MycotopiaCommonStocksMember 2021-12-31 0001653606 2021-12-20 0001653606 EHVVF:PromissoryNoteMember 2021-12-31 0001653606 EHVVF:PromissoryNoteMember 2021-01-01 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2021-01-01 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-01-01 2020-01-02 0001653606 EHVVF:CollaborationAgreementMember us-gaap:CommonStockMember 2020-01-01 2020-01-02 0001653606 EHVVF:CollaborationAgreementMember us-gaap:CommonStockMember 2020-01-02 0001653606 EHVVF:CollaborationAgreementMember 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-12-31 0001653606 EHVVF:CollaborationAgreementMember 2021-11-15 2021-11-16 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2021-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-12-31 0001653606 EHVVF:StrategicAllianceAgreementMember 2020-09-14 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-09-14 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2021-12-31 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-12-31 0001653606 us-gaap:WarrantMember 2020-12-31 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember 2020-12-30 2020-12-31 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember 2021-01-20 2021-01-21 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember us-gaap:CommonStockMember 2021-01-20 2021-01-21 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001653606 EHVVF:FormerAndCurrentDirectorsMember EHVVF:StockPurchaseAgreementMember 2021-01-18 2021-01-19 0001653606 EHVVF:FormerAndCurrentDirectorsMember EHVVF:StockPurchaseAgreementMember 2021-01-19 0001653606 EHVVF:FormerAndCurrentDirectorsMember EHVVF:StockPurchaseAgreementMember us-gaap:CommonStockMember 2021-01-18 2021-01-19 0001653606 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteAndAccruedInterestMember 2021-01-01 2021-12-31 0001653606 EHVVF:FindersFeeAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember srt:MinimumMember 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember srt:MaximumMember 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember srt:MaximumMember 2020-01-01 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember srt:MinimumMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember EHVVF:ConsultantMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember EHVVF:EhaveMember 2021-01-01 2021-12-31 0001653606 us-gaap:CommonStockMember EHVVF:MycotopiaMember 2021-01-01 2021-12-31 0001653606 us-gaap:SubsequentEventMember EHVVF:RejuvIvIncMember EHVVF:PurchaseAgreementMember 2022-01-07 2022-01-08 0001653606 EHVVF:RejuvIvIncMember us-gaap:SubsequentEventMember EHVVF:PurchaseAgreementMember 2022-01-08 0001653606 us-gaap:SubsequentEventMember EHVVF:PurchaseAgreementMember 2022-01-07 2022-01-08 0001653606 us-gaap:SubsequentEventMember 2022-01-01 2022-05-27 0001653606 us-gaap:SubsequentEventMember EHVVF:WesanaHealthHoldingsIncMember 2022-01-01 2022-05-27 0001653606 us-gaap:SubsequentEventMember EHVVF:MycotopiaTherapiesIncMember 2022-05-18 0001653606 us-gaap:SubsequentEventMember EHVVF:MycotopiaTherapiesIncMember 2022-05-17 2022-05-18 0001653606 us-gaap:SubsequentEventMember EHVVF:EiVenturesIncMember 2022-05-17 2022-05-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CAD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 20-F

 

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the fiscal year ended December 31, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the transition period from ___________ to ___________

 

OR

 

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  Date of event requiring this shell company report

 

Commission file number: 333-207107

 

EHAVE, INC

(Exact name of Registrant as specified in its charter)

 

Canada

(Jurisdiction of incorporation or organization)

 

100 SE 2nd St., Suite 2000

Miami, FL 33131

(Address of principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Securities registered pursuant to Section 12(g) of the Act.

 

  Common Shares, no par value  
  (Title of Class)  

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

 

  None  
  (Title of Class)  

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 244,523,925 common shares as December 31, 2021

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒
        Emerging growth company ☒

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP

International Financial Reporting Standards as issued by the

International Accounting Standards Board

 Other
     
☒ ☐ ☐

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

 

Item 17 ☐ Item 18 ☐

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

 

 

 

 

 

EHAVE INC.

 

FORM 20-F

 

TABLE OF CONTENTS

 

Item 1. Identity of Directors, Senior Management and Advisers 4
Item 2. Offer Statistics and Expected Timetable 4
Item 3. Key Information 4
Item 4. Information on the Company 17
Item 4A. Unresolved Staff Comments 27
Item 5. Operating and Financial Review and Prospects 27
Item 6. Directors, Senior Management and Employees 31
Item 7. Major Shareholders and Related Party Transactions 34
Item 8. Financial Information 36
Item 9. The Offer and Listing 36
Item 10. Additional Information 37
Item 11. Quantitative and Qualitative Disclosures About Market Risk 49
Item 12. Description of Securities Other Than Equity Securities 49
Item 13. Defaults, Dividend Arrearages and Delinquencies 49
Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 49
Item 15. Controls and Procedures 50
Item 16. [Reserved] 51
Item 16A. Audit Committee Financial Expert 51
Item 16B. Code of Ethics 51
Item 16C. Principal Accountant Fees and Services 51
Item 16D. Exemptions from the Listing Standards for Audit Committees 52
Item 16E. Purchase of Equity Securities by the Issuer and Affiliated Purchases 52
Item 16F. Change in Registrant’s Certifying Accountants 52
Item 16G. Corporate Governance 52
Item 16H. Mine Safety Disclosure 52
Item 17. Financial Statements 52
Item 18 Financial Statements 52
Item 19. Exhibits 53
Signatures 54
Financial Statements 55

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This annual report contains “forward-looking statements”. Forward-looking statements reflect the current view about future events. When used in this annual report, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this annual report relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to develop and commercialize new and improved products and services; our ability to raise capital to fund continuing operations; a continued decline in general economic conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products and services; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; changes in government regulation; our ability to complete customer transactions and capital raising transactions; and other factors (including the risks contained in the section of this annual report entitled “Risk Factors”) relating to our industry, our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

The forward-looking statements in this annual report are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control, including without limitation:

 

● Our limited operating history makes evaluating our business and future prospects difficult and may increase the risk of your investment.
● We have a history of operating losses and expect to continue incurring losses for the foreseeable future.
● If we are unable to obtain additional funding, our business operations will be harmed.
● Our independent auditors have expressed their concern as to our ability to continue as a going concern.
● Our inability to regain or maintain the eligibility to have our common shares quoted on OTC Markets, which may have an unfavorable impact on our stock price and liquidity.
● Our products may not be successful in gaining market acceptance, which would negatively impact our revenues.
● If we are unable to keep up with rapid technological changes in our field, we will be unable to operate profitably.
● Many of our potential competitors are better established and have significantly greater resources which may make it difficult for us to compete in the markets in which we intend to sell our products.
● If we lose any of our key management personnel or consultants, we may not be able to successfully manage our business or achieve our objectives.
● Developments or assertions by us or against us relating to intellectual property rights could materially impact our business.
● Our products could infringe on the intellectual property rights of others which may result in costly litigation and, if we do not prevail, could also cause us to pay substantial damages and prohibit us from selling or licensing our products.
● We have identified material weaknesses in our internal control over financial reporting, and if we are unable to achieve and maintain effective internal control over financial reporting or effective disclosure controls, we may be at risk to accurately report financial results or detect fraud, which could have a material adverse effect on our business.
● The market for our products is immature and volatile and if it does not develop, or if it develops more slowly than we expect, the growth of our business will be harmed.
● If our security measures are breached and unauthorized access to a customer’s data are obtained, our products may be perceived as insecure, we may incur significant liabilities, our reputation may be harmed, and we could lose sales and customers.
● If we fail to comply with applicable health information privacy and security laws and other state and federal privacy and security laws, we may be subject to significant liabilities, reputational harm and other negative consequences, including decreasing the willingness of current and potential customers to work with us.
● Our proprietary software may not operate properly, which could damage our reputation, give rise to claims against us or divert application of our resources from other purposes, any of which could harm our business and operating results.
● We depend on data centers operated by third parties for our products, and any disruption in the operation of these facilities could adversely affect our business.
● If currency exchange rates fluctuate substantially in the future, the results of our operations, which are reported in U.S. dollars, could be adversely affected.
● We may not be in compliance with rules and regulations of the U.S. Food and Drug Administration (the “FDA”) should they become applicable to any products we develop in the future.
● The results of any future clinical trials that we may need to perform in the future may not support our medical device candidate requirements or intended use claims or may result in the discovery of unanticipated inconsistent data.

 

3

 

 

PART I

 

ITEM 1 - Identity of Directors, Senior Management and Advisers

 

All items in this section are not required, as this 20-F filing is made as an annual report.

 

ITEM 2 - Offer Statistics and Expected Timetable

 

All items in this section are not required, as this 20-F filing is made as an annual report.

 

ITEM 3. KEY INFORMATION

 

  A. Selected Financial Data

 

The selected financial data presented below for the three years ended December 31, 2021, is presented in U.S. dollars and is derived from our financial statements prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”). We have derived the selected financial data as of December 31, 2021, 2020, and 2019, and for the years ended December 31, 2021, 2020, and 2019, from our audited financial statements included elsewhere in this Annual Report on Form 20-F. The information set forth below should be read in conjunction with our financial statements (including notes thereto) included under Item 18 and “Operating and Financial Review and Prospects” included under Item 5 and other information provided elsewhere in this annual report on Form 20-F and our financial statements and related notes. The selected financial data in this section is not intended to replace the financial statements and is qualified in its entirety thereby.

 

   2021   2020   2019 
   $   $   $ 
Revenues from continuing operations   —    —    — 
Net loss   (8,693,748)   (3,514,736)   (3,637,368)
Net comprehensive loss   (8,706,935)   (3,528,589)   (3,794,909)
Basic and diluted loss per share (1)   (0.05)   (.111)   (.18)
Total assets   2,509,176    1,955,607    496,737 
Shareholders’ deficit   (522,912)   (2,273,372)   (2,230,775)
Cash dividends declared per share (2)   —    —    — 
Weighted average number of common shares outstanding   140,342,653    32,622,248    21,454,189 

 

Notes:

 

(1) On May 29, 2019 the Company effected a 100 for 1 reverse split. All share amounts have been adjusted for the split. In 2021 we issued 177,353,963, in 2020 we issued 40,980,848 shares of common stock and 2019 we issued 25,413,839 shares of common stock (2,541,383,900 pre-split shares) pursuant to certain transactions set forth in Item 4, below.

 

(2) We have not declared or paid any dividends since incorporation.

 

Exchange Rate Data

 

The following table sets forth the exchange rates for Canadian dollars expressed in U.S. dollars that have been used in the audited financial statements included elsewhere in this Annual Report on Form 20-F.

 

$1 Canadian dollar equivalent in U.S. dollars    
At December 31, 2020   0.7800 
At December 31, 2021   0.7911 
Average for the year ended December 31, 2020   0.7974 

 

4

 

 

  B. Capitalization and Indebtedness

 

Not required as this 20-F filing is made as an annual report.

 

  C. Reasons for the Offer and Use of Proceeds

 

Not required as this 20-F filing is made as an annual report.

 

  D. Risk Factors

 

Investment in our common shares involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this Annual Report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the Securities and Exchange Commission (“SEC”) actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flow.

 

RISKS RELATED TO OUR BUSINESS AND INDUSTRY

 

Our limited operating history makes evaluating our business and future prospects difficult and may increase the risk of your investment.

 

We have a very limited operating history on which investors can base an evaluation of our business, operating results and prospects. We have no operating history with respect to commercializing our software applications and products. Consequently, it is difficult to predict our future revenues, if any, and appropriately budget for our expenses, and we have limited insight into trends that may emerge and affect our business.

 

We began processes to develop relationships with potential customers and distribution partners in November 2016. Completion of our cognitive assessment and remediation tools and the further development and commercialization of our products is dependent upon the availability of sufficient funds. This limits our ability to accurately forecast the cost of the development of our products. If the markets and applications of our products do not develop as we expect or develop more slowly than we expect, our business, prospects, financial condition and operating results will be harmed.

 

We have a history of operating losses and expect to continue incurring losses for the foreseeable future.

 

We were incorporated in 2011. We reported a net loss of $8,693,748 for the fiscal year ended December 31, 2021 and had a net loss of $3,514,736 during the fiscal year ended December 31, 2020. As of December 31, 2021, we had an accumulated deficit of $26,316,815. We cannot anticipate when, if ever, our operations will become profitable. We expect to incur significant net losses as we develop and commercialize our products and pursue our business strategy. We intend to invest significantly in our business before we expect cash flow from operations to be adequate to cover our operating expenses. If we are unable to execute our business strategy and grow our business, for any reason, our business, prospects, financial condition and results of operations will be adversely affected.

 

As reflected in the financial statements for the years ended December 31, 2021, and December 31, 2020, included elsewhere in this Annual Report on Form 20-F, we had no revenues from continuing operations in 2021 and 2020 and need additional cash resources to maintain its operations. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital. We cannot predict when, if ever, we will be successful in raising additional capital and, accordingly, we may be required to cease operations at any time, if we do not have sufficient working capital to pay our operating costs.

 

5

 

 

If we are unable to obtain additional funding, our business operations will be harmed.

 

We raised an aggregate of $3,014,000 through loans and issuance of convertible debentures and warrants and pursuant to our Regulation A Offering in 2021. We raised an aggregate of $2,238,170 through issuance of convertible debentures and warrants in 2020. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years due to development costs associated with Ehave Dashboard products and the rollout of Ketadash. As a result of these expected losses and negative cash flows from operations, along with our current cash position, based on our current projections, we may not have sufficient resources to fund operations through the fourth quarter of 2022. To the extent that we are required to raise additional funds to conduct research and acquire facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no assurances that we will be successful in obtaining the level of financing needed for our operations, and we may be unable to secure such funding when needed in adequate amounts or on acceptable terms, if at all. Any additional equity financing may involve substantial dilution to our then existing shareholders.

 

Our independent auditors have expressed their concern as to our ability to continue as a going concern.

 

We reported an accumulated deficit of $26,316,815 and had a stockholders’ deficit of $3,600,483 at December 31, 2021. As a result of our financial condition, we have received a report from our independent registered public accounting firm for our financial statements for the years ended December 31, 2021 and 2020 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern without the infusion of significant additional capital. There can be no assurance that management will be successful in implementing its plans. If we are unable to raise additional financing, we may cease operations.

 

Our products may not be successful in gaining market acceptance, which would negatively impact our revenues.

 

Currently, our business strategy is to continue to support the clinical trials of our therapeutic video games, develop the Ehave Dashboard, and gain access to additional technologies at a time and in a manner that we believe is best for our development. We may have difficulties in reaching market acceptance, which could negatively impact our revenues, for a number of reasons including:

 

  ● any delays in securing partnerships and strategic alliances;
  ● any technical delays and malfunctions;
  ● failure to receive regulatory approval on a timely basis or at all; and
  ● failure to receive a sufficient level of reimbursement from government, insurers or other third-party payors.

 

If we are unable to keep up with rapid technological changes in our field, we will be unable to operate profitably.

 

Our industry is characterized by extensive research efforts and rapid technological progress. If we fail to anticipate or respond adequately to technological developments, our ability to operate profitably could suffer. We cannot assure you that research and discoveries by other companies will not render our software or potential products uneconomical or result in products superior to those we develop or that any products or services we develop will be preferred to any existing or newly-developed products.

 

Many of our potential competitors are better established and have significantly greater resources which may make it difficult for us to compete in the markets in which we intend to sell our products.

 

The market for the products we develop is highly competitive. Many of our potential competitors are well established with larger and better resources, longer relationships with customers and suppliers, greater name recognition and greater financial, technical and marketing resources than we have. Increased competition may result in price reductions, reduced gross margins, loss of market share and loss of licensees, any of which could materially and adversely affect our business, operating results and financial condition. We cannot ensure that prospective competitors will not adopt technologies or business plans similar to ours or develop products which may be superior to ours or which may prove to be more popular. It is possible that new competitors will emerge and rapidly acquire market share. We cannot ensure that we will be able to compete successfully against future competitors or that the competitive pressures will not materially and adversely affect our business, operating results and financial condition.

 

6

 

 

If we lose any of our key management personnel or consultants, we may not be able to successfully manage our business or achieve our objectives.

 

Our future success depends in large part upon the leadership and performance of our management and consultants. The Company’s operations and business strategy are dependent upon the knowledge and business contacts of our executive officers and our consultants. Although, we hope to retain the services of our officers and consultants, if any of our officer or consultants should choose to leave us for any reason before we have hired additional personnel, our operations may suffer. If we should lose their services before we are able to engage and retain qualified employees and consultants to execute our business plan, we may not be able to continue to develop our business as quickly or efficiently.

 

In addition, we must be able to attract, train, motivate and retain highly skilled and experienced technical employees in order to successfully develop our business. Qualified technical employees often are in great demand and may be unavailable in the time frame required to satisfy our business requirements. We may not be able to attract and retain sufficient numbers of highly skilled technical employees in the future. The loss of technical personnel or our inability to hire or retain sufficient technical personnel at competitive rates of compensation could impair our ability to successfully grow our business. If we lose the services of any of our personnel, we may not be able to replace them with similarly qualified personnel, which could harm our business.

 

Developments or assertions by us or against us relating to intellectual property rights could materially impact our business.

 

Pursuant to an amendment to the collaboration agreement, effective January 1, 2014, with Toronto’s Hospital for Sick Children (the “Hospital”), all intellectual property rights to the cognitive assessment and rehabilitation software jointly developed with the Hospital belong to the Hospital. Our agreement with Multi-Health Systems Inc. (“MHS”), as amended, provides that all right, title and interest in and to certain tests and other materials published by MHS relating to the tests are and will remain solely and exclusively vested in MHS.

 

We will attempt to protect proprietary and intellectual property rights to our products through licensing and distribution arrangements although we currently do not have any patents or applications for our products.

 

Litigation may also be necessary in the future to enforce our intellectual property rights or to determine the validity and scope of the proprietary rights of others or to defend against claims of invalidity. Such litigation could result in substantial costs and the diversion of resources.

 

As we create or adopt new software, we will also face an inherent risk of exposure to the claims of others that we have allegedly violated their intellectual property rights.

 

Our products could infringe on the intellectual property rights of others which may result in costly litigation and, if we do not prevail, could also cause us to pay substantial damages and prohibit us from selling or licensing our products.

 

Third parties may assert infringement or other intellectual property claims against us. We may have to pay substantial damages, including damages for past infringement if it is ultimately determined that our products or technology infringe a third party’s proprietary rights. Further, we may be prohibited from selling or providing products before we obtain additional licenses, which, if available at all, may require us to pay substantial royalties or licensing fees. Even if claims are determined to be without merit, defending a lawsuit takes significant time, may be expensive and may divert management’s attention from our other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our business to be harmed and our stock price to decline.

 

7

 

 

We have identified material weaknesses in our internal control over financial reporting, and if we are unable to achieve and maintain effective internal control over financial reporting or effective disclosure controls, we may be at risk to accurately report financial results or detect fraud, which could have a material adverse effect on our business.

 

As directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring an annual assessment by management of the effectiveness of a public company’s internal controls over financial reporting and an attestation report by the company’s independent auditors addressing this assessment, if applicable. As discussed in Item 15 “Controls and Procedures” based on a review of our internal controls over financial reporting, management concluded that our internal controls over financial reporting was not effective due to the existence of a material weakness relating to a lack of sufficient accounting records and underlying supporting detail as of December 31, 2021. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. Management has since addressed this weakness and has implemented the necessary changes to have effective controls over financial reporting. For additional information, see Item 15 “Controls and Procedures.”

 

We cannot assure you that we will be able to remediate our existing material weaknesses in a timely manner, if at all, or that in the future additional material weaknesses will not exist, reoccur or otherwise be discovered, a risk that is significantly increased in light of the complexity of our business. If our efforts to remediate these material weaknesses, as described in Item 15 “Controls and Procedures”, are not successful or if other deficiencies occur, our ability to accurately and timely report our financial position, results of operations, cash flows or key operating metrics could be impaired, which could result in late filings of our annual or interim reports under the Exchange Act, restatements of our consolidated financial statements or other corrective disclosures. Our failure to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm our business and negatively impact the trading price of the common shares. In addition, future changes in our accounting, financial reporting, and regulatory environment may create new areas of risk exposure. Failure to modify our existing control environment accordingly may impair our controls over financial reporting and cause our investors to lose confidence in the reliability of our financial reporting, which may adversely affect our share price, suspension of trading or delisting of our common shares by Pink Open Market, or, if we regain the eligibility to have our common shares quoted on the OTCQB Venture Market, the OTCQB Venture Market, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity. Furthermore, if we continue to have these existing material weaknesses, other material weaknesses or significant deficiencies in the future, it could create a perception that our financial results do not fairly state our financial condition or results of operations. Any of the foregoing could have an adverse effect on the value of our shares.

 

The market for our products is immature and volatile and if it does not develop, or if it develops more slowly than we expect, the growth of our business will be harmed.

 

The market for software-based systems for mental health or treatments using psychedelics is a new and unproven market, and it is uncertain whether it will achieve and sustain demand and market adoption. Our success will depend to a substantial extent on the willingness of customers and healthcare professionals to use our systems, as well as on our ability to demonstrate the value of our software and products to customers and to develop new applications that provide value to customers and users. If customers and users do not perceive the benefits of our products, then our market may not develop at all, or it may develop more slowly than we expect, either of which could significantly adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.

 

If our security measures are breached and unauthorized access to a customer’s data are obtained, our products may be perceived as insecure, we may incur significant liabilities, our reputation may be harmed, and we could lose sales and customers.

 

Our products involve the storage and transmission of customers’ proprietary information, as well as protected health information, or PHI, which, in the United States, is regulated under the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, collectively “HIPAA,” and other state and federal privacy and security laws. Because of the extreme sensitivity of this information, the security features of our product are very important. If our security measures, some of which will be managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive data, including HIPAA-regulated protected health information. A security breach or failure could result from a variety of circumstances and events, including but not limited to third-party action, employee negligence or error, malfeasance, computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors, and catastrophic events.

 

8

 

 

If our security measures were to be breached or fail, our reputation could be severely damaged, adversely affecting customer or investor confidence, customers may curtail their use of or stop using our products and our business may suffer. In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violations of HIPAA and other state and federal privacy and security regulations, significant costs for investigation, remediation and disclosure and for measures to prevent future occurrences. In addition, any potential security breach could result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been caused by such breaches, incentives offered to customers or other business partners in an effort to maintain the business relationships after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.

 

We plan to outsource important aspects of the storage and transmission of customer information, and thus rely on third parties to manage functions that have material cyber-security risks. These outsourced functions include services such as software design and product development, software engineering, database consulting, data-center security, IT, network security, data storage and Web application firewall services. We cannot assure you that any measures that are taken will adequately protect us from the risks associated with the storage and transmission of customers’ proprietary information and protected health information.

 

We may experience cyber-security and other breach incidents that may remain undetected for an extended period. Because techniques used to obtain unauthorized access or to sabotage systems change frequently and generally are not recognized until launched against us, we may be unable to anticipate these techniques or to implement adequate preventive measures. In addition, in the event that our customers authorize or enable third parties to access their data or the data of their employees on our systems, we cannot ensure the complete integrity or security of such data in our systems as we would not control access. If an actual or perceived breach of our security occurs, or if we are unable to effectively resolve such breaches in a timely manner, the market perception of the effectiveness of our security measures could be harmed, we could be subject to regulatory action or other damages and we could lose sales and customers.

 

If we fail to comply with applicable health information privacy and security laws and other state and federal privacy and security laws, we may be subject to significant liabilities, reputational harm and other negative consequences, including decreasing the willingness of current and potential customers to work with us.

 

Once our products are deployed in the United States, we will be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA established uniform federal standards for certain “covered entities,” which include health care providers, health plans, and health care clearing houses, governing the conduct of specified electronic health care transactions and protecting the security and privacy of protected health information, or PHI. The Health Information Technology for Economic and Clinical Health Act, or HITECH, which was signed into law on February 17, 2009, makes certain of HIPAA’s privacy and security standards directly applicable to “business associates,” which are individuals or entities that create, receive, maintain, or transmit PHI in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA’s requirements and seek attorney’s fees and costs associated with pursuing federal civil actions.

 

In addition, states have enacted privacy and security laws and regulations that regulate the use and disclosure of certain data, with some state laws covering medical and healthcare information. These laws vary by state and could impose additional requirements and penalties on us. For example, some states impose restrictions on the use and disclosure of health information pertaining to mental health or substance abuse. Further, state laws and regulations may require us to notify affected individuals in the event of a data breach involving individually identifiable information, which may be broader than the type of information covered by HIPAA. In addition, the Federal Trade Commission may use its consumer protection authority to initiate enforcement actions in data privacy and security matters.

 

9

 

 

If we are unable to protect the privacy and security of our customers’ data, we could be found to have breached our contracts with our customers, we could face civil and criminal penalties under federal and state laws, we could be subject to litigation and we could suffer reputational harm or other damages. We may not be able to adequately address the business, technical and operational risks created by HIPAA and other privacy and security regulations. Furthermore, we are unable to predict what changes to HIPAA or other laws or regulations might be made in the future or how those changes could affect our business or the costs of compliance.

 

Our proprietary software may not operate properly, which could damage our reputation, give rise to claims against us or divert application of our resources from other purposes, any of which could harm our business and operating results.

 

Proprietary software development is time-consuming, expensive and complex, and may involve unforeseen difficulties. We may encounter technical obstacles, and it is possible that we discover additional problems that prevent our proprietary applications from operating properly. We are currently implementing software with respect to a number of new applications and services. If our software does not function reliably or fails to achieve client expectations in terms of performance, clients could assert liability claims against us or attempt to cancel their contracts with us. This could damage our reputation and impair our ability to attract or maintain clients.

 

Moreover, data services are complex as those we offer have in the past contained, and may in the future develop or contain, undetected defects or errors. Material performance problems, defects or errors in our existing or new software and applications and services may arise in the future and may result from interface of our offering with systems and data that we did not develop and the function of which is outside of our control or undetected in our testing. These defects and errors and any failure by us to identify and address them could result in loss of revenue or market share, diversion of development resources, injury to our reputation and increased service and maintenance costs. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating results.

 

We depend on data centers operated by third parties for our products, and any disruption in the operation of these facilities could adversely affect our business.

 

We provide our products through a third-party data center. While we control and have access to our servers and all of the components of our network that are located in our external data centers, we do not control the operation of these facilities. The owners of our data centers have no obligation to renew agreements with us on commercially reasonable terms, or at all. If we are unable to renew any such agreements we may enter into on commercially reasonable terms, or if our data center operator is acquired, we may be required to transfer our servers and other infrastructure to new data center facilities, and we may incur significant costs and possible service interruption in connection with doing so.

 

Problems faced by our third-party data center locations could adversely affect the experience of our customers. The operators of the data centers could decide to close their facilities without adequate notice. In addition, any financial difficulties, such as bankruptcy, faced by the operators of the data centers or any of the service providers with whom we or they contract may have negative effects on our business, the nature and extent of which are difficult to predict. Additionally, if our data centers are unable to keep up with our growing needs for capacity, this could have an adverse effect on our business. For example, a rapid expansion of our business could affect the service levels at our data centers or cause such data centers and systems to fail. Any changes in third-party service levels at our data centers or any disruptions or other performance problems with our products could adversely affect our reputation or result in lengthy interruptions in our services. Interruptions in our services might reduce our revenue, cause us to issue refunds to customers for prepaid and unused subscriptions, subject us to potential liability or adversely affect our renewal rates.

 

If currency exchange rates fluctuate substantially in the future, the results of our operations, which are reported in U.S. dollars, could be adversely affected.

 

As our trials are primarily based in Canada and we seek to operate our business on a global scale, we are exposed to the effects of fluctuations in currency exchange rates. We incur certain operating expenses in Canadian dollars. Fluctuations in the exchange rates between the U.S. dollar and the Canadian dollar could result in the dollar equivalent of such expenses being higher. This could have a negative impact on our reported results of operations. Although we may in the future decide to undertake foreign exchange hedging transactions to cover a portion of our foreign currency exchange exposure, we currently do not hedge our exposure to foreign currency exchange risks.

 

10

 

 

Our future U.S. operations and relationships with healthcare providers, investors, consultants, third-party payors, patients, and other customers may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which in the event of a violation could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

 

Our future U.S. operations and arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other federal and state healthcare laws and regulations. These laws may constrain the business and/or financial arrangements and relationships through which we market, sell and distribute our products. Potentially applicable U.S. laws include:

 

● the federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable by Medicare, Medicaid or any other federal healthcare program;
   
● federal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government healthcare programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
   
● HIPAA, which imposes federal criminal and civil liability for executing, or attempting to execute, a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;
   
● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and
   
● analogous state laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply to referrals and items or services reimbursed by any third-party payers, including commercial insurers, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.

 

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Our risk of being found in violation of these laws is increased by the fact that some of these laws are open to a variety of interpretations. If our past or present operations, practices, or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our customers may be unwilling to use our products and our business may be impaired.

 

11

 

 

We may not be in compliance with rules and regulations of the U.S. Food and Drug Administration (the “FDA”) should they become applicable to any products we develop in the future.

 

We have no current plans to market, advertise or sell computerized cognitive assessment aids in the United States. Types of computerized cognitive assessment aids for the measurement and assessment of behavioral and cognitive abilities such as brain games are games purporting to increase intelligence or cognitive function are currently regulated by the FDA as Class II medical devices. Such brain games may be subject to clinical processes to determine their accuracy or validity. Terminology such as “neuroplasticity”, “attention” and “working memory” have become ubiquitous as the “brain game” market has grown. Current clinical practice refers to the use of cognitive software for the measurement of deficits as an “assessment”, and the use of software tools as rehabilitation methods as “remediation”. Should we decide in the future to market, advertise, or sell products that may be considered by the FDA as computerized cognitive assessment aids, we may be required to undergo costly and time-consuming clinical trials to prove the accuracy and validity of our computerized cognitive assessment aids, should we have any such products to market, sell or advertise in the future.

 

The results of any future clinical trials that we may need to perform in the future may not support our medical device candidate requirements or intended use claims or may result in the discovery of unanticipated inconsistent data.

 

We have no current plans to market, advertise or sell computerized cognitive assessment aids in the United States. The clinical trial process may fail to demonstrate that our computerized cognitive assessment aids that we may develop in the future, are safe, effective, and consistent for the desired or proposed indicated uses, which could cause us to abandon a product and may delay development of others. Any requirement to perform unanticipated clinical trials or delay or termination of any such unanticipated future clinical trials may delay or inhibit our ability to commercialize any computerized cognitive assessment aids that we may develop in the future; and affect our ability to generate revenues.

 

A security breach or disruption or failure in a computer or communications systems could adversely affect us.

 

Our operations depend on the continued and secure functioning of our computer and communications systems and the protection of electronic information (including sensitive personal information as well as proprietary or confidential information) stored in computer databases maintained by us or by third parties. Such systems and databases are subject to breach, damage, disruption or failure from, among other things, cyber-attacks and other unauthorized intrusions, power losses, telecommunications failures, fires and other natural disasters, armed conflicts or terrorist attacks. We may be subject to threats to our computer and communications systems and databases of unauthorized access, computer hackers, computer viruses, malicious code, cyber-crime, cyber-attacks and other security problems and system disruptions. Unauthorized persons may attempt to hack into our systems to obtain personal data relating to clinical trial participants or employees or our confidential or proprietary information or of third parties or information relating to our business and financial data. If, despite our efforts to secure our systems and databases, events of this nature occur, we could expose clinical trial participants or employees to financial or medical identity theft, lose clinical trial participants or employees or have difficulty attracting new clinical trial participants or employees, be exposed to the loss or misuse of confidential information or business and financial data, have disputes with clinical trial participants or employees, suffer regulatory sanctions or penalties under applicable laws, incur expenses as a result of a data privacy breach, or suffer other adverse consequences including legal action and damage to our reputation.

 

RISKS ASSOCIATED WITH OUR COMMON SHARES AND COMPANY

 

We expect that our stock price will fluctuate significantly.

 

The trading price of our common shares may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

 

  ● announcement of new products by our competitors;
     
  ● release of new products by our competitors;
     
  ● adverse regulatory decisions;
     
  ● developments in our industry or target markets; and
     
  ● general market conditions including factors unrelated to our operating performance.

 

12

 

 

Recently, the stock market in general has experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme market volatility in the price of our common shares which could cause a decline in the value of our shares.

 

Market prices for securities of software development companies generally are volatile and the share price for our common shares has been historically volatile. This increases the risk of securities litigation. Factors such as announcements of technological innovations, new commercial products, patents, the development of proprietary rights, results of clinical trials, regulatory actions, publications, financial results, our financial position, future sales of shares by us or our current shareholders and other factors could have a significant effect on the market price and volatility of the common shares.

 

We are unable to predict the impact of COVID-19 on our company.

 

Our diagnostic and treatment tools, MegaTeam and Ninja Reflex, are currently used in hospitals and other medical settings. Because of strain on hospitals and their resources by treatment of patients with COVID-19, hospitals and other facilities are canceling or postponing non-emergency treatments which may include the use of our tools for the treatment of ADHD and related illnesses. Additionally, people are generally avoiding medical facilities except in emergency situations and therefore would not be seeking to utilize our tools in such a setting. While we do not expect this trend to continue indefinitely, its duration and impact cannot be quantified at this time and may negatively impact our business as it is related to MegaTeam and Ninja Reflex.

 

If our business is unsuccessful, our shareholders may lose their entire investment.

 

Although shareholders will not be bound by or be personally liable for our expenses, liabilities or obligations beyond their total original capital contributions, should we suffer a deficiency in funds with which to meet our obligations, the shareholders as a whole may lose their entire investment in our Company.

 

Trading of our common shares on the Pink Open Market is limited and sporadic, making it difficult or impossible for our shareholders to sell their shares or liquidate their investments.

 

There is a very limited market for our common shares. On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market. Prior to the listing of our common shares for trading on the OTCQB Venture Market in November 2016, there was no public market for our common shares. The Pink Open Market is a significantly more limited market than the OTCQB Venture Market and established exchanges such as the New York Stock Exchange or NASDAQ. There is no assurance that a sufficient market will develop in our shares, and the lack of an active market will impair your ability to sell your common shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair value of our common shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. Even after trading volume increases, trading through the Pink Open Market or the OTCQB Venture Market, if our shares regain eligibility to be quoted on the OTCQB Venture Market, is frequently thin and highly volatile.

 

13

 

 

Our common shares are subject to the “penny stock” rules of the SEC and we have no established market for our securities, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

 

The SEC has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (i) that a broker or dealer approve a person’s account for transactions in penny stocks; and (ii) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (i) obtain financial information and investment experience objectives of the person; and (ii) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (i) sets forth the basis on which the broker or dealer made the suitability determination; and (ii) that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common shares and cause a decline in the market value of our stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

We are a “foreign private issuer”, and you may not have access to the information you could obtain about us if we were not a “foreign private issuer”.

 

We are considered a “foreign private issuer” under the Securities Act of 1933, as amended. As a foreign private issuer we will not have to file quarterly reports with the SEC nor will our directors, officers and 10% stockholders be subject to Section 16(b) of the Exchange Act. Such exemption may result in shareholders having less data and there being fewer restrictions on insiders’ activities in our securities. As a foreign private issuer, we will not be subject to the proxy rules of Section 14 of the Exchange Act. Furthermore, Regulation FD does not apply to non-U.S. companies and will not apply to us. Accordingly, you may not be able to obtain information about us as you could obtain if we were not a “foreign private issuer”.

 

14

 

 

Because the majority of our assets and of our officers and directors are located outside the United States, it may be difficult for an investor to enforce within the United States any judgments obtained against us or any of our officers and directors.

 

A majority of our assets are presently located outside of the United States. In addition, some of our directors and officers are nationals and/or residents of countries other than the United States, and all or a substantial portion of such persons’ assets are located outside the United States. As a result, it may be difficult for an investor to effect service of process or enforce within the United States any judgments obtained against us or our officers or directors, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. In addition, there is uncertainty as to whether the courts of Canada would recognize or enforce judgments of United States courts obtained against us or our directors and officers predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. There is even uncertainty as to whether the Canadian courts would have jurisdiction to hear original actions brought in Canada against us or our directors and officers predicated upon the securities laws of the United States or any state thereof.

 

Because we do not intend to pay any cash dividends on our common shares, our shareholders will not be able to receive a return on their shares unless they sell them.

 

We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our common shares in the foreseeable future. Unless we pay dividends, our shareholders will not be able to receive a return on their shares unless they sell them at a price higher than that which they initially paid for such shares.

 

Because we are not subject to compliance with rules requiring the adoption of certain corporate governance measures, our shareholders have limited protections against interested director transactions, conflicts of interest and similar matters.

 

The Sarbanes-Oxley Act of 2002, as well as rule changes proposed and enacted by the SEC, the New York Stock Exchange, the NYSE American and NASDAQ, as a result of Sarbanes-Oxley Act of 2002, require the implementation of various measures relating to corporate governance. These measures are designed to enhance the integrity of corporate management and the securities markets and apply to securities which are listed on those exchanges. Because we will not be seeking to be listed on any of the exchanges, we will not be presently required to comply with many of the corporate governance provisions.

 

Our authorized capital consists of an unlimited number of shares of one class designated as common shares. We may, in the future, issue additional common shares, which would reduce investors’ percent of ownership and may dilute our share value.

 

Our Articles of Incorporation authorizes the issuance of an unlimited number of our common shares, no par value, of which 276,775,899  shares are currently issued and outstanding. The future issuance of common shares may result in substantial dilution in the percentage of our common shares held by our then existing shareholders. We may value any common shares issued in the future on an arbitrary basis. The issuance of common shares for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors and may have an adverse effect on any trading market of our common shares.

 

15

 

 

Offers or availability for sale of a substantial number of our common shares may cause the price of our common shares to decline.

 

If our shareholders sell substantial amounts of our common shares in the public market, including shares issued in the public offering and shares issued upon conversion of outstanding convertible notes or exercise of outstanding warrants, or upon the expiration of any statutory holding period, under Rule 144, or upon the exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common shares could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 

We qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act, or JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.

 

For so long as we are an emerging growth company, we will not be required to:

 

● have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002;

 

● comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

 

● submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and

 

● disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.

 

We will remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

 

Until such time, however, we cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.

 

In addition, when these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot predict or estimate the amount of additional costs we may incur as a result of us ceasing to be an emerging growth company or the timing of such costs. In addition, once we no longer qualify as an emerging growth company under the JOBS Act and lose the ability to rely on the exemptions related thereto, depending on our status as per Rule 12b-2 of the Securities Exchange Act of 1934, as amended, our independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002. We will be performing the system and process evaluation and testing (and any necessary remediation) required to comply with the management certification and eventual auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 when we are no longer an emerging growth company. This process will require the investment of substantial time and resources, including by our senior management. As a result, this process may divert internal resources and take a significant amount of time and effort to complete.

 

16

 

 

Since we have elected under Section 107 of the JOBS Act to use the extended transition period with respect to complying with new or revised accounting standards, our financial statements may not be comparable to companies that comply with public company effective dates making it more difficult for an investor to compare our results with other public companies.

 

Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 102(b)(2)(B) of the Act for complying with new or revised accounting standards. In other words, as an emerging growth company we can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

We may be classified as a Passive Foreign Investment Company, or PFIC, for U.S. federal income tax purposes in 2021 and may continue to be, or become, a PFIC in future years, which may have negative tax consequences for U.S. investors.

 

We will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is “passive income” or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Based on our estimated gross income, the average value of our gross assets, and the nature of our business, we may be classified as a PFIC in the current taxable year and may be treated, or may become, a PFIC in future years. If we are treated as a PFIC for any taxable year during which a U.S. investor held our common shares, certain adverse U.S. federal income tax consequences could apply to the U.S. investor. See “Item 10. Additional Information – E. Taxation– Passive Foreign Investment Company Rules.”

 

ITEM 4. INFORMATION ON THE COMPANY

 

  A. History and Development of the Company

 

We were incorporated under the laws of the Province of Ontario (specifically under the Business Corporations Act (Ontario)) on October 31, 2011, in the Province of Ontario, Canada, and did business as Behavioural Neurological Applications and Solutions. Effective November 4, 2015, we changed our name to Ehave, Inc.

 

Our principal office is located at 100 SE 2nd St., Suite 2000, Miami, FL 33131 and our telephone number is (954) 233-3511.

 

The SEC maintains an Internet site that contains reports and other information regarding us that we file electronically with the SEC website at www.sec.gov. We also make available free of charge on our website at www.ehave.com, as soon as reasonably practicable after such reports are available on the SEC website.

 

We are not aware of any indication of any public takeover offers by third parties in respect of our common shares during our last and current financial years.

 

Sale of Ehave Connect Assets

 

On March 22, 2019, we entered into an Asset Purchase Agreement with ZYUS Life Sciences Inc. (“ZYUS”), pursuant to which we sold to ZYUS all of our property and assets, including intellectual property, relating to our business relating to our technology stack, data models, user interface flows, application programming interfaces and all existing builds to the health informatics Ehave Connect platform, which includes but is not limited to the input, tracking and extraction of clinical data, but excluding intellectual property in certain patient outcome reporting applications, clinical games, clinical patient data, facts related to patient assessments and personal property (the “Asset Sale”). The Ehave Connect platform contains components specifically designed to be used by patients using alternative treatments to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling.

 

In connection with the Agreement, ZYUS (i) paid us a total purchase price of CAD $1.2 million (US$895,122) in cash, CAD $260,000 (US$193,943) of which was provided to us upon execution of a non-binding term sheet and CAD $100,000 (US$74,594) of which was provided to us on April 30, 2019, pursuant to an advance, and (ii) issued to us at closing 361,011 common shares of ZYUS (the “Consideration Shares”). ZYUS has a security interest in the Consideration Shares in support of any indemnity claims by ZYUS pursuant to the Agreement until the second anniversary of the closing date.

 

17

 

 

The Agreement also contains representations, warranties and covenants of the parties customary for transactions similar to those contemplated by the Agreement. Pursuant to the Agreement, ZYUS, among other things, agreed not to redeem, purchase or otherwise acquire any of its outstanding shares or other securities, subject to certain exceptions, from the date of the Agreement and until the closing date of the Asset Sale, and we agreed to enter into a six month lock-up agreement restricting the resale of the Consideration Shares if ZYUS completes an initial public offering or going public transaction. Such representations and warranties are made solely for purposes of the Agreement and, in some cases, may be subject to qualifications and limitations agreed to by the parties in connection with the negotiated terms of the Agreement and may have been qualified by disclosures that were made in connection with the parties’ entry into the Agreement.

 

The Agreement also contains indemnification provisions by each party. We will deliver a security agreement granting ZYUS a security interest in the Consideration Shares in support of any indemnity claims by ZYUS pursuant to the Agreement until the second anniversary of the closing date.

 

In addition, we agreed to enter into a non-competition agreement with ZYUS, pursuant to which we agree not to, for a period of four years from the date of the non-competition agreement, within Canada and the United States, conduct business or have any financial or other interest in any business that is the same as or substantially similar to or is competitive with the business of a healthcare software development company for stakeholders in health sectors related to plant-based therapeutics. The non-competition agreement also includes a confidentiality provision that prohibits us from using the confidential information relating to the assets acquired in the Asset Sale for its own benefit or for the benefit of others.

 

The foregoing descriptions of the Agreement, the security agreement and the non-competition agreement are qualified in their entirety by reference to the full text of the Agreement, a form of the security agreement and a form of the non-competition agreement, a copy of which is attached to our Annual Report on Form 20-F as Exhibits 4.60, 4.61 and 4.62 filed on May 15, 2019.

 

On May 22, 2019, the Asset Sale closed. Pursuant to the Purchase Agreement, at closing, the Company received from ZYUS (i) CAD$840,000 in cash (the remaining portion of the total cash purchase price of CAD $1.2 million), of which CAD $260,000 had been provided to us upon execution of a non-binding term sheet and CAD$100,000 had been provided to us on April 30, 2019, pursuant to an advance, and (ii) 361,011 common shares of ZYUS, priced at CAD$5.54 per share.

 

On the closing date, pursuant to the Purchase Agreement, the Company executed (i) a six month lock-up agreement restricting the resale of the Consideration Shares if ZYUS completes an initial public offering or going public transaction; (ii) a security agreement granting ZYUS a security interest in the Consideration Shares in support of any indemnity claims by ZYUS pursuant to the Purchase Agreement until the second anniversary of the closing date; and (iii) a non-competition agreement with ZYUS, pursuant to which we agreed not to, for a period of four years from the date of the non-competition agreement, within Canada and the United States, conduct business or have any financial or other interest in any business that is the same as or substantially similar to or is competitive with the business of a healthcare software development company for stakeholders in health sectors related to plant-based therapeutics. The non-competition agreement also includes a confidentiality provision that prohibits the Company from using confidential information relating to the assets acquired in the Asset Sale for its own benefit or for the benefit of others.

 

In connection with the closing of the Asset Sale, the Company terminated certain collaboration and services agreements with certain third-party partners.

 

Share Consolidation

 

At the special meeting of our shareholders held on May 6, 2019, our shareholders approved a resolution authorizing the amendment of our articles to consolidate our issued and outstanding common shares in up to three consecutive share consolidations to occur at any time as determined by our board of directors, within one calendar year of the date of the special meeting, provided that the first consolidation, the second consolidation, and the third consolidation shall collectively effect a consolidation on a basis of between (i) two pre-consolidation shares to one post-consolidation share, and (ii) 200 pre-consolidation shares to one post-consolidation share. On May 13, 2019, we determined a share consolidation ratio of 100 pre-consolidation shares to one post-consolidation share, which was effective as of May 29, 2019.

 

18

 

 

Removal of our Common shares from the OTCQB Venture Market to Pink Open Market

 

On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable to cure our bid price deficiency. The OTCQB Venture Market requires a minimum bid price of $0.01. Broker-dealers often decline to trade in over-the-counter stocks that are quoted on the OTC Pink tier given the market for such securities are often limited, the stocks are more volatile, and the risk to investors is greater. The share consolidation effective as of May 29, 2019, did cure the bid price deficiency; however, the expected increase in the price of our common shares from the share consolidation may not be maintained, and there can be no assurance that the market price of our common shares following the share consolidation will remain above the minimum bid price requirement to restore or maintain eligibility for quotation of our common shares on OTCQB Venture Market. As of the date of this report we have not made a new application for our common shares to be quoted on the OTCQB Venture Market.

 

Sale of Myctopia Therapies (Florida)

 

In December 2020, Ehave, Mycotopia Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave (“MYC”) and 20/20 Global, Inc., a Nevada corporation (“20/20 Global”), and the former officers and directors of 20/20 Global, entered into definitive agreements that provided for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of MYC from Ehave under a Stock Purchase Agreement, attached hereto as an Exhibit, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management under a Change of Control and Funding Agreement. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitutes approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash, through a Stock Purchase Agreement (“MYC SPA”) with 20/20 Global stockholders Mark D. Williams, Colin Gibson, and The Robert and Joanna Williams Trust. Prior to these transactions, neither 20/20 Global nor its officers and directors had a material relationship with Ehave, MYC, or their respective officers and directors. As a result of these transactions, Ehave now controls the board and management of 20/20 Global.

 

A closing of the transactions contemplated by the above-described documents was initially scheduled for January 4, 2021, and then delayed by agreement. All of the above transactions were closed on January 19, 2021.

 

As a result of the MYC SPA, 20/20 Global is adopting MYC’s business plan and MYC became a wholly owned subsidiary of 20/20 Global, through which 20/20 will now conduct operations. MYC is a development-stage enterprise that proposes to develop a business to provide psychedelic-enhanced holistic methodologies to improve mental wellbeing. In the next five years, its business model will focus on the following areas: palliative care, depression, and anxiety.

 

Under the Change of Control and Funding Agreement (each, attached hereto), the current directors and officers of 20/20 Global resigned and were replaced by designees of Ehave. Specifically, Mark D. Williams and Colin Gibson resigned as officers and directors, and Benjamin Kaplan and Mark Croskery were appointed to serve as replacement directors for 20/20 Global. The agreements also provided for Mr. Kaplan, the CEO of Ehave to serve as president and secretary of 20/20 Global.

 

  B. Business Overview

 

We are creating a mental health data platform that integrates with our proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient and (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

 

MegaTeam is currently available on the Apple iOS App Store and Google Play.

 

Through its KetaDash subsidiary, the Company provides a platform for medical practitioners to administer healthcare services to patients at home

 

Ketadash

 

KetaDash Inc. (Ketadash), a wholly owned subsidiary of Ehave, Inc. (Ehave), provides a platform for medical practitioners to administer healthcare services to patients at home. In order to facilitate the launch of Ketadash, Ehave acquired 100% of Rejuv IV inc. (Rejuv IV) through a stock purchase agreement on January 8, 2021. Ehave then consolidated Rejuv IV into its Ketadash brand. KetaDash addresses the needs of patients currently suffering from mental illnesses such as depressive disorder, bipolar disorder and post-traumatic stress disorder. KetaDash improves brain wellness and cognitive function with psychedelic medicine administered by a registered nurse in the comfort of your own home with Ketadash’s mobile wellness therapies. Ketadash provides Ketamine treatments, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. In addition to Ketamine treatments, Ketadash generates revenue by offering its clients and patients IV Drip Detox and Hangover Cures, IV Vitamin Therapy for pain management, Hydration Therapy for Health & Wellness, and IV Therapy for athletic advantage and fitness recovery. Ketadash uses certified nurses, who are always prompt and will arrive on time to administer a patient’s IV drip of choice in the comfort of their home. Ketadash’s products and services have been made public through their website https://ketadash.com/ .

 

MegaTeam and Ninja Reflex Digital Assessment and Rehabilitation Applications

 

Our MegaTeam and Ninja Reflex assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities in populations with attention deficit and hyperactivity disorder, or ADHD. Methodologies commonly used today involve repetitive performance of tasks using digital interface. These tasks are repeatedly administered to the patient in order to obtain accurate measures. Many of the assessments used today had been developed using programming methodologies whereby the task is simply exhibited on screen and the patient is instructed to respond to stimuli. Our research has found that patients, in particular those with symptoms of ADHD, have difficulty completing the necessary regiment of tasks due to lack of engagement. Additionally, these tasks are often administered in a clinical setting, often resulting in the patient and their accompanying parent or guardian staying in clinical settings for an extended time. Our products have been developed to address these primary concerns as well as to enable a breadth of cognitive tasks to be assessed and an individualized cognitive rehabilitation program to be administered remotely.

 

The MegaTeam and NinjaReflex applications involve the imbedding of cognitive assessment and rehabilitation tasks within an engaging video game environment. MegaTeam and NinjaReflex were designed and programmed with the intention of providing comparable engagement to video game play. In the design, narrative and programming of our MegaTeam and NinjaReflex games, we utilize experts in children’s digital content and programming. Our tools have been developed on Unity, a common game development platform that can be used on most fixed and mobile devices, enabling the expansion of narrative and the adaptation of new character and game environments to maintain long-term engagement of product differentiation. The underlying cognitive tools and data remain unchanged as the “skin” is adapted for future versions and client profiles. A significant part of the MegaTeam and NinjaReflex development involved assessing user engagement and consultation on characters, narrative and graphic design.

 

MegaTeam and NinjaReflex applications have been designed for deployment on multiple digital interfaces including PC, Mac, Android and iOS systems. Our applications may be used in a clinic or a patient’s home or remotely, provided there is an adequate data connection.

 

19

 

 

Based on feedback from users and clinical psychologists regarding strong user engagement of our MegaTeam and NinjaReflex products, we believe that our products have a strong capacity for training compliance.

 

Developed MegaTeam and NinjaReflex products include: (1) Stop Signal Reaction Time Assessment (2) N Back Assessment (3) Inhibitory Control Rehabilitation (4) and Working Memory Rehabilitation. We are planning the development of a broader suite of cognitive tasks and rehabilitation mechanisms in order to increase the addressable mental health indications.

 

Ehave Connect Software Platform

 

On March 22, 2019, we entered into the Agreement with Zyus, pursuant to which we will sell to Zyus all of our assets relating to its health informatics Ehave Connect platform. The Ehave Connect platform contains components specifically designed to be used by medical cannabis patients to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling.

 

Ehave Connect is a cloud-based platform that allows for the input, tracking and extraction of clinical data. Based on the clinical data collected, Ehave Connect is intended to provide patient management and digital assessment tools to healthcare providers and physicians so that they are better equipped to provide diagnosis and treatment to patients in their care.

 

The sale of the Ehave Connect Platform was completed on May 22, 2019.

 

Third Party Content

 

We believe that it is critical to partner across the mental healthcare community, and we have secured partnerships with industry leaders.

 

Partnership with MHS

 

In December 2016, we signed an agreement with MHS, a leading provider of psychological assessment tools. We have licensed MHS’s gold standard Connors® suite of ADHD assessments, as well as the Davidson Trauma Scale and SPAN assessments for PTSD. We expect to offer MHS’s entire catalogue of tests in time, and in so doing we believe that we can enhance the evaluation of any mental health indication. We plan to move into areas such as anxiety, depression, OCD, autism, and more.

 

The Hospital for Sick Children

 

In December 2011, we entered into a collaboration with Toronto’s Hospital for Sick Children to identify the clinical needs, design and processes required to create clinical grade toolsets. In addition to specific tools, we have developed a content delivery and patient data platform, known as Resource Knowledge Information Access that enables content to be deployed, monitored, analyzed and accessed remotely by clinicians and patients. These tools were used during randomized control studies of the MegaTeam game and will be used in future trials with the Hospital for Sick Children.

 

Third-party Contract Services

 

We believe that we have the expertise of understanding the complexities of mental health assessments and rehabilitation methodologies, along with game design and programming. Researchers and developers of digital applications for mental health may recognize the advantage of engaged users, but lack the expertise in game based translation. We intend to market our company to researchers and developers with fee-based services to enhance their digital applications. We are working closely with mental health research networks to avail our existing MegaTeam and NinjaReflex tools as well as our programming expertise to enhance and commercialize new products and services.

 

20

 

 

Business Strategy

 

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

 

Our business strategy is to develop and MegaTeam and Ninja Reflex in an effective and timely manner and gain access to additional technologies at a time and in a manner that we believe is best for our development. We intend to achieve our business strategy by focusing on these key areas:

 

● Development of the Ehave Dashboard, an extensible platform upon which powerful, condition-specific applications can be designed, built, clinically validated, and deployed

 

● expanding MegaTeam and Ninja Reflex with additional game titles, and participate in further clinical studies with Hospital for Sick Children on the CHILD-BRIGHT network, which is a Canadian research network that aims to improve the lives of children with brain-based development disabilities we are a partner to and provider of in-kind services and support);

 

● forming strategic alliances with publishers of psychological assessments, at a time and in a manner where such alliances may complement and expand our research and development efforts on the product and provide sales and marketing capabilities;

 

● developing relationships with pharmaceutical and insurance companies that could be instrumental in deploying our technology to drug development and treatment monitoring; and

 

● developing relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.

 

● develop a Multi-Tier Global Partnership with MyLifeID that will allow individuals to carry their health and mental health records with them at all times. This partnership allows individuals to store their health and mental health history on the MyLifeID Pocket Cloud™, which will be able to be accessed by medical providers through Ehave’s dashboard.

 

● plans to utilize its mental health informatics platform and assets acquired from CureDash Inc., in January 2021, to optimize patient care and health outcomes in conjunction with Ketamine therapy for mental health. Ehave plans to advance Ketamine therapy research and commercialization through its wholly-owned subsidiary, KetaDash.

 

Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals. Our product development presently being conducted is primarily of a research and development nature.

 

Market

 

We anticipate that the principal markets for our software products will initially include North America. Thereafter, we hope to expand our markets to Europe and Asia. Currently our products are being deployed in Canada. Currently, Ketadash operates in California, though the Company intends to expand to other states.

 

21

 

 

Mental healthcare, including its assessment and treatment, is a significant market. Forty-four million adults in the United States are estimated to experience mental illness per year, which is 20% of the population. The size of the U.S. mental health treatment market is $113 billion, and the size of private insurance spending on mental health is $32 billion. The size of the cognitive assessment market world-wide is over $2.4 billion. (Source: Mental Health America - State of Mental Health Report, 2016; SAMSHA Spending Estimates Project, 2010; MarketsandMarkets, 2015).

 

ADHD is a common affliction with worldwide prevalence estimated at approximately 7% (Source: “Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis”, Rae Thomas, Sharon Sanders, Jenny Doust, Elaine Beller, Paul Glasziou, Pediatrics Feb 2015, peds.2014-3482; DOI: 10.1542/peds.2014-3482). ADHD symptoms typically start or are first noticed in preschool age children (“Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis”, Rae Thomas, Sharon Sanders, Jenny Doust, Elaine Beller, Paul Glasziou, Pediatrics Feb 2015, peds.2014-3482; DOI: 10.1542/peds.2014-3482). While symptoms may decline with age, ADHD symptoms and impairments can persist into adolescence and adulthood (Source: “A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanism”, Julia Geissler and Klaus-Peter Lesch, Expert Review Of Neurotherapeutics Vol. 11 , Iss. 10,2011).

 

On March 5, 2019, the Food and Drug Administration (FDA) approved the first new medication for major depression in decades, a nasal spray called esketamine, derived from ketamine.

 

Because treatment with esketamine might be so helpful to patients with treatment-resistant depression (meaning standard treatments had not helped them), the FDA expedited the approval process to make it more quickly available. In a study of patients with treatment resistant depression, 22 patients were examined after they finished the induction phase of 8–10 repeated intravenous ketamine infusions. They showed a 47.2% reduction response in depression, showing significantly decreased depression symptoms without impairing cognitive performance. Dai, D., Miller, C., Valdivia, V. et al. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. BMC Psychiatry 22, 140 (2022). https://doi.org/10.1186/s12888-022-03789-3

 

Competition

 

For our MegaTeam and Ninja Reflex game applications, we are aware of a few competitors, including Akili Interactive, Attentiv, Myndlift and C8Sciences. Many of these companies are currently conducting clinical trials. Our strategy for game development starts from using known proven clinical measures rather than creating new measures, and we believe that the advantage of this methodology is that broad normative data does not need to be established and the barrier to clinical adoption may be lower with known measures that clinicians are already comfortable with.

 

While our KetaDash program is not intended to compete generally with Electronic Health Records (EHR) systems, we view general EHR systems as our main competition. Such systems from Epic, Allscripts and GE Healthcare are leaders in the EHR market, have been in business for many years and are better funded than our offering. However, because we intend to focus on specifically on Ketamine clinics, we believe our software will be attractive to the market we intend to serve and will offer specializations not readily available in more general EHR systems.

 

There are several companies offering Ketamine infusion therapy for the treatment of mental illness, including Novamind and Field Trip Health. KetaDash differentiates itself from these companies as Ketadash provides Ketamine treatments in a patient’s home instead of making them go to a clinic. This will allow us to expand more quickly as we do not require physical locations and are not burdened with the ongoing rent expense.

 

Product Differentiation

 

We strive to provide the best tools and resources for today’s populations suffering from mental illness. Many of the incumbent products have been developed and validated in their academic forms, which, we believe, lack appeal for today’s clients and practitioners. We believe there is a demand for real time, data-rich digital tools that enable individual treatment and ongoing monitoring, while a significant portion of the existing market for cognitive assessment and therapy relies upon paper-based tools and checklists that have little or no connected monitoring capacity or real-time progress reporting. As such, we seek to develop products with the following key features: (1) user engagement, (2) data richness, (3) clinically validated, and (4) multi-screen and mobile deployment.

 

Our assessment products are derived from designs and methods clinically studied. Our plans include the study of our derived products and cognitive rehabilitation software through clinical studies led by hospitals. These studies include multiple phases from pilot studies through affected population studies and allow the measurement, using various criteria and techniques, of the effect of our cognitive rehabilitation program on target populations.

 

Likewise we are applying the same methodology to our KetaDash offering. As the use of Ketamine in the treatment of mental health is an emerging field, we intend the KetaDash software to provide the data richness necessary to evaluate patient progress and outcomes.

 

22

 

 

Marketing

 

Our marketing channels consist of direct sales and leveraging partners for market outreach. Our current strategy is for direct sales to publishing partners, medical device partners, medical professionals and pharmaceutical companies. Through these partnerships, we gain access to clinicians and the patients they serve.

 

We also engage a public relations firm to help reach media outlets.

 

Regulatory Requirements

 

Our future business operations and activities in the U.S. may be directly or indirectly subject to subject to certain federal and state laws relating to the privacy and security of health information, and state and federal laws designed to guard against healthcare fraud and abuse, including, but not limited to, those described below.

 

● HIPAA, as amended by HITECH, established comprehensive requirements related to the privacy, security, and transmission of individually identifiable health information. It governs patient privacy practices of healthcare providers, health plans, and healthcare clearinghouses (or “covered entities”), as well as their respective business associates to the extent that they perform services for or on behalf of the covered entities that involve the use or disclosure of protected health information. HIPAA also mandates notification in the event of a breach and regulates standardization of data content, codes and formats used in healthcare transactions. Covered entities and business associates may be subject to significant civil and criminal penalties, as well as enforcement by state attorneys general, for violations of HIPAA or its implementing regulations.
   
● HIPAA also imposes federal criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.
   
● The federal Anti-Kickback Statute which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs.
   
● The federal Civil False Claims Act imposes liability on any person or entity, which, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The “qui tam” or “whistleblower” provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government, alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery.
   
● The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies.
   
● Analogous state fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to items or services reimbursed under Medicaid, other state programs, or, in some states, private third-party payors. In addition, many U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical information, and many states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards, and data security breach notification requirements. These state laws, which may be even more stringent than the HIPAA requirements, many of which differ from each other in significant ways and are often not preempted by the federal requirements.

 

23

 

 

FDA’s Medical Device Regulation

 

The FDA has broad authority over the regulation of medical devices marketed for sale in the United States. The FDA regulates the research, clinical testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, promotion, distribution and production of medical devices. The FDA also regulates the export of medical devices manufactured in the United States to international markets.

 

Under the Food, Drug, and Cosmetic Act, or FDCA, the FDA classifies medical devices into one of three classes: Class 1, Class 2 or Class 3. Medical devices deemed to pose lower risk are placed into either Class 1 or Class 2.

 

Class 1 medical devices are deemed to pose the lowest risk to the patient. Accordingly, Class 1 medical devices are subject to the lowest degree of regulatory scrutiny and need only comply with the FDA’s General Controls. The General Controls include compliance with the registration, listing, adverse event reporting requirements, and applicable portions of the Quality Systems Regulation, or QSR, as well as the general misbranding and adulteration prohibitions. Unless specifically exempted in the regulations, general controls require a company that intends to market a Class 1 medical device, like us, to gain clearance for marketing through the 510(k) process. Many Class 1 medical devices, however, are exempt from 510(k) clearance because the level of risk is low.

 

Class 2 medical devices are considered higher risk devices than Class I medical devices. Class 2 medical devices are subject to General Controls as well as additional Special Controls. Special Controls may include labeling requirements, mandatory performance standards, and post market surveillance. Generally, companies that intend to market Class 2 medical devices, like us, must comply with applicable regulations and submit a 510(k) premarket submission for review to receive clearance to list and market their medical devices. The 510(k) must establish substantial equivalence to a predicate medical device. Some Class 2 medical devices are exempt from filing a 510(k) but in some instances, Class II medical devices may be required to file a Premarket Approval, or PMA, application.

 

Medical devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared medical device, are classified as Class 3 medical devices and require a PMA before commercialization.

 

All medical device manufacturers must register their establishments with the FDA; such registrations require the payment of user fees. In addition, both 510(k) premarket submissions and PMA applications are subject to the payment of user fees, paid at the time of submission for FDA review.

 

The use of forms and tools for the measurement and assessment of behavioral and cognitive abilities are considered computerized cognitive assessment aids by the FDA. The FDA currently classifies such products as Class II medical devices. Currently we are engaging in clinical trials of Ehave MegaTeam games outside of the United States. Such clinical trials are being performed to prove efficacy and may have supporting evidence in the event that we filed an marketing application in the United States and the FDA requires this data before we are able to market, advertise or sell our Ehave MegaTeam games in the United States.

 

510(k) Clearance Pathway

 

If required to obtain 510(k) clearance for our Ehave MegaTeam games or any other computerized cognitive assessment aid products in the future, such products may be classified as medical devices and we would may be required to submit a premarket notification demonstrating that the proposed medical device is substantially equivalent to a previously cleared 510(k) device. FDA’s 510(k) clearance pathway usually takes from three to twelve months. On average the review time is approximately six months, but it can take significantly longer than twelve months in some instances, as the FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.

 

After a medical device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, require a PMA. The FDA requires each manufacturer to determine whether the proposed change requires submission of a new 510(k) notice, or a premarket approval, but the FDA can review any such decision and can disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or premarket approval is obtained. If the FDA requires us to seek 510(k) clearance or premarket approval for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device until we obtain this clearance or approval. Also, in these circumstances, we may be subject to significant regulatory fines or penalties. We have made and plan to continue to make additional product enhancements to products that we believe do not require new 510(k) clearances, but we cannot guarantee that the future enhancements, should they occur, will be exempt from new 510(k) clearances.

 

24

 

 

De Novo Reclassification

 

If we decide to market, advertise or sell our Ehave MegaTeam games or any other any other computerized cognitive assessment aid products in the future, such products may not have a suitable predicate medical device to be cleared as a 510(k) medical device. If the FDA finds that there is no suitable predicate medical device, it will automatically be considered our Ehave MegaTeam games or any other computerized cognitive assessment aid products that we apply for clearance to market, advertise or sell in the future a Class III medical device. However, in instances where a medical device is novel and there is no suitable predicate device, but that medical device is deemed to be of low to moderate risk, the FDA may reclassify the device to Class I or Class II via de novo reclassification petition pathway. This process involves the submission of a de novo reclassification petition, and the FDA’s acceptance that “special controls” are adequate to ensure the product’s performance and safety.

 

The FDA now allows de novo reclassification petitions, a mechanism by which a sponsor can directly submit a detailed de novo reclassification petition as the device’s initial submission without having to first receive a not substantially equivalent, or NSE, decision on a 510(k) submission. Historically, the de novo reclassification pathway typically would take at least 9 to 12 months from filing to clearance. Since the enactment of the 21st Century Cures Act, de novo classification petitions may be submitted to the FDA at any time and does not require a FDA finding of not substantially equivalent to a 510(k) application before the petition is made. FDA must respond to any de novo classification requests within 120 days of a completed petition.

 

In the future, we may decide to submit a de novo reclassification petition for our Ehave MegaTeam games or any other computerized cognitive assessment aid products that we may develop. To support a de novo reclassification petition, our objective would be to demonstrate that the proposed medical device poses a low to moderate risk to patients. If the FDA determines that such a product is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA application process.

 

Alternatively, if we seek 510(k) clearance and our medical device is found not substantially equivalent, or NSE, the FDA will consider a de novo petition if our proposed medical device has been determined to be NSE due to: (1) the lack of an identifiable predicate medical device, (2) a new intended use, or (3) different technological characteristics to a predicate device that raise different questions of safety and effectiveness. The de novo classification request should include a description of the medical device, labeling for the device, reasons for the recommended classification and information to support the recommendation. Should the FDA believe our proposed medical device’s general controls or general and special controls provides reasonable assurance of safety and effectiveness, the FDA may classify our medical device as a Class II medical device. If the FDA classifies the device into Class II, we will then receive an approval order to market the device. This device type can then be used as a predicate device for future 510(k) submissions. However, if the FDA subsequently determines that the device will remain in the Class III category, then we may not be marketed until we have obtained a PMA.

 

Premarket Approval Pathway

 

A PMA application must be submitted if a medical device cannot be cleared through the 510(k) process or by de novo reclassification petition. The PMA application process is generally more costly and time consuming than the 510(k) process. A PMA application must be supported by extensive data including, but not limited to, analytical, preclinical, clinical trials, manufacturing, statutory preapproval inspections, and labeling to demonstrate to the FDA’s satisfaction the safety and effectiveness of the medical device for its intended use.

 

25

 

 

After a PMA application is sufficiently complete, the FDA will accept the application and begin an in-depth review of the submitted information. By statute, the FDA has 180 days to review the “accepted application,” although, generally, review of the application can take between one and three years, but it may take significantly longer. During this review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the medical device. The preapproval inspections conducted by the FDA include an evaluation of the manufacturing facility to ensure compliance with the QSR, as well as inspections of the clinical trial sites by the Bioresearch Monitoring group to evaluate compliance with good clinical practice and human subject protections. New premarket approval applications or premarket approval application supplements are required for modifications that affect the safety or effectiveness of the medical device, including, for example, certain types of modifications to the medical device’s indication for use, manufacturing process, labeling and design. Significant changes to an approved PMA require a 180-day supplement, whereas less substantive changes may utilize a 30-day notice, or the 135-day supplement. PMA supplements often require submission of the same type of information as a PMA application, except that the supplement is limited to information needed to support any changes from the medical device covered by the original PMA application, and may not require as extensive clinical data or the convening of an advisory panel. None of our products are currently approved under a premarket approval and we do not believe that we will ever have a product that requires a PMA.

 

Clinical Trials

 

Clinical trials are almost always required to support a PMA application or de novo reclassification petition and are sometimes required for a 510(k) premarket notification. If we decide to market, advertise or sell our Ehave MegaTeam and NinjaReflex games or any other any other computerized cognitive assessment aid products that we may develop in the future, and if the FDA believes that such product presents a potential “significant risk” to health, safety, or the welfare of a human subject, the FDA may require us to collect safety and effectiveness data on human subjects regardless of our device’s classification. If we are required to collect data on human subjects, the FDA will require us to file an application for an Investigational Device Exemption, or IDE with the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate pre-clinical data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a “non-significant risk” device and eligible for more abbreviated investigational device exemption requirements. Clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the appropriate institutional review boards at the clinical trial sites. Future clinical trials of our motion preservation designs will require that we obtain an IDE from the FDA prior to commencing clinical trials and that the trial be conducted under the oversight of an institutional review board at the clinical trial site. Our clinical trials must be conducted in accordance with FDA regulations and other federal and state regulations concerning human subject protection, including informed consent and healthcare privacy. A clinical trial may be suspended by the FDA or the IRB at any time for various reasons, including a belief that the risks to the study participants outweigh the benefits of participation in the study. Even if a study is completed, the results of our clinical trials may not demonstrate the safety and efficacy of the medical device, or may be equivocal or otherwise not be sufficient to obtain approval of our Ehave MegaTeam and NinjaReflex game or any other computerized cognitive assessment aid products that we may develop in the future. At this time, we do not plan on marketing, advertising or selling our Ehave MegaTeam and NinjaReflex games or any other computerized cognitive assessment aid products in the United States and therefore, do not anticipate performing clinical trials in the United States.

 

Patents and Trade Secrets

 

The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.

 

We have not registered any patents in respect of Megateam and NinjaReflex; however, we maintain our proprietary server architecture and mobile applications as trade secrets. We have registered the trade name “Ehave, Inc.” and own the domain “ehave.com.”

 

We rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.

 

26

 

 

We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business measurements to protect confidential information, these agreements may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.

 

Seasonality of Business

 

Our results of operations have not been materially impacted by seasonality.

 

  C. Organizational Structure

 

The following is a list of our principal subsidiaries and consolidated affiliated entities as of the date of this annual report on Form 20-F:

 

Name   Place of Formation   Relationship
Mycotopia Therapies, Inc.   Nevada   Majority Owned Subsidiary (1)
KetaDash LLC   Florida   Wholly Owned Subsidiary
HPPD Inc.   Florida   Wholly Owned Subsidiary

 

(1) On January 19, 2021, we sold Mycotopia Therapies, Inc. (Florida) to 20/20 Global, Inc. (now known as Mycotopia Therapies, Inc., a Nevada corporation) for $350,000 in cash. Simultaneously, we purchased a majority of the issued and outstanding stock of 20/20 Global for its majority stockholders. We own approximately 70% of 20/20 Global and Mycotopia Therapies, Inc. (Florida) is a wholly owned subsidiary of 20/20 Global.

 

  D. Property, Plants and Equipment

 

We currently reimburse our CEO for office space that he has under lease. Our lease expense is $2,500 per month. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.

 

ITEM 4A. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

 

You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form 20-F. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs, including our belief as to the potential of MegaTeam and Ninja Reflex applications as an effective remediation tool for ADHD and our expectations as to the success of our research and related content distribution in 2022 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties]. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 20-F, particularly those in “Item 3. Key Information – D. Risk Factors.” See also “Special Note Regarding Forward-Looking Statements.”

 

With respect to the forward-looking statements made within this Item 5, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our continuing development programs, the results of our clinical trials, our ability to obtain commercial sales, and future expense levels being within our current expectations. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements except as required by applicable law.

 

27

 

 

Overview

 

We are creating a medical psychedelics and mental health data platform that integrates with our proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient, and (2) adaptation of custom and third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

 

Additionally, through our KetaDash subsidiary, we provide a platform for medical practitioners to administer healthcare services to patients at home, with an emphasis on providing ketamine infusion services.

 

We qualify as an “emerging growth company” under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

 

● have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;
   
● comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);
   
● submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and
   
● disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation.

 

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

We will remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires companies to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and judgments are subject to an inherent degree of uncertainty, and actual results may differ. Our significant accounting policies are more fully described in Note 1 to our financial statements included elsewhere in this Annual Report. Critical accounting estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances, and are particularly important to the portrayal of our financial position and results of operations. Our estimates are primarily guided by observing the following critical accounting policies.

 

28

 

 

Financial Overview

 

Our operations have been funded, to date, primarily through the sale of our common shares in a public offering and series of private placements of convertible notes and warrants. For the year ended December 31, 2021, we raised an aggregate of approximately $3,014,000 to fund our operations, from the issuance of convertible notes and warrants and through our offering pursuant to Regulation A.

 

During the year ended December 31, 2021, we issued convertible promissory notes in the principal amount of $1,713,700, in the aggregate. The principal amount includes $223,950 of original issue discount and 6,787,000 warrants with an exercise price of $0.01 per share. The term of the notes are 18 months and carry an effective interest rate of 10.00%. The notes mature from July 2022 to August 2022. The convertible promissory notes are convertible into shares of common stock at $0.01 per share. During the year ended December 31, 2021, we converted $1,469,004 of principal debt and interest, and issued 141,635,524 shares of common stock, in the aggregate, upon conversion of the convertible promissory notes. 

 

Operating Losses

 

Since our inception, we have incurred significant operating losses. Our net losses were $8,613,529 and $3,514,736 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $26,256,033. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase significantly as we plan to continue development and commercialization of MegaTeam, NinjaReflex and KetaDash products as well as to engage in continuing research and development related to products and services.

 

  A. Operating Results

 

Years Ended December 31, 2021, and December 31, 2020

 

Revenues

 

We have no revenue from continuing operations for the years ended December 31, 2021 and 2020.

 

General and Administrative

 

General and administrative expenses increased $2,759,725 to $6,681,261 for the year ended December 31, 2021 compared to $3,921,536 for the year ended December 31, 2020. The increase was primarily due to the increase of stock-based compensation in the amount of $1,887,807, compensation to the Chief Executive Officer of $592,137, and medical advisory board fees, related travel, consulting and professional fees in the amount of $279,781.

 

29

 

 

Other income and expenses

 

The Company recorded other expense for the year ended December 31, 2021 in the amount of $2,012,487 compared to $406,800 of other income for the year ended December 31, 2020. The increase in expense in the amount of $2,419,287 primarily relates to the increase in amortization expense of $1,136,698, the decrease in gain on settlement of debt in the amount of $4,180,451, and the decrease in other income of $176,933, offset by the decrease in the loss on the change in fair value of derivative liability in the amount of $3,004,387, the decrease in interest expense of $70,408.

 

  B. Liquidity and Capital Resources

 

Through December 31, 2021, we have incurred an accumulated deficit of $26,316,815, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as a net loss of $8,693,748 and negative operating cash flows during the year ending December 31, 2021. Our total cash balance as of December 31, 2021 was $2,350,741. At December 31, 2021, we had a working capital deficit of $474,950. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years due to development costs associated with our Ehave Dashboard, MegaTeam, and Ninja Reflex products, until our products reach commercial profitability. As a result of these expected losses and negative cash flows from operations, along with our current cash position, based on our current projections, we may not have sufficient resources to fund operations through the third quarter of 2022. Therefore, there is substantial doubt about our ability to continue as a going concern.

 

Our plans include the continued commercialization of our products and raising capital through a combination of equity offerings, debt financings, other third-party funding and other collaborations and strategic partnerships. There are no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. We are exploring various financing options including equity funding and strategic collaboration. However, there are no assurances that we will be successful in obtaining the level of financing needed for our operations or that any such financing would be on terms favorable to us. Any future financing may involve substantial dilution to existing investors. If we are unsuccessful in commercializing our products and raising capital, we may need to reduce activities, curtail or cease operations.

 

On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable to cure our bid price deficiency. We expect the share consolidation, expected to be effective as of May 27, 2019, to cure the bid price deficiency; however, the expected increase in the price of our common shares from the share consolidation may not be maintained, and there can be no assurance that the market price of our common shares following the share consolidation will remain above the minimum bid price requirement to restore or maintain eligibility for quotation of our common shares on OTCQB Venture Market. If we fail to restore or maintain the eligibility for quotation of our common shares on OTCQB Venture Market, our ability to obtain additional financing through the public or private sale of our securities would be adversely affected.

 

Operating Activities

 

Net cash used in operating activities for the year ended December 31, 2021 was $1,963,788, which includes a net loss of $8,693,748, offset by non-cash adjustments of $6,178,437 principally related to stock based compensation expense of $2,816,602, equity payable to the Chief Executive Officer recorded as operating expense of $1,282,826, impairment of fixed assets of $100,000, amortization of debt discount of $1,939,675, non-cash interest expense of $18,954, depreciation expense of $19,899, and loss on settlement of debt of $480. The change in net working capital items resulted in an increase the cash of $551,523 primarily related to the increase in account payable and other payables of $224,638, and the decrease in prepaid expenses and other current assets of $326,885.

 

Investing Activities

 

Net cash used in investing activities for the year ended December 31, 2021 was $212,582 from the purchase of fixed assets.

 

Financing Activities

 

Net cash provided by financing activities for the year ended December 31, 2021 was $2,664,921, principally related to the proceeds from convertible notes in the amount of $1,512,000 and the proceeds from Reg A investments of $1,502,000, offset by repayment of promissory notes of $349,079.

 

  C. Research and Development, Patents, and Licenses, etc.

 

Ongoing research and development is critical to our success. We seek to engage with reputable research and clinical institutions to access and assist tools and methods developed. We hope to finance our research and development with government and research grants and internal funds. Our research and development is comprised primarily of software development expenditures. We intend to continue to research and develop new technologies and products for the mental health market. There can be no assurance that we can achieve any or all of our research and development goals.

 

  D. Trend Information

 

It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures. The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of development activity being undertaken at any one time and the availability of funding from investors and prospective strategic partners. See discussion in Parts A and B of Item 5: “Operating and Financial Review and Prospects” for a description of the trend information relevant to us. Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.

 

  E. Off-Balance Sheet Arrangements

 

We are not party to any transactions, agreements or other contractual arrangements with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

 

F.

 Tabular Disclosure of Contractual Obligations

 

We have the following contractual obligations as of December 31, 2020:

 

Contractual Obligations

 

   Payments Due by Period 
    

Total

$

    

Less than 1 year

$

    

2-3 years

$

    

4-5 years

$

    

After 5 years

$

 
Capital lease obligations   -    -    -    -    - 
Operating lease (1)   -    -    -    -    - 
Purchase obligations   -    -    -    -    - 
Other long term obligations   -    -    -    -    - 
Total contractual obligations   -    -    -    -    - 

 

Note:

 

(1) Our operating leases are comprised of our office leases and exclude our portion of operating costs. Our office lease was terminated in June 2019.

 

We expect to fund our capital expenditure requirements and commitments with existing working capital.

 

30

 

 

  G. Safe Harbor

 

We seek safe harbor for our forward-looking statements contained in Items 5.E and F. See “Cautionary Note Regarding Forward-Looking Statements”.

 

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

 

  A. Directors and Senior Management

 

The following table sets forth the names, ages and positions of our current board members and executive officers:

 

Name   Age   Position with the Company  

Director of the

Company Since

Ben Kaplan   52   President, Chief Executive Officer   June 24, 2019
Jay Cardwell   62   Chief Financial Officer   October 1, 2020
Binyomin Posen   29   Chairman of the Board, Director   August 21, 2018
Zeke Kaplan   36   Director   August 21, 2018

 

The business address of our officers and directors is c/o Ehave, Inc., 100 SE 2nd St., Suite 2000, Miami, FL 33160.

 

Our directors are elected for a term of one year and serve until such director’s successor is duly elected and qualified. Our executive officer serves at the pleasure of the Board of Directors. None of our directors have any family relationships with any of our other directors or executive officer.

 

Certain of our directors are associated with other companies, which may give rise to conflicts of interest. In accordance with the Business Corporations Act (Ontario), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract. In addition, the directors are required to act honestly and in good faith with a view to the best interests of Ehave Inc.

 

We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or officer.

 

Biographies

 

Benjamin Kaplan, CEO

 

Mr. Kaplan has served as the CEO of Ehave for the past 16 months and on the board since June 2020 as Chairman. Ben has been an entrepreneur working for over 20 years in the financial sector, beginning in New York City. He is an investor in many companies both public and private, with a focus on international growth and potential for a global presence. In 2014, Ben was a Founding member of Kaya Jamaica Inc. the largest cannabis company in the Caribbean (GROWKAYA.com). Ben sits on the Board of Kaya. In 2014, Ben invested in Surna (OTCQB: SRNA), a global HVAC company that provides engineering and build outs high technology facilities. In 2015 Ben made an investment in Kalytera (TSX: KALY), a botanical-based Pharma company out of Israel carrying on research towards curing various illnesses and with Phase 2 trials for a cure for GVHD (graft versus host disease). In 2014 Ben invested Surna (OTCQB: SRNA), a global HVAC company that provides engineering and build outs high technology facilities. In 2015 Ben made an investment in Kalytera (TSX: KALY), a botanical-based Pharma company out of Israel carrying on research towards curing various illnesses and with Phase 2 trials for a cure for GVHD (graft versus host disease). In 2018 Ben, with a group of investors, acquired a 30,000 strong sales force in over 20 countries as part of the acquisition of Stemtech.com out of bankruptcy. Ben sits on the board of Stemtech.

 

31

 

 

Binyomin Posen, Chairman of the Board, Director

 

Mr. Posen is a Senior Analyst at Plaza Capital Limited, where he focuses on corporate finance, capital markets and helping companies to go public. After three and a half years of studies overseas, he returned to complete his baccalaureate degree in Toronto. Upon graduating (on the Dean’s List) he began his career as an analyst at a Toronto boutique investment bank where his role consisted of raising funds for IPOs and RTOs, business development for portfolio companies and client relations. He is currently director and senior officer at Agau Resources Inc. and director of Senternet Phi Gamma Inc. and director and senior officer at Jiminex Inc. Currently, Mr. Posen is Director, Chief Executive & Financial Officer of Prominex Resource Corp., Director, Chief Executive & Financial Officer at Jiminex, Inc., Director, Chief Executive & Financial Officer at Shane Resources Ltd., Director, Chief Executive & Financial Officer for Sniper Resources Ltd., President, CEO, CFO, Secretary & Director at Agau Resources, Inc., Chief Executive Officer, CFO & Director at Academy Explorations Ltd., Director, Chief Executive & Financial Officer of Hinterland Metals, Inc. and President at 2778533 Ontario, Inc.

 

Jay Cardwell, CFO

 

James Cardwell has more than 37 years of experience in, among other things, U.S. Securities and Exchange Commission (“SEC”) reporting and compliance, financial reporting and tax research and compliance. Since July 2015, Mr. Cardwell has served as Chief Operating Officer and Tax Director of The CFO Squad LLC, a company which provides chief financial officer support services including, but not limited to, pre-audit services, SEC and tax compliance and financial reporting services to both international and domestic private and public companies with a concentration in the healthcare industry. From June 2019 until October 2020, Mr. Cardwell served as interim Chief Financial Officer of NanoVibronix, Inc. From June 2019 until October 2020, Mr. Cardwell served as interim Chief Financial Officer of Esports Entertainment Group, Inc. From August 2018 until December 2018, Mr. Cardwell served as interim Chief Financial Officer of Newgioco Group, Inc. From January 2018 until May 2018, Mr. Cardwell served as interim Chief Financial Officer of VerifyMe, Inc. Since March 2021, has served as the CFO for Artemis Acquisition Corp. Mr. Cardwell graduated from Illinois State University with a Bachelor of Science degree in accounting. Upon graduation, Mr. Cardwell began his career at Arthur Andersen & Co and served as Senior Tax Consultant. For over 30 years, Mr. Cardwell served in various capacities for public and private companies Mr. Cardwell is a certified public accountant in the State of New York.

 

Zeke Kaplan, Director

 

Mr. Kaplan is a entrepreneur based out of Toronto Canada. Focused primarily in the construction and real estate industries, Zeke leads a full service construction company, ZZ Contracting, and was awarded Design Lines Top 3 Projects of 2019. His work has been featured in Dwell, Azure, Toronto Life, the Globe and Mail, Architonic, and his YouTube feature has over 1M views. He has also built a sizeable real estate portfolio focused on income generating properties. In addition to sitting on the Board of Ehave, Zeke has been very active in the startup space primarily in the e-commerce, construction, cannabis, and psychedelic industries, respectively. Zeke graduated from McGill University with a First Class Honors B.A. and was the associate editor of Cannons during his time there.

 

  B. Compensation

 

Directors

 

In the year ended December 31, 2021, each director who was not an officer was entitled to the following compensation:

 

$62,500 in common shares payable quarterly based upon an average of the closing price of the common shares during the 20 trading days immediately prior to the end of the quarter or at such time that the director has elected to take the shares,

 

Or

 

$32,500 in cash with $15,000 paid prior to December 31, 2021, and the remainder to be paid during 2022. Additionally, $1,500 per quarter for expenses for 2021 with payment to be made in 2022.

 

Committee Compensation: For serving on the audit committee of the board those committee members will receive $5,000 in cash yearly, paid quarterly

 

In the year ended December 31, 2020, each director who was not an officer was awarded 387,597 shares of the Company’s common stock.

 

32

 

 

Officers

 

Summary Compensation Table

 

The following table sets forth information concerning the total compensation paid to our officers in 2019. Our officers are paid fees in Canadian dollars. These amounts are presented in U.S. dollars and have been converted at the average rate of exchange for 2019 ($1.00 = CAD$1.3267).

 

Name and principal

position

  Year  

Salary

$

  

Share-

based

awards

$

  

Option-

based

awards

$ (1)

  

Bonus

$

  

All other

compensation

$

  

Total

compensation

$

 
Benjamin Kaplan, CEO   2021    288,000    1,282,826    -    -    120,400    1,691,226 
    2020    180,000    1,874,963    720,695    -    -    2,775,658 
Jay Cardwell   2021    18,000    -    -    -    -    18,000 
    2020    4,500    -    -    -    -    4,500 

 

Notes:

 

(1) The value of share and option-based awards are based on the grant date assumptions as disclosed in Note 9 “Stock Based Compensation” in our 2021 audited financial statements.

 

Narrative Discussion

 

We have entered into a consulting agreement with the following Executive Officers (each an “Consulting Agreement”). Pursuant to the terms of the Consulting Agreements, the salary for the year 2021 and 2020 are:

 

Name and principal position  Year   Salary $(1) 
Mr. Benjamin Kaplan   2021    288,000 
Chief Executive Officer   2020    180,000 
           
Jay Cardwell   2021    18,000 
Chief Financial Officer   2020    18,000 

 

Benjamin Kaplan

 

The Company and Mr. Kaplan entered into a CEO Consulting Agreement for a period of 36 months and sets Mr. Kaplan’s cash compensation at $24,000 per month, grants Mr. Kaplan up to an additional 5% of equity upon a “significant transaction” as defined in the Agreement and payments upon reaching certain milestones. This summary is limited by and is subject to the terms of the Agreement that is attached hereto as an Exhibit.

 

  C. Board Practices

 

Our directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced. Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced. Our officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.

 

33

 

 

Directors’ Contracts

 

We receive a director’s consent from each of the independent directors upon their acceptance of their director’s position.

 

We do not have any contracts with any of its directors which provide for benefits upon the termination of employment.

 

Compensation Committee

 

Our compensation committee consists of two outside, independent directors under Canadian law: Mr. Kaplan and Mr. Posen. Mr. Kaplan serves as chairman of the compensation committee. The members of the compensation committee have not been officers of the company. Our compensation committee is responsible for making recommendations to the board of directors regarding compensation terms for our officers and directors and for determining salaries and incentive compensation for our executive officers and incentive compensation for our other employees and consultants.

 

Audit Committee

 

Our audit committee consists of Mr. Posen and Mr. Kaplan. Mr. Posen serves as chairman of the audit committee. The audit committee’s function is to ensure that the Company’s management has designed and implemented an effective system of internal financial controls, assesses the integrity of the financial statements and related financial disclosure of the Company, and reviews the Company’s compliance with regulatory and statutory requirements as they relate to financial statements, taxation matters and disclosure of financial information. The audit committee also reports to the board of directors with respect to such matters and recommends the selection of independent auditors. Additionally, the committee monitors and reports on the independence and performance of the Company’s independent auditors.

 

  D. Employees

 

Our CEO, Benjamin Kaplan, has been our only full-time employee since he became CEO in 2019.

 

  E. Share Ownership

 

The following table sets forth certain information as of May 17, 2021, regarding the beneficial ownership of our common shares by each of our directors and all of our executive officers and directors as a group.

 

  

Number of common shares

beneficially
owned (1)

  

% of

Outstanding common

shares (2)

 
Directors and Executive Officers          
Ben Kaplan (3)   17,705,121    6.3%
Binyomin Posen   387,597    <1% 
Zeke Kaplan   387,597    <1% 
All officers and directors as a group (3 persons):   18,480,315    6.6%

 

Notes:

 

(1) Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Ordinary shares relating to options currently exercisable or exercisable within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.
   
(2)  Based on 279,525,899 shares issued and outstanding as at May 23, 2022.
   
(3) Ben Kaplan was appointed CEO on June 24, 2019. He is entitled to a 5% equity interest in the Company as a signing bonus that was not previously issued and was subsequently changed to be a warrant that was exercised for 14,136,587 shares on April 16, 2022. He was issued 3,447,844 shares for his service on the Board of Directors as of April 8, 2022. He is also entitled to 5% equity interest on a diluted bases in relation to a significant transaction clause in his consulting agreement.

 

The following table sets forth the amount and terms of options to acquire common shares of our Company we have granted to our directors, senior management and key employees:

 

Option Plan

 

Our Equity Incentive Plan, as amended (“Equity Plan”) sets the maximum number of common shares which may be issued pursuant to the Equity Plan at the lesser of 10,000,000 or 10% of the number of issued and outstanding common shares of the Company.

 

The Equity Plan authorizes the board of directors of the Company or a committee of the board of directors to issue options to directors, officers, employees and consultants of the Company.

 

The purpose of the SOP is to provide consultants, officers, directors and employees with a proprietary interest in the Company in order to: (i) increase the interest in the Company’s welfare of those individuals who share primary responsibility for the management, growth and protection of the business of the Company; (ii) furnish an incentive to such individuals to continue providing their services to the Company and its subsidiaries; and (iii) provide a means through which the Company and its subsidiaries may attract qualified persons to engage as consultants, officers, directors and employees.

 

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

 

  A. Major Shareholders

 

The following table lists the beneficial ownership of our securities as of May 23, 2022, by each person known by us to be the beneficial owner of 5% or more of the outstanding shares of any class of our securities. As of May 23, 2022, 279,525,899 of our ordinary shares were outstanding. As at May 23, 2022, with the exception of Shareholders disclosed in “Item 6.E Share Ownership”, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares, of more than 5% of the outstanding common shares, except as follows:

 

Name of Beneficial Owner 

Number of

Shares

Beneficially

Owned

  

Percentage of

Shares

Outstanding

 
Margarita Kaplinskaya   19,977,169    7.15%

 

The voting rights of our major shareholders do not differ from the voting rights of holders of our shares who are not major shareholders. Each of the above listed securities entitles the holder to one vote at our company’s shareholder meetings.

 

Shares Held in the United States

 

The following table indicates, as of May 23, 2002, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S. addresses, the portion of the outstanding common shares held by U.S. holders of record, and the percentage of common shares held by U.S. holders of record. This table does not indicate beneficial ownership of common shares.

 

Total Number of

Holders of Record

  

Total Number of

Common Shares

Issued and

Outstanding

  

Number of

US Holders

of

Record

  

Number of

Common Shares

Held by

US Holders of

Record

  

Percentage of

Common Shares Held

by US Holders of

Record

 
 59    279,525,899    18    25,568,167    9.15%

 

Change of Control

 

As of May 23, 2022, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.

 

34

 

 

Control by Others

 

To the best of the Company’s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.

 

  B. Related Party Transactions

 

Since January 1, 2020, and through the date hereof we entered into related party transactions as follows:

 

● We have entered into consulting contracts with each of our officers (see Item 6).

 

● On October 1, 2020, the Company entered into a consulting agreement with the Company’s CFO, James Cardwell for an initial term of one year, which was extended for an additional year upon its anniversary. Compensation pursuant to the agreement shall be a minimum of $1,500 per month. As of December 31, 2021 and 2020, the Company has accrued $4,500 and $16,500, respectively, as accrued expense in relations to this agreement.

 

● On January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with Benjamin Kaplan to serve as the Company’s CEO for an initial term of 36 months. As of December 31, 2021 and 2020, the Company has accrued $3,953,949 and $2,194,963, respectively, as accrued expense in relation to the Executive Consulting Agreement.

 

● During the period ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $11,000, in the aggregate, including $1,000 of original issue discount and 110,000 warrants, in the aggregate, with an exercise price of $0.01 per share. During the year ended December 31, 2021, this note was converted into 110,000 shares of common stock.

 

  C. Interests of Experts and Counsel

 

Not applicable

 

35

 

 

ITEM 8. FINANCIAL INFORMATION

 

  A. Statements and Other Financial Statements

 

Financial Statements

 

The financial statements filed as part of this annual report are filed under Item 18.

 

Legal Proceedings

 

The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.

 

The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.

 

Dividend Policy

 

We have not paid any dividends on our common shares. We anticipate that, for the foreseeable future, we will retain any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for at least the next several years. We may pay dividends on our common shares in the future if we generate profits and in accordance with the Business Corporations Act (Ontario). Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.

 

  B. Significant Changes

 

Except as otherwise disclosed in this Annual Report on Form 20-F, no significant change has occurred since December 31, 2020.

 

ITEM 9. THE OFFER AND LISTING

 

  A. Offering and Listing Details

 

Our common shares are quoted on the Pink Open Market under the symbol “EHVVF.” Our common shares were quoted on the OTCQB Venture Market under the symbol “EHVVF” from November 21, 2016, until they were removed to the Pink Open Market on April 30, 2019, because we were unable to cure our bid price deficiency. Prior to being quoted on the OTCQB Venture Market, there was no established market for our common shares. Our common shares trade and have traded on a limited or sporadic basis and should not be deemed to constitute an established public trading market. Broker-dealers often decline to trade in over-the-counter stocks that are quoted on the Pink Open Market given the market for such securities are often limited, the stocks are more volatile, and the risk to investors is greater. These factors may reduce the potential market for our common shares by reducing the number of potential investors. This may make it more difficult for investors in our common shares to sell shares to third parties or to otherwise dispose of their shares. This could cause our share price to decline, and there is no assurance that there will be liquidity in our common shares.

 

In addition, The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny stock. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to a few exceptions which we do not meet. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated therewith.

 

36

 

 

  B. Plan of Distribution

 

Not applicable

 

  C. Markets

 

Our common shares are quoted on the Pink Open Market under the symbol “EHVVF”.

 

  D. Selling Shareholders

 

Not applicable

 

  E. Dilution

 

Not applicable

 

  F. Expenses of the Issue

 

Not applicable

 

ITEM 10. ADDITIONAL INFORMATION

 

  A. Share Capital

 

Not applicable

 

  B. Memorandum and Articles of Association

 

Articles of Continuance

 

We are governed by our amended articles of incorporation (the “Articles”) under the Business Corporations Act of Ontario (the “Act”) and by our by-laws (the “By-laws”). Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.

 

Directors

 

Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director’s remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company’s articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.

 

Rights, Preferences and Dividends Attaching to Shares

 

The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.

 

On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their pro rata share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.

 

No other classes of shares are currently permitted to be issued.

 

37

 

 

Action Necessary to Change the Rights of Shareholders

 

The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class’s shareholders.

 

Annual and Special Meetings of Shareholders

 

Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21 days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the US. Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders. Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.

 

Limitations on the Rights to Own Shares

 

The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common shares.

 

Disclosure of Share Ownership

 

In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer’s outstanding voting securities is an insider and must, within 10 days of becoming an insider, file a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 10 days from the day on which the change takes place.

 

The rules in the US governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act. In general, such persons must file, within 10 days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section 13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are traded.

 

Other Provisions of Articles and By-laws

 

There are no provisions in the Articles or By-laws:

 

● delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;
   
● discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of shares;
   
● requiring disclosure of share ownership; or
   
● governing changes in capital, where such provisions are more stringent than those required by law.

 

38

 

 

  C. Material Contracts

 

We have employment contracts with our chief executive officer as summarized in Item 6B.

 

On January 21, 2021 we entered into an Asset Sale Purchase Agreement with CureDash Inc., to purchase substantial all the assets of CureDash for a total purchase price of $100,000 payable via the issuance of 353,622 shares of common stock and the payment of $60,000 in cash.

 

In December 2020, we entered into definitive agreements with Ehave, Inc., an Ontario corporation (“Ehave”), Mycotopia Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave (“MYC”), and the former and current directors of 20/20 Global that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of MYC from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management under a Change of Control and Funding Agreement. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitute approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash through a Stock Purchase Agreement with 20/20 Global stockholders Mark D. Williams, Colin Gibson, and The Robert and Joanna Williams Trust.

 

Subsequent to the year end, on May 18, 2022, Mycotopia Therapies Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Agreement” whereby the Company will merge with a wholly owned subsidiary of PSLY.com. Simultaneously E,iVentures, Inc. (“E.i”) will merge with a separate wholly owned subsidiary of PSLY.com.

 

At closing each share of common stock of the Company, par value $.001 per share (the “Company Common Stock”), issued and outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.

 

At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).

 

The closing of the Merger will take place as soon as practicable (and, in any event, within two (2) Business Days) after satisfaction of all conditions to the Mergers.

 

  D. Exchange Controls

 

Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section E, Taxation.

 

Restrictions on Share Ownership by Non-Canadians

 

There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our company, except that the Investment Canada Act (the “Investment Canada Act”) may require review and approval by the Minister of Industry (Canada) of certain acquisitions of “control” of our Company by a “non-Canadian.”

 

Investment Canada Act

 

Under the Investment Canada Act, transactions exceeding certain financial thresholds, and which involve the acquisition of control of a Canadian business by a non-Canadian, are subject to review and cannot be implemented unless the Minister of Industry and/or, in the case of a Canadian business engaged in cultural activities, the Minister of Canadian Heritage, are satisfied that the transaction is likely to be of “net benefit to Canada”. If a transaction is subject to review (a “Reviewable Transaction”), an application for review must be filed with the Investment Review Division of Industry Canada and/or the Department of Canadian Heritage prior to the implementation of the Reviewable Transaction. The responsible Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada taking into account, among other things, certain factors specified in the Investment Canada Act and any written undertakings that may have been given by the applicant. The Investment Canada Act contemplates an initial review period of up to 45 days after filing; however, if the responsible Minister has not completed the review by that date, the Minister may unilaterally extend the review period by up to 30 days (or such longer period as may be agreed to by the applicant and the Minister) to permit completion of the review. Direct acquisitions of control of most Canadian businesses by or from World Trade Organization (“WTO”) investors are reviewable under the Investment Canada Act only if, in the case of an acquisition of voting securities, the value of the worldwide assets of the Canadian business or, in the case of an acquisition of substantially all the assets of a Canadian business, the value of those assets exceed C$295 million for the year 2008 (this figure is adjusted annually to reflect inflation). Indirect acquisitions (e.g., an acquisition of a US corporation with a Canadian subsidiary) of control of such businesses by or from WTO investors are not subject to review, regardless of the value of the Canadian businesses’ assets. Significantly lower review thresholds apply where neither the investor nor the Canadian business is WTO investor controlled or where the Canadian business is engaged in uranium mining, certain cultural businesses, financial services or transportation services.

 

Even if the transaction is not reviewable because it does not meet or exceed the applicable financial threshold, the non-Canadian investor must still give notice to Industry Canada and, in the case of a Canadian business engaged in cultural activities, Canadian Heritage, of its acquisition of control of a Canadian business within 30 days of its implementation.

 

39

 

Competition Act

 

The Competition Act (Canada) (the “Competition Act”) requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the “Commissioner”) in respect of proposed transactions that exceed certain financial and other thresholds. If a proposed transaction is subject to pre-merger notification, a pre-merger notification filing must be submitted to the Commissioner and a waiting period must expire or be waived by the Commissioner before the transaction may be completed. The parties to a proposed transaction may choose to submit either a short-form filing (in respect of which there is a 14-day statutory waiting period) or a long-form filing (in respect of which there is a 42-day statutory waiting period). However, where the parties choose to submit a short-form filing, the Commissioner may, within 14 days, require that the parties submit a long-form filing, in which case the proposed transaction generally may not be completed until 42 days after the long-form filing is submitted by the parties.

 

The Commissioner may, upon request, issue an advance ruling certificate (“ARC”) in respect of a proposed transaction where she is satisfied that she would not have sufficient grounds on which to apply to the Competition Tribunal for an order under the merger provisions of the Competition Act. If the Commissioner issues an ARC in respect of a proposed transaction, the transaction is exempt from the pre-merger notification provisions. In addition, if the transaction to which the ARC relates is substantially completed within one year after the ARC is issued, the Commissioner cannot seek an order of the Competition Tribunal under the merger provisions of the Competition Act in respect of the transaction solely on the basis of information that is the same or substantially the same as the information on the basis of which the ARC was issued.

 

If the Commissioner is unwilling to issue an ARC, she may nevertheless issue a “no action” letter waiving notification and confirming that she is of the view that grounds do not then exist to initiate proceedings before the Competition Tribunal under the merger provisions of the Competition Act with respect to the proposed transaction, while preserving, during the three years following completion of the proposed transaction, her authority to initiate proceedings should circumstances change.

 

Regardless of whether pre-merger notification is required, the Commissioner may apply to the Competition Tribunal (a special purpose tribunal) for an order under the merger provisions of the Competition Act. If the Competition Tribunal finds that the transaction is or is likely to prevent or lessen competition substantially, it may order that the parties not proceed with the transaction or part of it or, in the event that the transaction has already been completed, order its dissolution or the disposition of some of the assets or shares involved. In addition, the Competition Tribunal may, with the consent of the person against whom the order is directed and the Commissioner, order that person to take any other action as is deemed necessary to remedy any substantial lessening or prevention of competition that the Competition Tribunal determines would or would likely result from the transaction.

 

  E. Taxation

 

CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

 

The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of common shares.

 

This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of common shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of common shares.

 

40

 

 

No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the “IRS”) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.

 

Scope of this Summary

 

Authorities

 

This summary is based on the Internal Revenue Code of 1986, as amended (the “Code”), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the “Canada-U.S. Tax Convention”), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.

 

U.S. Holders

 

For purposes of this summary, the term “U.S. Holder” means a beneficial owner of common shares that is for U.S. federal income tax purposes:

 

● an individual who is a citizen or resident of the United States;
   
● a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;
   
● an estate whose income is subject to U.S. federal income taxation regardless of its source; or
   
● a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

 

U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed

 

This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a “functional currency” other than the U.S. dollar; (e) own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire common shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold common shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); or (h) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Company. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada) (the “Tax Act”); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold common shares in connection with carrying on a business in Canada; (d) persons whose common shares constitute “taxable Canadian property” under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of common shares.

 

41

 

 

If an entity or arrangement that is classified as a partnership (or other “pass-through” entity) for U.S. federal income tax purposes holds common shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as “pass-through” entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of common shares.

 

Passive Foreign Investment Company Rules

 

PFIC Status of the Company

 

If the Company were to constitute a “passive foreign investment company” under the meaning of Section 1297 of the Code (a “PFIC”, as defined below) for any year during a U.S. Holder’s holding period, then certain potentially adverse rules may affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of common shares. The Company may be a PFIC for its current tax year and subsequent tax years. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.

 

In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621.

 

The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the “PFIC income test”) or (b) 50% or more of the value of the Company’s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the “PFIC asset test”). “Gross income” generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and “passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.

 

For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, “passive income” does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain “related persons” (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.

 

42

 

 

Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company’s direct or indirect equity interest in any company that is also a PFIC (a ‘‘Subsidiary PFIC’’), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any “excess distributions,” as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of common shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of common shares are made.

 

Default PFIC Rules Under Section 1291 of the Code

 

If the Company is a PFIC for any tax year during which a U.S. Holder owns common shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of common shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a “qualified electing fund” or “QEF” under Section 1295 of the Code (a “QEF Election”) or makes a mark-to-market election under Section 1296 of the Code (a “Mark-to-Market Election”). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a “Non-Electing U.S. Holder.”

 

A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of common shares and (b) any “excess distribution” received on the common shares. A distribution generally will be an “excess distribution” to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder’s holding period for the common shares, if shorter).

 

Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of common shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any “excess distribution” received on common shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder’s holding period for the respective common shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible.

 

If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds common shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such common shares were sold on the last day of the last tax year for which the Company was a PFIC.

 

QEF Election

 

A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its common shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its common shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder’s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder. Generally, “net capital gain” is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and “ordinary earnings” are the excess of (a) “earnings and profits” over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as “personal interest,” which is not deductible.

 

43

 

 

A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents “earnings and profits” of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder’s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of common shares. The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as “timely” if such QEF Election is made for the first year in the U.S. Holder’s holding period for the common shares in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder’s holding period for the common shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a “purging” election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such common shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a “purging” election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its common shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs.

 

A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.

 

U.S. Holders should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Holders with information that such U.S. Holders are required to report under the QEF rules, in the event that the Company is a PFIC. Thus, U.S. Holders may not be able to make a QEF Election with respect to their common shares. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.

 

A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.

 

Mark-to-Market Election

 

A U.S. Holder may make a Mark-to-Market Election only if the common shares are marketable stock. The common shares generally will be “marketable stock” if the common shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be “regularly traded” for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the common shares are “regularly traded” as described in the preceding sentence, the common shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this regard.

 

44

 

 

A U.S. Holder that makes a Mark-to-Market Election with respect to its common shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such common shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder’s holding period for the common shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the common shares.

 

A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares, as of the close of such tax year over (b) such U.S. Holder’s adjusted tax basis in such common shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder’s adjusted tax basis in the common shares, over (b) the fair market value of such common shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).

 

A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder’s tax basis in the common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of common shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations.

 

A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the common shares cease to be “marketable stock” or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.

 

Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the common shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.

 

Other PFIC Rules

 

Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of common shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which common shares are transferred.

 

Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses common shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such common shares.

 

Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.

 

45

 

 

The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares.

 

General Rules Applicable to the Ownership and Disposition of Common Shares

 

The following discussion describes the general rules applicable to the ownership and disposition of the common shares but is subject in its entirety to the special rules described above under the heading “Passive Foreign Investment Company Rules.”

 

Distributions on Common Shares

 

A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated “earnings and profits” of the Company, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated “earnings and profits” of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder’s tax basis in the common shares and thereafter as gain from the sale or exchange of such common shares. (See “Sale or Other Taxable Disposition of Common Shares” below). However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the common shares will constitute ordinary dividend income. Dividends received on common shares by corporate U.S. Holders generally will not be eligible for the “dividends received deduction.” Subject to applicable limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.

 

Sale or Other Taxable Disposition of Common Shares

 

Upon the sale or other taxable disposition of common shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder’s tax basis in such common shares sold or otherwise disposed of. A U.S. Holder’s tax basis in common shares generally will be such holder’s U.S. dollar cost for such common shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the common shares have been held for more than one year.

 

Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.

 

Additional Considerations

 

Additional Tax on Passive Income

 

Certain U.S. Holders that are individuals, estates or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a portion of their “net investment income,” which includes dividends on the common shares and net gains from the disposition of the common shares. Further, excess distributions treated as dividends, gains treated as excess distributions under the PFIC rules discussed above, and mark-to-market inclusions and deductions are all included in the calculation of net investment income.

 

46

 

 

Treasury Regulations provide, subject to the election described in the following paragraph, that solely for purposes of this additional tax, that distributions of previously taxed income will be treated as dividends and included in net investment income subject to the additional 3.8% tax. Additionally, to determine the amount of any capital gain from the sale or other taxable disposition of common shares that will be subject to the additional tax on net investment income, a U.S. Holder who has made a QEF Election will be required to recalculate its basis in the common shares excluding QEF basis adjustments.

 

Alternatively, a U.S. Holder may make an election which will be effective with respect to all interests in controlled foreign corporations and QEFs held in that year or acquired in future years. Under this election, a U.S. Holder pays the additional 3.8% tax on QEF income inclusions and on gains calculated after giving effect to related tax basis adjustments. U.S. Holders that are individuals, estates or trusts should consult their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the common shares.

 

Receipt of Foreign Currency

 

The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of common shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.

 

Foreign Tax Credit

 

Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the common shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder’s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder’s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.

 

Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder’s U.S. federal income tax liability that such U.S. Holder’s “foreign source” taxable income bears to such U.S. Holder’s worldwide taxable income. In applying this limitation, a U.S. Holder’s various items of income and deduction must be classified, under complex rules, as either “foreign source” or “U.S. source.” Generally, dividends paid by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty, and if an election is properly made under the Code. However, the amount of a distribution with respect to the common shares that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated separately with respect to specific categories of income. The foreign tax credit rules are complex, and each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.

 

47

 

 

Backup Withholding and Information Reporting

 

Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their common shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.

 

Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, common shares will generally be subject to information reporting and backup withholding tax, at the rate of 24%, if a U.S. Holder (a) fails to furnish such U.S. Holder’s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder’s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.

 

The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.

 

THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.

 

  F. Dividends and Paying Agents

 

Not applicable

 

  G. Statements by Experts

 

Not applicable

 

  H. Documents on Display

 

We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at http://www.sec.gov. We also make available free of charge on our website at www.ehave.com, as soon as reasonably practicable after such reports are available on the SEC website.

 

We “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form 20-F and more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form 20-F.

 

As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.

 

48

 

 

We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address Prateek Dwivedi, Chief Executive Officer, 277 Lakeshore Road East, Suite 203, Oakville, Ontario, Canada L6J 6J3, +1(905)362-1499, info@ehave.com

 

  I. Subsidiary Information

 

Mycotopia Therapies, Inc., a subsidiary of the Company, was formed in the State of Florida on December 23, 2019. On January 19, 2021 it was sold to 20/20 Global Inc., a Nevada corporation. Simultaneously with the sale of Mycotopia to 20/20 Global, Ehave acquired 75.77% of the issued and outstanding stock of 20/20 Global, making it a majority owned subsidiary. Our CEO and Chairman, Ben Kaplan is also the CEO and a director of 20/20 Global. 20/20 Global recently changed its name to Mycotopia Therapies, Inc. and trades under the symbol TPIA.

 

On May 18, 2022, Mycotopia Therapies Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Agreement” whereby the Company will merge with a wholly owned subsidiary of PSLY.com. Simultaneously E,iVentures, Inc. (“E.i”) will merge with a separate wholly owned subsidiary of PSLY.com.

 

At closing each share of common stock of the Company, par value $.001 per share (the “Company Common Stock”), issued and outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.

 

At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).

 

The closing of the Merger will take place as soon as practicable (and, in any event, within two (2) Business Days) after satisfaction of all conditions to the Mergers.

 

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Foreign Currency Risk

 

We operate primarily in Canada and the United States. Therefore, we are exposed to foreign currency risk associated with our expenses outside of Canada. We do not use financial derivative instruments to manage this market risk.

 

Interest Rate Risk

 

None of the Company’s long-term debt contain interest rate provisions that may be subject to fluctuations in market interest rates. As such, the Company does not have significant interest rate risk or has entered into any financial instruments to mitigate such risk.

 

We do not use financial instruments for trading purposes and are not parties to any leverage derivatives. We do not currently engage in hedging transactions. See “Currency and Exchange Rates” and Item 4 – “Information on the Company”.

 

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.

 

Not applicable.

PART II

 

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.

 

None

 

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.

 

  A. Modification of Instruments Defining Rights of Security Holders

 

None

 

  B. Modification or Issuance of Other Class of Securities

 

None

 

  C. Withdrawal or Substitution of Security

 

None

 

49

 

 

  D. Change of Trustee or Paying Agent

 

None

 

  E. Use of Proceeds

 

None.

 

ITEM 15. CONTROLS AND PROCEDURES

 

  A. Evaluation of Disclosures and Procedures

 

During the review by our Chief Executive Officer and Chief Financial Officer of our Company’s disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), and based on the evaluation of these controls and procedures as of the end of the period covered by this annual report, it was determined that a material weakness was identified in our controls for ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

  B. Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. As required by Rule 13a-15(c) of the Exchange Act, our management conducted an evaluation of our company’s internal control over financial reporting as of December 31, 2021, based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal controls over financial reporting were not effective due to the existence of a material weakness as it relates to a lack of sufficient segregation of duties with qualified accounting personnel to ensure financial statements are prepared timely and in accordance with applicable professional standards as of December 31, 2021. Management has since addressed this weakness and has implemented the necessary changes to have effective controls by engaging an independent outside accounting consulting firm to assist with the preparation of its financial statements and regulatory filings.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

  C. Attestation Report of the Registered Public Accounting Firms

 

Not applicable.

 

  D. Changes in Internal Controls over Financial Reporting

 

Other than changes being implemented to address the material weakness discussed above, there were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

50

 

 

ITEM 16. [RESERVED]

 

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT

 

Our Audit Committee is comprised of Mr. Posen and Mr. Kaplan Our Board has determined that Mr. Posen is an audit committee financial expert. Mr. Posen is independent either under the Rule 5605(d)(2) of the NASDAQ Capital Market and Rule 10A-3 of the Exchange Act.

 

ITEM 16B. CODE OF ETHICS

 

Our board of directors has adopted a Code of Conduct for all Company personnel, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of this Code of Conduct may be found on our website at http://www.ehave.com.

 

There were no amendments to our Code of Conduct during the fiscal year ended December 31, 2021. We did not grant any waivers to the provisions of our Code of Conduct during the fiscal year ended December 31, 2021.

 

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees and Services

 

During the financial years ended December 31, 2021, and 2020, Turner Stone and Company, L.L.P. received the following fees:

 

   2021   2020 
Item  $   $ 
Audit fees   51,720    37,975 
Audit-related fees   —    — 
Tax fees   —    — 
All other fees   —    — 
Total   51,720    37,975 

 

Audit Fees

 

Audit fees were for professional services rendered by Turner Stone and Company for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, accounting consultations and subscription to on-line accounting services.

 

Audit-related Fees

 

Audit-related fees are the aggregate fees billed for assurance and related services by Turner Stone and Company that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit Fees.

 

Tax Fees

 

Tax fees are the aggregate fees billed for professional services rendered for tax compliance, tax advice, and tax planning.

 

ll Other Fees

 

Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.

 

The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee’s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.

 

51

 

 

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

 

Not applicable.

 

ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES

 

None.

 

ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANTS

 

None.

 

ITEM 16G. CORPORATE GOVERNANCE

 

Not applicable.

 

ITEM 16H. MINE SAFETY DISCLOSURE

 

Not applicable.

 

PART III

 

ITEM 17. FINANCIAL STATEMENTS.

 

Not applicable.

 

ITEM 18 FINANCIAL STATEMENTS

 

The financial statements appear on pages F-1 through F-16.

 

52

 

 

ITEM 19. EXHIBITS.

 

The following exhibits are filed as part of this annual report:

 

Exhibit
Number		   Description
     
1.1   Articles of Incorporation (1)
1.2   Articles of Amendment to the Articles of Incorporation dated November 30, 2011 (2)
1.3   Articles of Amendment to the Articles of Incorporation dated May 13, 2015 (3)
1.4   Articles of Amendment to the Articles of Incorporation dated June 26, 2015 (4)
1.5   Articles of Amendment to the Articles of Incorporation dated November 4, 2015 (5)
1.6   Articles of Amendment to the Articles of Incorporation dated May 28, 2019 (5A)
1.7   Bylaws No. 2 (6)
4.6   License Agreement, dated April 24, 2015, between the Company and The Governing Counsel of the University of Toronto (12)
4.13   Master Services Agreement, dated December 8, 2015 with Blog Inc LLC (dba Cress & Company) (19)
4.23   Amendment to API Integration & Distribution Agreement, dated as of May 4, 2017, between the Company and MHS (29)
4.64   Executive Consulting Agreement dated June 24, 2019 between the Company and Ben Kaplan (70)
4.65   2020 Ehave Equity Incentive Plan (71)
12.1*   Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12.2*   Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
13.1*   Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13.2*   Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS+   XBRL Instance File
101.SCH+   XBRL Taxonomy Extension Schema Document
101.CAL+   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+   XBRL Taxonomy Extension Label Linkbase Document
101.PRE+   XBRL Taxonomy Presentation Linkbase Document

 

*Filed herewith

+ To be filed by amendment

 

(1) Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(2) Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(3) Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(4) Incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(5) Incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(5A) Incorporated by reference to Exhibit 3.1 to the Company’s Report on Form 6-k filed with the SEC on May 24, 2019
(6) Incorporated by reference to Exhibit 3.5 to the Form 6-K filed with the SEC on January 12, 2017.
(12) Incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(19) Incorporated by reference to Exhibit 10.27 to the Company’s Registration Statement on Form F-1/A filed with the SEC on March 11, 2016.
(29) Incorporated by reference to Exhibit 4.23 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(70) Incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K filed with the SEC on July 22, 2019
(71) Incorporated by reference to Exhibit 4.1 to the Company’s Report on Form 6-K filed with the SEC on August 20, 2020.

 

53

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

Date: May 27, 2022

 

EHAVE, INC.

 

/s/ Ben Kaplan  
Ben Kaplan  
Chief Executive Officer  
   
/s/ Jay Cardwell  
Jay Cardwell  
Chief Financial Officer  

 

54

 

 

INDEX TO

 

CONSOLIDATED FINANCIAL STATEMENTS

 

Page
Financial Statements  
   
Report of Independent Registered Accounting Firm PCAOB ID NO: 76 F – 1
Consolidated Balance Sheets as of December 31, 2021 and 2020 F – 2
Consolidated Statements of Operations and Other Comprehensive Loss for the years ended December 31, 2021 and 2020 F – 3
Consolidated Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2021 and 2020 F – 4
Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020 F – 5
Notes to the Consolidated Financial Statements F – 6

 

55

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of EHAVE, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of EHAVE, Inc. (the “Company”) as of December 31, 2021 and 2020 and the related consolidated statements of operations and other comprehensive loss, changes in stockholders’ deficit and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Explanatory Paragraph – Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered continuing losses and negative cash flows from operations, has negative working capital and accumulated deficit and negative stockholders’ equity, all of which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Turner, Stone & Company, LLP

 

We have served as the Company’s auditor since 2015.

Dallas, Texas

May 27, 2022

 

F-1
 

 

EHAVE, INC.

CONSOLIDATED BALANCE SHEETS

(Expressed in U.S. Dollars)

 

  $2021   $2020 
   As of December 31, 
   2021   2020 
         
ASSETS          
           
CURRENT ASSETS:          
Cash  $2,350,741   $1,865,110 
Prepaid expenses   -    24,247 
Investments   26,250    26,250 
Other current assets   50,000    40,000 
Total current assets   2,426,991    1,955,607 
           
Property and equipment   82,185    - 
           
TOTAL ASSETS  $2,509,176   $1,955,607 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $1,834,742   $1,349,866 
Promissory note   -    349,079 
Current portion of convertible notes, net of debt discount   1,067,199    222,493 
Total current liabilities   2,901,941    1,921,438 
           
Long-term portion of convertible notes, net of debt discount   130,147    432,578 
TOTAL LIABILITIES   3,032,088    2,354,016 
           
COMMITMENTS AND CONTINGENCIES (NOTE 6)   -     -  
           
STOCKHOLDERS’ DEFICIT:          
Common Stock, no par value, unlimited shares authorized, 244,523,925 and 67,169,962 shares issued and outstanding, respecively   24,631,466    17,328,406 
Equity payable   3,157,789    1,874,963 
Accumulated deficit   (26,316,815)   (19,729,562)
Accumulated other comprehensive income   114,597    127,784 
TOTAL EHAVE, INC. STOCKHOLDERS’ DEFICIT   1,587,037    (398,409)
Non-controlling interest   (2,109,949)   - 
TOTAL STOCKHOLDERS’ DEFICIT   (522,912)   (398,409)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $2,509,176   $1,955,607 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2
 

 

EHAVE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS

(Expressed in U.S. Dollars)

 

  $2021   $2020 
   For the Years Ended December 31, 
   2021   2020 
         
         
Operating expenses          
General and administrative  $6,681,261   $3,921,536 
           
Total operating expenses   6,681,261    3,921,536 
           
OPERATING LOSS   (6,681,261)   (3,921,536)
           
Other income (expenses)          
Interest expense   (70,953)   (141,361)
Amortization expense   (1,941,054)   (804,356)
(Loss) gain on settlement of debt   (480)   4,179,971 
Change in fair value of derivative liability   -    (3,004,387)
Other income   -    176,933 
           
Net loss from continuing operations   (8,693,748)   (3,514,736)
           
Net loss   (8,693,748)   (3,514,736)
Less: loss attributable to the noncontrolling interest   2,106,495    - 
Net loss attributable to Ehave, Inc. stockholders  $(6,587,253)  $(3,514,736)
           
Other comprehensive loss          
Foreign exchange translation adjustment   (13,187)   (13,853)
Total other comprehensive loss   (13,187)   (13,853)
           
Comprehensive loss  $(8,706,935)  $(3,528,589)
           
NET LOSS PER SHARE ATTRIBUTABLE TO EHAVE, INC. STOCKHOLDERS          
Basic and diluted  $(0.05)  $(0.11)
WEIGHTED AVERAGE SHARES OUTSTANDING:          
Basic and diluted   140,342,653    32,622,248 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

EHAVE, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Expressed in U.S. Dollars)

 

   Shares   Amount   Payable   (Deficit)  Income   Equity   Interest   Equity 
   Common Stock   Equity   Accumulated   Accumulated Other
Comprehensive		   Total
Ehave, Inc.		   Non-Controlling   Total 
   Shares   Amount   Payable   (Deficit)  Income   Equity   Interest   Equity 
Balance, January 1, 2020   25,413,920   $13,842,414   $-    (16,214,826)  $141,637   $(2,230,775)  $-   $(2,230,775)
Fair value of warrants and beneficial conversion feature issued in connection with convertible debt   -    2,112,765    -    -    -    2,112,765    -    2,112,765 
Common stock issued upon conversion of convertible promissory notes   37,818,154    378,182    -    -    -    378,182    -    378,182 
Common stock issued for Curedash   353,622    40,000    -    -    -    40,000    -    40,000 
Common stock issued for Psytech   1,050,000    26,250    -    -    -    26,250    -    26,250 
Common stock issued upon cashless warrant exercise   100,909    -    -    -    -    -    -    - 
Stock based compensation   2,433,357    928,795    -    -    -    928,795    -    928,795 
Equity payable to Chief Executive Officer   -    -    1,874,963    -    -    1,874,963         1,874,963 
Foreign exchange translation   -    -    -    -    (13,853)   (13,853)   -    (13,853)
Net loss   -    -    -    (3,514,736)   -    (3,514,736)   -    (3,514,736)
Balance, December 31, 2020   67,169,962    17,328,406    1,874,963    (19,729,562)   127,784    (398,409)   -    (398,409)
Disposal and re-acquisition of Mycotopia Therapies, Inc.   -    3,454         -    -    3,454    (3,454)   - 
Common stock issued for regulation A offerings   22,682,142    1,502,000    -    -         1,502,000    -    1,502,000 
Fair value of warrants and beneficial conversion feature issued in connection with convertible debt   -    1,512,000    -    -    -    1,512,000    -    1,512,000 
Common stock issued upon conversion of convertible promissory notes   141,635,524    1,469,004    -    -    -    1,469,004    -    1,469,004 
Common stock issued upon cashless warrant exercise   5,681,985    -    -    -    -    -    -    - 
Stock based compensation   7,354,312    2,816,602    -    -    -    2,816,602    -    2,816,602 
Equity payable to Chief Executive Officer   -    -    1,282,826    -    -    1,282,826    -    1,282,826 
Foreign exchange translation   -    -    -    -    (13,187)   (13,187)   -    (13,187)
Net loss   -    -         (6,587,253)   -    (6,587,253)   (2,106,495)   (8,693,748)
Balance, December 31, 2021   244,523,925   $24,631,466   $3,157,789    (26,316,815)  $114,597   $1,587,037   $(2,109,949)  $(522,912)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

EHAVE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in U.S. Dollars)

 

  $2021)  $2020)
   For the Years Ended December 31,
   2021   2020 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $(8,693,748)  $(3,514,736)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   19,899    - 
Stock based compensation   2,816,602    928,795 
Amortization of debt discount   1,939,675    896,348 
Non-cash interest expense   18,954    - 
Equity payable to Chief Executive Officer recorded as operating expense   1,282,826    1,874,963 
Impairment of fixed assets   100,000    - 
Loss (gain) on settlement of debt   480    (4,179,971)
Gain on forgiveness of development grant   -    (176,933)
Change in fair value of derivative liability   -    3,004,387 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   326,885    451,550 
Accounts payable and other payables   224,638    677,576 
NET CASH USED IN OPERATING ACTIVITIES   (1,963,788)   (38,021)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of fixed assets   (212,582)   - 

Proceeds from sale of subsidiary

   

350,000

    

-

 
Purchase of subsidiary   

(350,000

)   

-

 
NET CASH USED IN INVESTING ACTIVITIES   (212,582)   - 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payment of promissory notes   (349,079)   (138,561)
Net proceeds from convertible notes   1,512,000    2,238,170 
Payment of convertible notes   -    (141,000)
Financing fees   -    (63,500)
Proceeds from Reg A investment   1,502,000    - 
NET CASH PROVIDED BY FINANCING ACTIVITIES   2,664,921    1,895,109 
           
Effect of exchange rate on cash   (2,920)   (9,508)
           
Net increase (decrease) in cash   485,631    1,847,580 
           
Cash, beginning of period   1,865,110    17,530 
Cash, end of period  $2,350,741   $1,865,110 
           
NON-CASH INVESTING AND FINANCING ACTIVITIES          
Common stock issued for conversion of debt  $1,469,004   $378,182 
Common stock issued for CureDash  $-   $40,000 
Common stock issued for Psytech       $$26,250
          
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

1. ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization and General Description of Business

 

EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.

 

The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

 

Mycotopia sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.

 

Basis of Presentation and principles of consolidation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia Therapies, Inc. (“Mycotopia”) of which the Company has a 75.77% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.

 

Foreign Currency Translation

 

The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

 

Foreign Currency Risk

 

The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

 

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Software Products and Research and Development

 

Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2021 and 2020, the Company recorded $101,633 and $0, respectively, as general and administrative expense for software development costs,

 

F-6
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising expense totaled $363,450 and $0 for the years ended December 31, 2021 and 2020, respectively.

 

Property and Equipment

 

Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $100,000

 

The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:

 

Medical equipment   5 years

 

As of December 31, 2021 and 2020, property and equipment consisted of the following:

 

  $2021   $2020 
   December 31, 
   2021   2020 
Medical equipment  $102,084   $- 
Total   102,084    - 
Less, accumulated depreciation   (19,899)   - 
Equipment, net  $82,185   $- 

 

During the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of approximately $19,899 and $0, respectively.

 

Impairment of Long-lived Assets

 

Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which are believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of property and equipment or intangible assets recognized during the years ended December 31, 2021 and 2020.

 

Leases

 

The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $4,000 per month. For the year ending December 31, 2021 and 2020, rent expense was $48,000 and $0. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.

 

F-7
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Income Taxes

 

Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

 

Net Loss per Common Share, basic

 

The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase 28,770,458 common shares and 142,928,343 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

 

Recent Accounting Pronouncements

 

During the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 

2. GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern.

 

Through December 31, 2021, the Company has incurred an accumulated deficit of $26,316,815, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $8,693,748 for the year ended December 31, 2021. Our total cash balance as of December 31, 2021 was $2,350,741. At December 31, 2021, we had a working capital deficit of $474,950. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern.

 

3. FAIR VALUE MEASUREMENT

 

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Other current assets, accounts payable and accrued expenses, and convertible notes are all stated at book value due to the term and nature of such items.

 

F-8
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

4. RELATED PARTY TRANSACTIONS

 

During the period ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $11,000, in the aggregate, including $1,000 of original issue discount and 110,000 warrants, in the aggregate, with an exercise price of $0.01 per share. During the year ended December 31, 2021, this note was converted into 110,000 shares of common stock.

 

On August 4, 2020, the Company issued 775,194 shares of common stock, in the aggregate, to two individuals who are a related party and directors of the Company for services rendered.

 

Consulting Agreement with the CEO

 

On January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with Benjamin Kaplan to serve as the Company’s CEO for an initial term of 36 months. As of December 31, 2021 and 2020, the Company has recorded $210,900 and $320,000, respectively, as accrued expense in relation to the Executive Consulting Agreement. As of December 31, 2021 and 2020, the Company has accrued $3,157,789 and $1,874,963, respectively, as equity payable in relation to the Executive Consulting Agreement. During the years ending December 31, 2021 and 2020, the Company has recorded $1,691,226 and $2,194,963 as general and administrative expense in relation to the executive consulting agreement. During the year ending December 31, 2021, the Company paid $517,500 to the CEO in relation to the Executive Consulting Agreement.

 

On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of 24 months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause.

 

On June 29, 2019, the Company and BK amended the Agreement as follows:

 

BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $0.01 USD per share and shall expire April 16, 2022.

 

During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695 (see Note 7).

 

Upon the closing of a Significant Transaction (defined as the closing of financing for at least $500,000 or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $1,000,000 USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement.

 

On January 1, 2021, the Company entered into a new consulting agreement with the CEO for a term of 36 months and will automatically renew for an additional 12 months. Compensation under the January 1, 2021 agreement is as follows:

 

Annual Salary Compensation

 

The Company shall pay the CEO a fee of $24,000 per month as annual salary compensation. During the year ended December 31, 2021, the Company recorded $288,000 as general and administrative expense for the CEO fee.

 

F-9
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Bonus

 

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.

 

Bonus (Canadian Dollars)   EBITDA Milestones (Canadian Dollars)
$100,000   1st $1,000,000
$100,000   2nd $1,000,000
$100,000   3rd $1,000,000
$100,000   4th $1,000,000
$100,000   5th $1,000,000

 

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days:

 

Bonus (Shares)   Market Capitalization Milestone (Canadian Dollars) 
5,000,000   $20,000,000 
5,000,000   $40,000,000 
5,000,000   $60,000,000 
5,000,000   $80,000,000 
5,000,000   $100,000,000 

 

Stock Grants – Significant Transactions

 

Upon the Company closing of a Significant Transaction, the CEO shall be granted shares of common stock or new series of preferred shares of the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt of such completed transaction. The CEO shall earn this grant for each Significant Transaction closed by the Company. A “Significant Transaction” shall mean a licensing transaction, merger with or acquisition of an operating company in a strategic or synergistic line of business, and a financing or direct or indirect share issuance transaction involving the Company, which as a whole, provides cash flow or equivalent value in excess of $250,000. For the years ending December 31, 2021 and 2020, the Company accrued $1,282,826 and $1,874,963, respectively, as equity payable in relation to the Significant Transaction milestones being met. These amounts were recorded as general and administrative expense in the Company’s consolidated statements of operations and comprehensive loss.

 

Equity Payable to Chief Executive Officer

 

As of December 31, 2021 and 2020, the Company recorded $3,157,789 and $1,874,963, respectively, as equity payable for Significant Transactions. During the years ended December 31, 2021 and 2020, the Company recorded $1,282,826 and $1,874,963, respectively, as general and administrative expense for Significant Transactions entered into during the periods.

 

Other Expenses

 

The Company will reimburse the CEO for other expenses of $3,000 per month.

 

Assistant

 

The Company will reimburse the CEO up to $700 per weeks to hire an assistant.

 

Rent

 

The Company will reimburse the CEO up to $4,000 per month to lease office space to be used for Company matters.

 

F-10
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Consulting Agreement with CFO

 

On October 1, 2020, the Company entered into a consulting agreement with the Company’s CFO, James Cardwell for an initial term of one year, which was extended for an additional year upon its anniversary. Compensation pursuant to the agreement shall be a minimum of $1,500 per month. As of December 31, 2021 and 2020, the Company has accrued $16,500 and $4,500, respectively, as accrued expense in relations to this agreement.

 

Consulting Agreement with Chief Technology Officer

 

On January 1, 2020, the Company entered into an executive employment agreement with the Chief Technology Officer. The Company shall pay the executive $120,000 annually for services rendered. During the year ended December 31, 2021, the Company issued 2,033,016 shares of common stock with a fair value of $130,113. As of December 31, 2021 and 2020, the Company recorded $138,360 and $129,180 as accrued expenses related to this agreement.

 

5. PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES

 

Convertible Notes

 

During the years ended December 31, 2021 and 2020, the Company issued convertible promissory notes (the “Notes”) with a term 18 months upon issuance. The Notes were issued with and original issue discount (an “OID”) of 10%, and mature beginning April 2022 thru August 2022. At December 31, 2021 the Notes are convertible into 142,928,343 shares of the Company’ common stock and 1,007,500 shares of Mycotopia common stock. During the years ended December 31, 2021 and 2020, the Company issued 141,635,524 and 37,818,154, respectively, shares of common stock upon conversion of the Notes and accrued interest.

 

The following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:

 

   As of
December 31,2021		 
Convertible promissory notes, balance at January 1, 2020  $- 
Issuances   2,544,487 
Conversions   (378,182)
Debt discount   (2,407,582)
Amortization of original issue discount (interest expense)   804,356 
Amortization of BCF and warrants (amortization expense)   91,992 
Convertible promissory notes, balance at December 31, 2020   655,071 
Issuances   1,713,700 
Conversions (not inclusive of accrued interest of $44,104)   (1,424,900)
Debt discount   (1,686,200)
Amortization of original issue discount (interest expense)   355,047 
Amortization of BCF and warrants (amortization expense)   1,584,628 
Convertible promissory notes, balance at December 31, 2021  $1,197,346 

 

Promissory Note

 

On December 20, 2021, the Company entered into a settlement agreement to apply the $302,637 tax refund from OIDMTC as payment for the promissory note recorded in the amount of $349,079 as of December 31, 2020. In connection with the settlement, previous amounts of principal and accrued interest due under the promissory note were forgiven in the aggregate amount of $350,739. As part of the settlement, the Company agreed to compensate the lenders and issued $50,569 worth of common stock. For the year ended December 31, 2021, the Company recorded in its consolidated statements of operations a loss on settlement of debt in the amount of $480.

 

F-11
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

6. COMMITMENTS AND CONTINGENCIES

 

Collaboration Agreement

 

The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2021 and 2020, the Company recorded $10,000 and $5,000, respectively, for the annual royalty due under the terms of the collaboration agreement.

 

Agreements

 

On January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant $6,500 per month for services rendered to be paid $2,500 in cash and $4,000 in common shares of the Company to be valued at a 20% discount to the lowest trading price for the five trading days prior to date upon which payment is due. As of December 31 2021 and 2020, the Company recorded $75,966 and $79,159 as accrued expenses related to this agreement.

 

On November 16, 2021, the Company entered into a consulting agreement for a term of three years to advise the Company and its Ketadash Subsidiary (see “Subsequent Events”) in establishing services to be provided in California. The Company will pay the consultant a percentage of gross profits as follows: (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001. As of December 31, 2021 and the date of this filing, no amounts have been earned under this contract.

 

Medical Advisory Board Agreements

 

During the period ended December 31, 2020, the Company entered into medical advisory board agreements with four members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $45,000 in cash and $155,000 worth of stock in common stock. As of December 31, 2021 and 2020, the Company has accrued $209,836 and $105,438 in relation to these agreements.

 

7. STOCKHOLDERS’ EQUITY (DEFICIT)

 

On September 15, 2020, the Company issued 1,050,000 shares of common stock in accordance with a strategic alliance agreement and as consideration for the purchase of 1,050,000 share of Psychedelitech, Inc. (“Psychedelitech”) (a private Ontario corporation). As a result of the transaction, the Company purchased 10% of Psychedelitech. The shares were recorded at fair value on the date of issuance of $26,250. As of December 31, 2021 and 2020, the investment in Psychedelitech is recorded at cost in the amount of $26,250.

 

During the year ended December 31, 2020, the Company issued 37,818,154 shares of common stock, in the aggregate, upon conversion of $378,182 of convertible promissory notes (see Note 5).

 

During the year ended December 31, 2020, the Company issued 100,909 shares of common stock upon the cashless exercise of 110,000 warrants.

 

On December 31, 2020, the Company issued 353,622 shares of common stock in relation to an asset sale and purchase agreement entered into on January 21, 2021 with CureDash, Inc. (a Deleware Corporation) (“CureDash” or the “Seller”). The shares were recorded at fair value on the date of issuance of $40,000. As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet. On January 21, 2021, the Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase price of the assets was $100,000 payable with the issuance of the 353,622 shares of common stock and $60,000 in cash which was paid upon closing on January 21, 2021. As of December 31, 2021, the Company recorded the purchase as an asset acquisition and recorded $100,000 as fixed assets where were impaired during the year ended December 31, 2021 (see Note 1, Property and Equipment).

 

F-12
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

On January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (“20/20 Global”) that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of Mycotopioa Therapies, Inc. (“MYC”), the Company’s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock from third parties, which constitutes approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash. There was a change in control of 20/20 Global’s board of directors and the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer. The Company acquired a controlling interest in 20/20 Global, changed its name to Mycotopia Therapies, Inc. (“Mycotopia”), and consolidated Mycotopia as of December 31, 2021. The Company recorded a non-controlling interest in the amount of negative $3,454 for the disposal of MYC and re-acquisition of Mycotopia. The purpose of this transaction was to monetize the Company’s subsidiary into a publicly traded company.

 

During the year ended December 31, 2021, the Company received aggregate investments of $1,502,000 and issued 22,682,142 shares of common stock, in the aggregate, from Regulation A Offerings.

 

During the year ended December 31, 2021, the Company issued 5,681,985 shares of common stock upon the cashless exercise of 6,709,890 warrants.

 

During the year ended December 31, 2021, the Company issued 141,635,524 shares of common stock, in the aggregate, upon the conversion of convertible promissory notes and accrued interest in the amount of $1,469,004, in the aggreage. (see Note 5).

 

STOCK BASED COMPENSATION

 

During the year ended December 31, 2020, the Company entered into a finder’s fee agreement with a consultant to assist the Company in procuring sources of financing such as equity, debt, or a merger or sale of the Company. Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. During the year ending December 31, 2020, the Company issued 1,250,000 shares of common stock which was recorded at fair value of $46,875 and paid $63,500 in relation to the finder’s fee agreement. The Company recognized these amounts as interest expense in the Company’s consolidated statements of operations and other comprehensive loss during the year ended December 31, 2020.

 

During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695. The Company expensed $720,695 as general and administrative expense in relation to this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock prices of $0.37 and $0.12, b) exercise price of $0.01, c) dividend rate of 0%, d) risk free rates of 0.20% and 0.13%, and e) expected volatility of 570% and 648%.

 

During the year ended December 31, 2020, the Company issued 1,183,357 shares of common stock, in the aggregate to consultants for services rendered. The Company expensed $161,225, in the aggregate, in relation to this issuance.

 

During the year ending December 31, 2021, the Company issued 7,354,312 shares of Ehave common stock for services rendered. The Company recorded stock based compensation of $2,816,602 for the fair value of the shares issued of $534,602 and $2,282,000 as equity for services rendered to Mycotopia.

 

F-13
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Warrants Issued

 

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021 and 2020.

   Underlying
Shares		   Weighted Average Exercise Price   Weighted Average Term (Years) 
Warrants outstanding at January 1, 2020   -   $       
Granted   28,803,368    0.01    1.41 
Exercised   (110,000)   0.01      
Forfeited   -           
Warrants outstanding at December 31, 2020   28,693,368    0.01    1.12 
Granted   6,787,000    0.01    1.50 
Exercised   (6,709,890)   0.01      
Forfeited   -           
Warrant outstanding at December 31, 2021   28,770,478   $0.01    0.44 

 

The intrinsic value of warrants outstanding as of December 31, 2021 was $3,288.

 

The warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   Year Ended December 31, 
   2021   2020 
Expected term, in years   1.5    2.83 
Expected volatility   100%   162.24%
Risk free interest rate   0.11%   0.44%
Dividend yield   -    - 

 

8. INCOME TAXES

 

The Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2021 and December 31, 2020 due to the Company’s operating losses.

 

As of December 31, 2021, the Company has a net operating loss for tax purposes of CAD $15,715,067 (2020 – CAD $11,448,330) that can be carried forward over 20 years.

 

Deferred Income Taxes

 

Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows:

  $-   $- 
   2021   2020 
Deferred tax assets (liabilities):          
Deferred tax asset, beginning  $1,074,000   $741,000 
Increase in valuation reserve   2,365,000    333,000 
Deferred tax asset, ending   3,439,000    1,074,000 
Valuation allowance   (3,439,000)   (1,074,000)
Net deferred tax assets  $-   $- 

 

F-14
 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

9. SUBSEQUENT EVENTS

 

On January 8, 2022, the Company entered into a stock purchase agreement to acquire 100% of the issued and outstanding shares of Rejuv IV, Inc., a California company, (or “Ketadash”) from the seller (the “Seller”). The purchase price of the shares is $250,000 payable as follows: (i) $75,000 in cash, and (ii) $175,000 of common stock valued at the average closing price for the five trading days preceding January 8, 2022. As of the date of this filing, the Company paid 100% of the purchase price, paid the $75,000 in cash and issued 19,977,169 shares of common stock.

 

Subsequent to year end, the Company issued 15,800,000 shares of common stock upon the conversion of $158,000 of convertible debt in accordance with the terms of the agreement.

 

Subsequent to year end, the Company issued 5,055,381 to a consultant for services rendered at a fair value of approximately $75,000.

 

Subsequent to year end, the Company received 212,488 shares of Wesana Health Holdings, Inc. in exchange for all of the Company’s Psytech shares.

 

Mycotopia Merger

 

On May 18, 2022, Mycotopia entered into an Agreement and Plan of Merger (the “Agreement” whereby Mycotopia will merge with a wholly owned subsidiary of PSLY.com. Simultaneously E,iVentures, Inc. (“E.i”) will merge with a separate wholly owned subsidiary of PSLY.com.

 

At closing each share of common stock of Mycotopia, par value $.001 per share (the “Mycotopia Common Stock”), issued and outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.

 

At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).

 

The closing of the Merger will take place as soon as practicable (and, in any event, within two (2) Business Days) after satisfaction of all conditions to the Merger.

 

F-15

  

 EX-12.1 2 ex12-1.htm

 

Exhibit 12.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

 

I, Benjamin Kaplan, certify that:

 

  1. I have reviewed this annual report on Form 20-F of Ehave, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
     
  4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

  5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

Date: May 27, 2022  
   
/s/ Benjamin Kaplan  
Benjamin Kaplan  
Chief Executive Officer and Chairman  

 

 

 

 EX-12.2 3 ex12-2.htm

 

Exhibit 12.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

 

I, Jay Cardwell, certify that:

 

  1. I have reviewed this annual report on Form 20-F of Ehave, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
     
  4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

  5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

Date: May 27, 2022

 

/s/ Jay Cardwell  
Jay Cardwell  
Chief Financial Officer  

 

 

 

 EX-13.1 4 ex13-1.htm

 

Exhibit 13.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT

 

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Ehave, Inc. (the “Company”) hereby certifies, to such officer’s knowledge that:

 

  1. The accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 27, 2022

 

/s/ Benjamin Kaplan  
Benjamin Kaplan  
Chief Executive Officer and Chairman  

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 EX-13.2 5 ex13-2.htm

 

Exhibit 13.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT

 

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Ehave, Inc. (the “Company”) hereby certifies, to such officer’s knowledge that:

 

  1. The accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 27, 2022

 

/s/ Jay Cardwell  
Jay Cardwell  
Chief Financial Officer  

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 EX-101.SCH 6 ehvvf-20211231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - FAIR VALUE MEASUREMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF BONUS AND MILESTONES (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ehvvf-20211231_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ehvvf-20211231_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ehvvf-20211231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Equity Payable [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Equity [Member] Noncontrolling Interest [Member] Legal Entity [Axis] Mycotopia Therapies Inc [Member] Long-Lived Tangible Asset [Axis] Software and Software Development Costs [Member] Medical Equipment [Member] Debt Instrument [Axis] Convertible Promissory Note Three [Member] Related Party [Axis] Related Party [Member] Title of Individual [Axis] Directors [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Executive Consulting Agreement [Member] Benjamin Kaplan [Member] Statistical Measurement [Axis] Minimum [Member] Chief Executive Officer [Member] Product and Service [Axis] Service [Member] Chief Techonology Officer [Member] Award Type [Axis] Bonus One [Member] Milestones One [Member] Bonus Two [Member] Milestones Two [Member] Bonus Three [Member] Milestones Three [Member] Bonus Four [Member] Milestones Four [Member] Bonus Five [Member] Milestones Five [Member] Market Capitalization Milestones One [Member] Market Capitalization Milestones Two [Member] Market Capitalization Milestones Three [Member] Market Capitalization Milestones Four [Member] Market Capitalization Milestones Five [Member] Convertible Promissory Note [Member] Mycotopia Common Stocks [Member] Promissory Note [Member] Collaboration Agreement [Member] Medical Advisory Board Agreements [Member] Strategic Alliance Agreement [Member] Psychedelitech Inc [Member] Warrant [Member] Asset Sale And Purchase Agreement [Member] Former And Current Directors [Member] Stock Purchase Agreement [Member] Convertible Promissory Note And Accrued Interest [Member] Finder's Fee Agreement [Member] Maximum [Member] Consultant [Member] Ehave [Member] Mycotopia [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Business Acquisition [Axis] RejuvIv Inc [Member] Purchase Agreement [Member] Wesana Health Holdings Inc [Member] E,i Ventures, Inc. [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Prepaid expenses Investments Other current assets Total current assets Property and equipment TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses Promissory note Current portion of convertible notes, net of debt discount Total current liabilities Long-term portion of convertible notes, net of debt discount TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES (NOTE 6) STOCKHOLDERS’ DEFICIT: Common Stock, no par value, unlimited shares authorized, 244,523,925 and 67,169,962 shares issued and outstanding, respecively Equity payable Accumulated deficit Accumulated other comprehensive income TOTAL EHAVE, INC. STOCKHOLDERS’ DEFICIT Non-controlling interest TOTAL STOCKHOLDERS’ DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Ordinary shares, par value Ordinary shares, shares authorized Ordinary shares, shares issued Ordinary shares, shares outstanding Income Statement [Abstract] Operating expenses General and administrative Total operating expenses OPERATING LOSS Other income (expenses) Interest expense Amortization expense (Loss) gain on settlement of debt Change in fair value of derivative liability Other income Net loss from continuing operations Net loss Less: loss attributable to the noncontrolling interest Net loss attributable to Ehave, Inc. stockholders Other comprehensive loss Foreign exchange translation adjustment Total other comprehensive loss Comprehensive loss NET LOSS PER SHARE ATTRIBUTABLE TO EHAVE, INC. STOCKHOLDERS Basic and diluted WEIGHTED AVERAGE SHARES OUTSTANDING: Basic and diluted Statement [Table] Statement [Line Items] Beginning Balance Beginning balance, shares Fair value of warrants and beneficial conversion feature issued in connection with convertible debt Common stock issued upon conversion of convertible promissory notes Common stock issued upon conversion of convertible promissory notes, shares Disposal and re-acquisition of Mycotopia Therapies, Inc. Common stock issued for CureDash, shares Common stock issued for Psytech Common stock issued for Psytech,shares Common stock issued upon cashless warrant exercise Common stock issued upon cashless warrant exercise, shares Stock based compensation Stock based compensation, shares Equity payable to Chief Executive Officer Foreign exchange translation Net loss Common stock issued for regulation A offerings common stock issued for regulation A offerrings, shares Fair value of warrants and beneficial conversion feature issued in connection with convertible debt Ending Balance Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Stock based compensation Amortization of debt discount Non-cash interest expense Equity payable to Chief Executive Officer recorded as operating expense Impairment of fixed assets Loss (gain) on settlement of debt Gain on forgiveness of development grant Change in fair value of derivative liability Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable and other payables NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Proceeds from sale of subsidiary Purchase of subsidiary NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Payment of promissory notes Net proceeds from convertible notes Payment of convertible notes Financing fees Proceeds from Reg A investment NET CASH PROVIDED BY FINANCING ACTIVITIES Effect of exchange rate on cash Net increase (decrease) in cash Cash, beginning of period Cash, end of period NON-CASH INVESTING AND FINANCING ACTIVITIES Common stock issued for conversion of debt Common stock issued for CureDash Common stock issued for Psytech SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES GOING CONCERN Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENT Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ EQUITY (DEFICIT) Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Organization and General Description of Business Basis of Presentation and principles of consolidation Foreign Currency Translation Foreign Currency Risk Cash and cash equivalents Software Products and Research and Development Advertising Costs Property and Equipment Impairment of Long-lived Assets Leases Income Taxes Net Loss per Common Share, basic Recent Accounting Pronouncements SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF BONUS AND MILESTONES SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES SCHEDULE OF NOTES PAYABLE SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, plant and equipment, useful life Total Less, accumulated depreciation Equipment, net Ownership percentage General and administrative expenses Advertising expense Depreciation Lease payments Rent expenses Warrants purchased Common stock issued upon conversion securities Accumulated deficit Net loss Working capital deficit Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Bonus EBITDA Milestones Bonus Market Capitalization Milestone Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Debt instrument, principal amount Debt original issue discount Aggregate of warrants Warrants exercise price Convertion of common stock Number of shares issued for services, shares Term of notes Interest expenses Interest expenses on debt Repayments to related party debt Payments to CEO Warrant expiry date Shares issued upon exercise of warrants Warrants issued during period, value Payment for contingent consideration Payment of consideration for rendered services Annual salary compensation Annual service Payments cashflows Other expenses Reimbursement Rent payments Minimum payments Accrued expense Issuance of common stock Common stock fair value Accrued expenses Convertible promissory notes, beginning balance Issuances Conversions Debt discount Amortization of original issue discount (interest expense) Amortization of BCF and warrants (amortization expense) Convertible promissory notes, ending balance Accrued interest Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt instrument, description Common stocks shares issued Debt converted into shares Tax refund Promissory notes Promissory notes payable Lenders and issued Operations loss on debt settlements Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Annual royalty debt common shares, value Debt paid in cash Debt percentage Accrued expense Debt description Underlying Shares Beginning balance Underlying Shares Granted Weighted average exercise price, granted Weighted average remaining contractual Llfe (Years), granted Underlying Shares Exercised Weighted average exercise price, exercised Underlying Shares Forfeited Weighted average exercise price, beginning balance Weighted average remaining contractual Llfe (Years), beginning balance Underlying Shares Ending balance Weighted average exercise price, ending balance Weighted average remaining contractual Llfe (Years), ending balance Expected term, in years Expected volatility Risk-free interest rate Dividend yield Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Stock issued, shares Equity percentage Stock issued Cost of the investment Conversion of common stock shares Conversion of common stock, value Number of warrants exercised Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Purchase of shares, value Purchase of shares Non controlling interest Investment received Investment received shares Compensation for services description Stock based compensation expense Stock price Dividend rate Number of stock issued for services Outstanding, intrinsic value, warrants Deferred tax asset, beginning Increase in valuation reserve Deferred tax asset, ending Valuation allowance Net deferred tax assets Net operating, loss Net operating loss, description Subsequent Event [Table] Subsequent Event [Line Items] Issued and outstanding shares, percentage Purchase price Cash Stock issued during period value new issues Business acquisition percentage Payment to acquire productive assets Stock issued during period shares new issues Stock issued during period value conversion of convertible securities Stock Issued During Period, Shares, Issued for Services Stock Issued During Period, Value, Issued for Services Common stock par value Common stock conversion basic Working capital deficit. Convertible Promissory Note Three [Member] Related Party [Member] Directors [Member] Equity payable. Gain loss on settlement of debt. Equity Payable [Member] Executive Consulting Agreement [Member] Benjamin Kaplan [Member] Common stock issued upon cashless warrant exercise. Common stock issued upon cashless warrant exercise,shares. Stock issued during equity payable to chief executive officer. Collaboration Agreement [Member] Noncash interest expense. Gain on forgiveness of development grant. Change in fair value of derivative liability. Common stock issued for conversion of debt. Common stock issued for curedash. Common stock issued for psytech. Equity payable to chief executive officer recorded as operating expense. Impairment of fixed assets. Payment of promissory notes. Payment of convertible notes. Proceeds from reg investment. Purchase of fixed assets. Organization And General Description Of Business [Policy Text Block] Foreign Currency Risk [Policy Text Block] Medical Equipment [Member] Schedule Of Estimated Useful Life [Table Text Block] Medical Advisory Board Agreements [Member] Strategic Alliance Agreement [Member] Psychedelitech Inc [Member] Convertible Promissory Note [Member] Class of warrant or right exercised. Asset Sale And Purchase Agreement [Member] Total Equity [Member] Liu [Member] Mycotopia Therapies Inc [Member] Former And Current Directors [Member] Stock Purchase Agreement [Member] Milestones One [Member] Milestones Two [Member] Milestones Three [Member] Payments to acquire equity securities shares. Milestones Four [Member] Milestones Five [Member] Bonus One [Member] Bonus Two [Member] Bonus Three [Member] Bonus Four [Member] Bonus Five [Member] Market Capitalization Milestones One [Member] Market Capitalization Milestones Two [Member] Market Capitalization Milestones Three [Member] Market Capitalization Milestones Four [Member] Market Capitalization Milestones Five [Member] Investment received. Investment received shares. Convertible Promissory Note And Accrued Interest [Member] Finder&#8217;s fee agreement [Member] Consultant [Member] Ehave [Member] Mycotopia [Member] Conversions of notes payable. Weighted average exercise price, Granted. Weighted average exercise price, Exercised. Weighted average exercise price, Beginning balance. Mycotopia Common Stocks [Member] Weighted average remaining contractual life (Years), Beginning Balance. Weighted Average Remaining Contractual Life (Years), Ending Balance. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants in Period Weighted Average Grant Date Fair Value [Table Text Block] Chief Techonology Officer [Member] Promissory Note [Member] Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term1. Net operating loss description. Deferred tax asset increase in valuation reserve. RejuvIv Inc [Member] Purchase Agreement [Member] Wesana Health Holdings Inc [Member] Share-based compensation arrangement by share-based payment award non-options granted weighted average remaining contractual term E,i Ventures, Inc. [Member] The amount of consideration recognized during the period for the milestone or milestones. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Operating Expenses Interest Expense, Other Amortization of Debt Issuance Costs Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Adjustments to Additional Paid in Capital, Warrant Issued Share-Based Payment Arrangement, Noncash Expense GainOnForgivenessOfDevelopmentGrant ChangeInFairValueOfDerivativeLiability Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Interest in Subsidiaries and Affiliates Net Cash Provided by (Used in) Investing Activities Payments of Financing Costs ProceedsFromRegInvestment Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations CommonStockIssuedForPsytech Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Shares, Issued Convertible Notes Payable Debt Instrument, Unamortized Discount, Current Accrued Liabilities, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Weighted average exercise price, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents EX-101.PRE 10 ehvvf-20211231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
 12 Months Ended
Dec. 31, 2021
shares
Cover [Abstract]  
Document Type 20-F
Amendment Flag false
Document Registration Statement false
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Period End Date Dec. 31, 2021
Document Fiscal Period Focus FY
Document Fiscal Year Focus 2021
Current Fiscal Year End Date --12-31
Entity File Number 333-207107
Entity Registrant Name EHAVE, INC
Entity Central Index Key 0001653606
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 100 SE 2nd St
Entity Address, Address Line Two Suite 2000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33131
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Document Accounting Standard U.S. GAAP
Entity Shell Company false
Entity Common Stock, Shares Outstanding 244,523,925
ICFR Auditor Attestation Flag false
Auditor Firm ID 76
Auditor Name Turner, Stone & Company, LLP
Auditor Location Dallas, Texas
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS:    
Cash $ 2,350,741 $ 1,865,110
Prepaid expenses 24,247
Investments 26,250 26,250
Other current assets 50,000 40,000
Total current assets 2,426,991 1,955,607
Property and equipment 82,185
TOTAL ASSETS 2,509,176 1,955,607
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 1,834,742 1,349,866
Promissory note 349,079
Current portion of convertible notes, net of debt discount 1,067,199 222,493
Total current liabilities 2,901,941 1,921,438
Long-term portion of convertible notes, net of debt discount 130,147 432,578
TOTAL LIABILITIES 3,032,088 2,354,016
COMMITMENTS AND CONTINGENCIES (NOTE 6)
STOCKHOLDERS’ DEFICIT:    
Common Stock, no par value, unlimited shares authorized, 244,523,925 and 67,169,962 shares issued and outstanding, respecively 24,631,466 17,328,406
Equity payable 3,157,789 1,874,963
Accumulated deficit (26,316,815) (19,729,562)
Accumulated other comprehensive income 114,597 127,784
TOTAL EHAVE, INC. STOCKHOLDERS’ DEFICIT 1,587,037 (398,409)
Non-controlling interest (2,109,949)
TOTAL STOCKHOLDERS’ DEFICIT (522,912) (398,409)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 2,509,176 $ 1,955,607
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Ordinary shares, par value $ 0 $ 0
Ordinary shares, shares authorized Unlimited Unlimited
Ordinary shares, shares issued 244,523,925 67,169,962
Ordinary shares, shares outstanding 244,523,925 67,169,962
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses    
General and administrative $ 6,681,261 $ 3,921,536
Total operating expenses 6,681,261 3,921,536
OPERATING LOSS (6,681,261) (3,921,536)
Other income (expenses)    
Interest expense (70,953) (141,361)
Amortization expense (1,941,054) (804,356)
(Loss) gain on settlement of debt (480) 4,179,971
Change in fair value of derivative liability (3,004,387)
Other income 176,933
Net loss from continuing operations (8,693,748) (3,514,736)
Net loss (8,693,748) (3,514,736)
Less: loss attributable to the noncontrolling interest 2,106,495
Net loss attributable to Ehave, Inc. stockholders (6,587,253) (3,514,736)
Other comprehensive loss    
Foreign exchange translation adjustment (13,187) (13,853)
Total other comprehensive loss (13,187) (13,853)
Comprehensive loss $ (8,706,935) $ (3,528,589)
NET LOSS PER SHARE ATTRIBUTABLE TO EHAVE, INC. STOCKHOLDERS    
Basic and diluted $ (0.05) $ (0.11)
WEIGHTED AVERAGE SHARES OUTSTANDING:    
Basic and diluted 140,342,653 32,622,248
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statement of Changes in Stockholders' Deficit - USD ($)
Common Stock [Member]
Equity Payable [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total Equity [Member]
Noncontrolling Interest [Member]
Total
Beginning Balance at Dec. 31, 2019 $ 13,842,414 $ (16,214,826) $ 141,637 $ (2,230,775) $ (2,230,775)
Beginning balance, shares at Dec. 31, 2019 25,413,920            
Fair value of warrants and beneficial conversion feature issued in connection with convertible debt $ 2,112,765 2,112,765 2,112,765
Common stock issued upon conversion of convertible promissory notes $ 378,182 378,182 $ 378,182
Common stock issued upon conversion of convertible promissory notes, shares 37,818,154           216,630,546
Disposal and re-acquisition of Mycotopia Therapies, Inc. $ 40,000 40,000 $ 40,000
Common stock issued for CureDash, shares 353,622            
Common stock issued for Psytech $ 26,250 26,250 26,250
Common stock issued for Psytech,shares 1,050,000            
Common stock issued upon cashless warrant exercise
Common stock issued upon cashless warrant exercise, shares 100,909            
Stock based compensation $ 928,795 928,795 928,795
Stock based compensation, shares 2,433,357            
Equity payable to Chief Executive Officer 1,874,963 1,874,963   1,874,963
Foreign exchange translation (13,853) (13,853) (13,853)
Net loss (3,514,736) (3,514,736) (3,514,736)
Ending Balance at Dec. 31, 2020 $ 17,328,406 1,874,963 (19,729,562) 127,784 (398,409) (398,409)
Ending balance, shares at Dec. 31, 2020 67,169,962            
Common stock issued upon conversion of convertible promissory notes $ 1,469,004 1,469,004 $ 1,469,004
Common stock issued upon conversion of convertible promissory notes, shares 141,635,524           142,928,343
Disposal and re-acquisition of Mycotopia Therapies, Inc. $ 3,454   3,454 (3,454)
Common stock issued upon cashless warrant exercise
Common stock issued upon cashless warrant exercise, shares 5,681,985            
Stock based compensation $ 2,816,602 2,816,602 2,816,602
Stock based compensation, shares 7,354,312            
Equity payable to Chief Executive Officer 1,282,826 1,282,826 1,282,826
Foreign exchange translation (13,187) (13,187) (13,187)
Net loss   (6,587,253) (6,587,253) (2,106,495) (8,693,748)
Common stock issued for regulation A offerings $ 1,502,000   1,502,000 1,502,000
common stock issued for regulation A offerrings, shares 22,682,142            
Fair value of warrants and beneficial conversion feature issued in connection with convertible debt $ 1,512,000 1,512,000 1,512,000
Ending Balance at Dec. 31, 2021 $ 24,631,466 $ 3,157,789 $ (26,316,815) $ 114,597 $ 1,587,037 $ (2,109,949) $ (522,912)
Ending balance, shares at Dec. 31, 2021 244,523,925            
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (8,693,748) $ (3,514,736)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 19,899
Stock based compensation 2,816,602 928,795
Amortization of debt discount 1,939,675 896,348
Non-cash interest expense 18,954
Equity payable to Chief Executive Officer recorded as operating expense 1,282,826 1,874,963
Impairment of fixed assets 100,000
Loss (gain) on settlement of debt 480 (4,179,971)
Gain on forgiveness of development grant (176,933)
Change in fair value of derivative liability 3,004,387
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 326,885 451,550
Accounts payable and other payables 224,638 677,576
NET CASH USED IN OPERATING ACTIVITIES (1,963,788) (38,021)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (212,582)
Proceeds from sale of subsidiary 350,000
Purchase of subsidiary (350,000)
NET CASH USED IN INVESTING ACTIVITIES (212,582)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payment of promissory notes (349,079) (138,561)
Net proceeds from convertible notes 1,512,000 2,238,170
Payment of convertible notes (141,000)
Financing fees (63,500)
Proceeds from Reg A investment 1,502,000
NET CASH PROVIDED BY FINANCING ACTIVITIES 2,664,921 1,895,109
Effect of exchange rate on cash (2,920) (9,508)
Net increase (decrease) in cash 485,631 1,847,580
Cash, beginning of period 1,865,110 17,530
Cash, end of period 2,350,741 1,865,110
NON-CASH INVESTING AND FINANCING ACTIVITIES    
Common stock issued for conversion of debt 1,469,004 378,182
Common stock issued for CureDash 40,000
Common stock issued for Psytech   26,250
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest
Cash paid for income taxes
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization and General Description of Business

 

EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.

 

The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

 

Mycotopia sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.

 

Basis of Presentation and principles of consolidation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia Therapies, Inc. (“Mycotopia”) of which the Company has a 75.77% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.

 

Foreign Currency Translation

 

The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

 

Foreign Currency Risk

 

The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

 

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Software Products and Research and Development

 

Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2021 and 2020, the Company recorded $101,633 and $0, respectively, as general and administrative expense for software development costs,

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising expense totaled $363,450 and $0 for the years ended December 31, 2021 and 2020, respectively.

 

Property and Equipment

 

Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $100,000

 

The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:

 

Medical equipment   5 years

 

As of December 31, 2021 and 2020, property and equipment consisted of the following:

 

  $2021   $2020 
   December 31, 
   2021   2020 
Medical equipment  $102,084   $- 
Total   102,084    - 
Less, accumulated depreciation   (19,899)   - 
Equipment, net  $82,185   $- 

 

During the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of approximately $19,899 and $0, respectively.

 

Impairment of Long-lived Assets

 

Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which are believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of property and equipment or intangible assets recognized during the years ended December 31, 2021 and 2020.

 

Leases

 

The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $4,000 per month. For the year ending December 31, 2021 and 2020, rent expense was $48,000 and $0. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Income Taxes

 

Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

 

Net Loss per Common Share, basic

 

The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase 28,770,458 common shares and 142,928,343 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

 

Recent Accounting Pronouncements

 

During the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
GOING CONCERN
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

2. GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern.

 

Through December 31, 2021, the Company has incurred an accumulated deficit of $26,316,815, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $8,693,748 for the year ended December 31, 2021. Our total cash balance as of December 31, 2021 was $2,350,741. At December 31, 2021, we had a working capital deficit of $474,950. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE MEASUREMENT
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENT

3. FAIR VALUE MEASUREMENT

 

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Other current assets, accounts payable and accrued expenses, and convertible notes are all stated at book value due to the term and nature of such items.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

4. RELATED PARTY TRANSACTIONS

 

During the period ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $11,000, in the aggregate, including $1,000 of original issue discount and 110,000 warrants, in the aggregate, with an exercise price of $0.01 per share. During the year ended December 31, 2021, this note was converted into 110,000 shares of common stock.

 

On August 4, 2020, the Company issued 775,194 shares of common stock, in the aggregate, to two individuals who are a related party and directors of the Company for services rendered.

 

Consulting Agreement with the CEO

 

On January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with Benjamin Kaplan to serve as the Company’s CEO for an initial term of 36 months. As of December 31, 2021 and 2020, the Company has recorded $210,900 and $320,000, respectively, as accrued expense in relation to the Executive Consulting Agreement. As of December 31, 2021 and 2020, the Company has accrued $3,157,789 and $1,874,963, respectively, as equity payable in relation to the Executive Consulting Agreement. During the years ending December 31, 2021 and 2020, the Company has recorded $1,691,226 and $2,194,963 as general and administrative expense in relation to the executive consulting agreement. During the year ending December 31, 2021, the Company paid $517,500 to the CEO in relation to the Executive Consulting Agreement.

 

On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of 24 months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause.

 

On June 29, 2019, the Company and BK amended the Agreement as follows:

 

BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $0.01 USD per share and shall expire April 16, 2022.

 

During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695 (see Note 7).

 

Upon the closing of a Significant Transaction (defined as the closing of financing for at least $500,000 or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $1,000,000 USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement.

 

On January 1, 2021, the Company entered into a new consulting agreement with the CEO for a term of 36 months and will automatically renew for an additional 12 months. Compensation under the January 1, 2021 agreement is as follows:

 

Annual Salary Compensation

 

The Company shall pay the CEO a fee of $24,000 per month as annual salary compensation. During the year ended December 31, 2021, the Company recorded $288,000 as general and administrative expense for the CEO fee.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Bonus

 

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.

 

Bonus (Canadian Dollars)   EBITDA Milestones (Canadian Dollars)
$100,000   1st $1,000,000
$100,000   2nd $1,000,000
$100,000   3rd $1,000,000
$100,000   4th $1,000,000
$100,000   5th $1,000,000

 

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days:

 

Bonus (Shares)   Market Capitalization Milestone (Canadian Dollars) 
5,000,000   $20,000,000 
5,000,000   $40,000,000 
5,000,000   $60,000,000 
5,000,000   $80,000,000 
5,000,000   $100,000,000 

 

Stock Grants – Significant Transactions

 

Upon the Company closing of a Significant Transaction, the CEO shall be granted shares of common stock or new series of preferred shares of the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt of such completed transaction. The CEO shall earn this grant for each Significant Transaction closed by the Company. A “Significant Transaction” shall mean a licensing transaction, merger with or acquisition of an operating company in a strategic or synergistic line of business, and a financing or direct or indirect share issuance transaction involving the Company, which as a whole, provides cash flow or equivalent value in excess of $250,000. For the years ending December 31, 2021 and 2020, the Company accrued $1,282,826 and $1,874,963, respectively, as equity payable in relation to the Significant Transaction milestones being met. These amounts were recorded as general and administrative expense in the Company’s consolidated statements of operations and comprehensive loss.

 

Equity Payable to Chief Executive Officer

 

As of December 31, 2021 and 2020, the Company recorded $3,157,789 and $1,874,963, respectively, as equity payable for Significant Transactions. During the years ended December 31, 2021 and 2020, the Company recorded $1,282,826 and $1,874,963, respectively, as general and administrative expense for Significant Transactions entered into during the periods.

 

Other Expenses

 

The Company will reimburse the CEO for other expenses of $3,000 per month.

 

Assistant

 

The Company will reimburse the CEO up to $700 per weeks to hire an assistant.

 

Rent

 

The Company will reimburse the CEO up to $4,000 per month to lease office space to be used for Company matters.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Consulting Agreement with CFO

 

On October 1, 2020, the Company entered into a consulting agreement with the Company’s CFO, James Cardwell for an initial term of one year, which was extended for an additional year upon its anniversary. Compensation pursuant to the agreement shall be a minimum of $1,500 per month. As of December 31, 2021 and 2020, the Company has accrued $16,500 and $4,500, respectively, as accrued expense in relations to this agreement.

 

Consulting Agreement with Chief Technology Officer

 

On January 1, 2020, the Company entered into an executive employment agreement with the Chief Technology Officer. The Company shall pay the executive $120,000 annually for services rendered. During the year ended December 31, 2021, the Company issued 2,033,016 shares of common stock with a fair value of $130,113. As of December 31, 2021 and 2020, the Company recorded $138,360 and $129,180 as accrued expenses related to this agreement.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES

5. PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES

 

Convertible Notes

 

During the years ended December 31, 2021 and 2020, the Company issued convertible promissory notes (the “Notes”) with a term 18 months upon issuance. The Notes were issued with and original issue discount (an “OID”) of 10%, and mature beginning April 2022 thru August 2022. At December 31, 2021 the Notes are convertible into 142,928,343 shares of the Company’ common stock and 1,007,500 shares of Mycotopia common stock. During the years ended December 31, 2021 and 2020, the Company issued 141,635,524 and 37,818,154, respectively, shares of common stock upon conversion of the Notes and accrued interest.

 

The following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:

 

   As of
December 31,2021		 
Convertible promissory notes, balance at January 1, 2020  $- 
Issuances   2,544,487 
Conversions   (378,182)
Debt discount   (2,407,582)
Amortization of original issue discount (interest expense)   804,356 
Amortization of BCF and warrants (amortization expense)   91,992 
Convertible promissory notes, balance at December 31, 2020   655,071 
Issuances   1,713,700 
Conversions (not inclusive of accrued interest of $44,104)   (1,424,900)
Debt discount   (1,686,200)
Amortization of original issue discount (interest expense)   355,047 
Amortization of BCF and warrants (amortization expense)   1,584,628 
Convertible promissory notes, balance at December 31, 2021  $1,197,346 

 

Promissory Note

 

On December 20, 2021, the Company entered into a settlement agreement to apply the $302,637 tax refund from OIDMTC as payment for the promissory note recorded in the amount of $349,079 as of December 31, 2020. In connection with the settlement, previous amounts of principal and accrued interest due under the promissory note were forgiven in the aggregate amount of $350,739. As part of the settlement, the Company agreed to compensate the lenders and issued $50,569 worth of common stock. For the year ended December 31, 2021, the Company recorded in its consolidated statements of operations a loss on settlement of debt in the amount of $480.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

6. COMMITMENTS AND CONTINGENCIES

 

Collaboration Agreement

 

The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2021 and 2020, the Company recorded $10,000 and $5,000, respectively, for the annual royalty due under the terms of the collaboration agreement.

 

Agreements

 

On January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant $6,500 per month for services rendered to be paid $2,500 in cash and $4,000 in common shares of the Company to be valued at a 20% discount to the lowest trading price for the five trading days prior to date upon which payment is due. As of December 31 2021 and 2020, the Company recorded $75,966 and $79,159 as accrued expenses related to this agreement.

 

On November 16, 2021, the Company entered into a consulting agreement for a term of three years to advise the Company and its Ketadash Subsidiary (see “Subsequent Events”) in establishing services to be provided in California. The Company will pay the consultant a percentage of gross profits as follows: (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001. As of December 31, 2021 and the date of this filing, no amounts have been earned under this contract.

 

Medical Advisory Board Agreements

 

During the period ended December 31, 2020, the Company entered into medical advisory board agreements with four members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $45,000 in cash and $155,000 worth of stock in common stock. As of December 31, 2021 and 2020, the Company has accrued $209,836 and $105,438 in relation to these agreements.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (DEFICIT)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
STOCKHOLDERS’ EQUITY (DEFICIT)

7. STOCKHOLDERS’ EQUITY (DEFICIT)

 

On September 15, 2020, the Company issued 1,050,000 shares of common stock in accordance with a strategic alliance agreement and as consideration for the purchase of 1,050,000 share of Psychedelitech, Inc. (“Psychedelitech”) (a private Ontario corporation). As a result of the transaction, the Company purchased 10% of Psychedelitech. The shares were recorded at fair value on the date of issuance of $26,250. As of December 31, 2021 and 2020, the investment in Psychedelitech is recorded at cost in the amount of $26,250.

 

During the year ended December 31, 2020, the Company issued 37,818,154 shares of common stock, in the aggregate, upon conversion of $378,182 of convertible promissory notes (see Note 5).

 

During the year ended December 31, 2020, the Company issued 100,909 shares of common stock upon the cashless exercise of 110,000 warrants.

 

On December 31, 2020, the Company issued 353,622 shares of common stock in relation to an asset sale and purchase agreement entered into on January 21, 2021 with CureDash, Inc. (a Deleware Corporation) (“CureDash” or the “Seller”). The shares were recorded at fair value on the date of issuance of $40,000. As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet. On January 21, 2021, the Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase price of the assets was $100,000 payable with the issuance of the 353,622 shares of common stock and $60,000 in cash which was paid upon closing on January 21, 2021. As of December 31, 2021, the Company recorded the purchase as an asset acquisition and recorded $100,000 as fixed assets where were impaired during the year ended December 31, 2021 (see Note 1, Property and Equipment).

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

On January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (“20/20 Global”) that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of Mycotopioa Therapies, Inc. (“MYC”), the Company’s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock from third parties, which constitutes approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash. There was a change in control of 20/20 Global’s board of directors and the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer. The Company acquired a controlling interest in 20/20 Global, changed its name to Mycotopia Therapies, Inc. (“Mycotopia”), and consolidated Mycotopia as of December 31, 2021. The Company recorded a non-controlling interest in the amount of negative $3,454 for the disposal of MYC and re-acquisition of Mycotopia. The purpose of this transaction was to monetize the Company’s subsidiary into a publicly traded company.

 

During the year ended December 31, 2021, the Company received aggregate investments of $1,502,000 and issued 22,682,142 shares of common stock, in the aggregate, from Regulation A Offerings.

 

During the year ended December 31, 2021, the Company issued 5,681,985 shares of common stock upon the cashless exercise of 6,709,890 warrants.

 

During the year ended December 31, 2021, the Company issued 141,635,524 shares of common stock, in the aggregate, upon the conversion of convertible promissory notes and accrued interest in the amount of $1,469,004, in the aggreage. (see Note 5).

 

STOCK BASED COMPENSATION

 

During the year ended December 31, 2020, the Company entered into a finder’s fee agreement with a consultant to assist the Company in procuring sources of financing such as equity, debt, or a merger or sale of the Company. Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. During the year ending December 31, 2020, the Company issued 1,250,000 shares of common stock which was recorded at fair value of $46,875 and paid $63,500 in relation to the finder’s fee agreement. The Company recognized these amounts as interest expense in the Company’s consolidated statements of operations and other comprehensive loss during the year ended December 31, 2020.

 

During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695. The Company expensed $720,695 as general and administrative expense in relation to this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock prices of $0.37 and $0.12, b) exercise price of $0.01, c) dividend rate of 0%, d) risk free rates of 0.20% and 0.13%, and e) expected volatility of 570% and 648%.

 

During the year ended December 31, 2020, the Company issued 1,183,357 shares of common stock, in the aggregate to consultants for services rendered. The Company expensed $161,225, in the aggregate, in relation to this issuance.

 

During the year ending December 31, 2021, the Company issued 7,354,312 shares of Ehave common stock for services rendered. The Company recorded stock based compensation of $2,816,602 for the fair value of the shares issued of $534,602 and $2,282,000 as equity for services rendered to Mycotopia.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 

Warrants Issued

 

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021 and 2020.

   Underlying
Shares		   Weighted Average Exercise Price   Weighted Average Term (Years) 
Warrants outstanding at January 1, 2020   -   $       
Granted   28,803,368    0.01    1.41 
Exercised   (110,000)   0.01      
Forfeited   -           
Warrants outstanding at December 31, 2020   28,693,368    0.01    1.12 
Granted   6,787,000    0.01    1.50 
Exercised   (6,709,890)   0.01      
Forfeited   -           
Warrant outstanding at December 31, 2021   28,770,478   $0.01    0.44 

 

The intrinsic value of warrants outstanding as of December 31, 2021 was $3,288.

 

The warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   Year Ended December 31, 
   2021   2020 
Expected term, in years   1.5    2.83 
Expected volatility   100%   162.24%
Risk free interest rate   0.11%   0.44%
Dividend yield   -    - 

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

8. INCOME TAXES

 

The Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2021 and December 31, 2020 due to the Company’s operating losses.

 

As of December 31, 2021, the Company has a net operating loss for tax purposes of CAD $15,715,067 (2020 – CAD $11,448,330) that can be carried forward over 20 years.

 

Deferred Income Taxes

 

Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows:

  $-   $- 
   2021   2020 
Deferred tax assets (liabilities):          
Deferred tax asset, beginning  $1,074,000   $741,000 
Increase in valuation reserve   2,365,000    333,000 
Deferred tax asset, ending   3,439,000    1,074,000 
Valuation allowance   (3,439,000)   (1,074,000)
Net deferred tax assets  $-   $- 

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

 

On January 8, 2022, the Company entered into a stock purchase agreement to acquire 100% of the issued and outstanding shares of Rejuv IV, Inc., a California company, (or “Ketadash”) from the seller (the “Seller”). The purchase price of the shares is $250,000 payable as follows: (i) $75,000 in cash, and (ii) $175,000 of common stock valued at the average closing price for the five trading days preceding January 8, 2022. As of the date of this filing, the Company paid 100% of the purchase price, paid the $75,000 in cash and issued 19,977,169 shares of common stock.

 

Subsequent to year end, the Company issued 15,800,000 shares of common stock upon the conversion of $158,000 of convertible debt in accordance with the terms of the agreement.

 

Subsequent to year end, the Company issued 5,055,381 to a consultant for services rendered at a fair value of approximately $75,000.

 

Subsequent to year end, the Company received 212,488 shares of Wesana Health Holdings, Inc. in exchange for all of the Company’s Psytech shares.

 

Mycotopia Merger

 

On May 18, 2022, Mycotopia entered into an Agreement and Plan of Merger (the “Agreement” whereby Mycotopia will merge with a wholly owned subsidiary of PSLY.com. Simultaneously E,iVentures, Inc. (“E.i”) will merge with a separate wholly owned subsidiary of PSLY.com.

 

At closing each share of common stock of Mycotopia, par value $.001 per share (the “Mycotopia Common Stock”), issued and outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.

 

At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).

 

The closing of the Merger will take place as soon as practicable (and, in any event, within two (2) Business Days) after satisfaction of all conditions to the Merger.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and General Description of Business

Organization and General Description of Business

 

EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.

 

The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

 

Mycotopia sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.

 
Basis of Presentation and principles of consolidation

Basis of Presentation and principles of consolidation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia Therapies, Inc. (“Mycotopia”) of which the Company has a 75.77% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.

 
Foreign Currency Translation

Foreign Currency Translation

 

The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

 
Foreign Currency Risk

Foreign Currency Risk

 

The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

 
Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 
Software Products and Research and Development

Software Products and Research and Development

 

Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2021 and 2020, the Company recorded $101,633 and $0, respectively, as general and administrative expense for software development costs,

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 
Advertising Costs

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising expense totaled $363,450 and $0 for the years ended December 31, 2021 and 2020, respectively.

 
Property and Equipment

Property and Equipment

 

Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $100,000

 

The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:

 

Medical equipment   5 years

 

As of December 31, 2021 and 2020, property and equipment consisted of the following:

 

  $2021   $2020 
   December 31, 
   2021   2020 
Medical equipment  $102,084   $- 
Total   102,084    - 
Less, accumulated depreciation   (19,899)   - 
Equipment, net  $82,185   $- 

 

During the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of approximately $19,899 and $0, respectively.

 
Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which are believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of property and equipment or intangible assets recognized during the years ended December 31, 2021 and 2020.

 
Leases

Leases

 

The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $4,000 per month. For the year ending December 31, 2021 and 2020, rent expense was $48,000 and $0. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.

 

 

EHAVE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

 
Income Taxes

Income Taxes

 

Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

 
Net Loss per Common Share, basic

Net Loss per Common Share, basic

 

The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase 28,770,458 common shares and 142,928,343 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

During the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT

The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:

 

Medical equipment   5 years
SCHEDULE OF PROPERTY AND EQUIPMENT

As of December 31, 2021 and 2020, property and equipment consisted of the following:

 

  $2021   $2020 
   December 31, 
   2021   2020 
Medical equipment  $102,084   $- 
Total   102,084    - 
Less, accumulated depreciation   (19,899)   - 
Equipment, net  $82,185   $- 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Tables)
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
SCHEDULE OF BONUS AND MILESTONES

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.

 

Bonus (Canadian Dollars)   EBITDA Milestones (Canadian Dollars)
$100,000   1st $1,000,000
$100,000   2nd $1,000,000
$100,000   3rd $1,000,000
$100,000   4th $1,000,000
$100,000   5th $1,000,000
SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days:

 

Bonus (Shares)   Market Capitalization Milestone (Canadian Dollars) 
5,000,000   $20,000,000 
5,000,000   $40,000,000 
5,000,000   $60,000,000 
5,000,000   $80,000,000 
5,000,000   $100,000,000 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables)
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
SCHEDULE OF NOTES PAYABLE

The following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:

 

   As of
December 31,2021		 
Convertible promissory notes, balance at January 1, 2020  $- 
Issuances   2,544,487 
Conversions   (378,182)
Debt discount   (2,407,582)
Amortization of original issue discount (interest expense)   804,356 
Amortization of BCF and warrants (amortization expense)   91,992 
Convertible promissory notes, balance at December 31, 2020   655,071 
Issuances   1,713,700 
Conversions (not inclusive of accrued interest of $44,104)   (1,424,900)
Debt discount   (1,686,200)
Amortization of original issue discount (interest expense)   355,047 
Amortization of BCF and warrants (amortization expense)   1,584,628 
Convertible promissory notes, balance at December 31, 2021  $1,197,346 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021 and 2020.

   Underlying
Shares		   Weighted Average Exercise Price   Weighted Average Term (Years) 
Warrants outstanding at January 1, 2020   -   $       
Granted   28,803,368    0.01    1.41 
Exercised   (110,000)   0.01      
Forfeited   -           
Warrants outstanding at December 31, 2020   28,693,368    0.01    1.12 
Granted   6,787,000    0.01    1.50 
Exercised   (6,709,890)   0.01      
Forfeited   -           
Warrant outstanding at December 31, 2021   28,770,478   $0.01    0.44 
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS

The warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   Year Ended December 31, 
   2021   2020 
Expected term, in years   1.5    2.83 
Expected volatility   100%   162.24%
Risk free interest rate   0.11%   0.44%
Dividend yield   -    - 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS

  $-   $- 
   2021   2020 
Deferred tax assets (liabilities):          
Deferred tax asset, beginning  $1,074,000   $741,000 
Increase in valuation reserve   2,365,000    333,000 
Deferred tax asset, ending   3,439,000    1,074,000 
Valuation allowance   (3,439,000)   (1,074,000)
Net deferred tax assets  $-   $- 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)
 12 Months Ended
Dec. 31, 2021
Medical Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 5 years
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total $ 102,084
Less, accumulated depreciation (19,899)
Equipment, net 82,185
Medical Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 102,084
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
General and administrative expenses $ 6,681,261 $ 3,921,536
Advertising expense 363,450 0
Impairment of fixed assets 100,000
Depreciation 19,899
Lease payments 4,000  
Rent expenses $ 48,000 $ 0
Warrants purchased 28,770,458 28,693,368
Common stock issued upon conversion securities 142,928,343 216,630,546
Software and Software Development Costs [Member]    
General and administrative expenses $ 101,633 $ 0
Mycotopia Therapies Inc [Member]    
Ownership percentage 75.77%  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
GOING CONCERN (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 26,316,815 $ 19,729,562
Net loss 8,693,748 3,514,736
Cash 2,350,741 $ 1,865,110
Working capital deficit $ 474,950  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF BONUS AND MILESTONES (Details)
 12 Months Ended
Dec. 31, 2021
CAD ($)
Bonus One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus $ 100,000
Milestones One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
EBITDA Milestones 1,000,000
Bonus Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus 100,000
Milestones Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
EBITDA Milestones 1,000,000
Bonus Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus 100,000
Milestones Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
EBITDA Milestones 1,000,000
Bonus Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus 100,000
Milestones Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
EBITDA Milestones 1,000,000
Bonus Five [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus 100,000
Milestones Five [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
EBITDA Milestones $ 1,000,000
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details)
 12 Months Ended
Dec. 31, 2021
CAD ($)
shares
Bonus One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus | shares 5,000,000
Market Capitalization Milestones One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Market Capitalization Milestone | $ $ 20,000,000
Bonus Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus | shares 5,000,000
Market Capitalization Milestones Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Market Capitalization Milestone | $ $ 40,000,000
Bonus Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus | shares 5,000,000
Market Capitalization Milestones Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Market Capitalization Milestone | $ $ 60,000,000
Bonus Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus | shares 5,000,000
Market Capitalization Milestones Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Market Capitalization Milestone | $ $ 80,000,000
Bonus Five [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Bonus | shares 5,000,000
Market Capitalization Milestones Five [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Market Capitalization Milestone | $ $ 100,000,000
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 12 Months Ended
Jan. 02, 2021
Aug. 04, 2020
Jan. 02, 2020
Jun. 24, 2019
Dec. 31, 2021
Dec. 31, 2020
Apr. 16, 2020
Related Party Transaction [Line Items]              
Convertion of common stock         110,000    
Shares issued upon exercise of warrants         28,770,458 28,693,368  
Annual service         $ 6,681,261 $ 3,921,536  
Payments cashflows         250,000    
Rent payments         48,000 0  
Minimum payments         1,500    
Accrued expense         $ 16,500 4,500  
Issuance of common stock         2,033,016    
Common stock fair value         $ 130,113    
Service [Member]              
Related Party Transaction [Line Items]              
Annual service     $ 120,000        
Executive Consulting Agreement [Member]              
Related Party Transaction [Line Items]              
Interest expenses         210,900 320,000  
Interest expenses on debt         3,157,789 1,874,963  
Repayments to related party debt         1,691,226 2,194,963  
Payments to CEO         517,500    
Annual service         1,282,826 $ 1,874,963  
Other expenses         3,000    
Reimbursement         700    
Rent payments         4,000    
Directors [Member]              
Related Party Transaction [Line Items]              
Number of shares issued for services, shares   775,194          
Benjamin Kaplan [Member]              
Related Party Transaction [Line Items]              
Warrants exercise price           $ 0.01  
Shares issued upon exercise of warrants           3,358,498  
Warrants issued during period, value           $ 720,695  
Annual service           720,695  
Benjamin Kaplan [Member] | Executive Consulting Agreement [Member]              
Related Party Transaction [Line Items]              
Warrants exercise price             $ 0.01
Term of notes 36 months     24 months      
Warrant expiry date             Apr. 16, 2022
Benjamin Kaplan [Member] | Executive Consulting Agreement [Member] | Minimum [Member]              
Related Party Transaction [Line Items]              
Payment for contingent consideration           500,000  
Payment of consideration for rendered services           1,000,000  
Chief Executive Officer [Member]              
Related Party Transaction [Line Items]              
Annual salary compensation         24,000    
Annual service         288,000    
Chief Techonology Officer [Member]              
Related Party Transaction [Line Items]              
Accrued expenses         $ 138,360 129,180  
Related Party [Member]              
Related Party Transaction [Line Items]              
Number of shares issued for services, shares   775,194          
Convertible Promissory Note Three [Member]              
Related Party Transaction [Line Items]              
Debt instrument, principal amount           11,000  
Debt original issue discount           $ 1,000  
Aggregate of warrants           110,000  
Warrants exercise price           $ 0.01  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Debt Disclosure [Abstract]    
Convertible promissory notes, beginning balance $ 655,071
Issuances 1,713,700 2,544,487
Conversions (1,424,900) (378,182)
Debt discount (1,686,200) (2,407,582)
Amortization of original issue discount (interest expense) 355,047 804,356
Amortization of BCF and warrants (amortization expense) 1,584,628 91,992
Convertible promissory notes, ending balance $ 1,197,346 $ 655,071
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)
Dec. 31, 2021
USD ($)
Debt Disclosure [Abstract]  
Accrued interest $ 44,104
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 20, 2021
Short-Term Debt [Line Items]      
Common stocks shares issued 142,928,343    
Tax refund     $ 302,637
Promissory notes $ 349,079  
Operations loss on debt settlements 480    
Promissory Note [Member]      
Short-Term Debt [Line Items]      
Promissory notes payable 350,739    
Lenders and issued $ 50,569    
Mycotopia Common Stocks [Member]      
Short-Term Debt [Line Items]      
Common stocks shares issued 1,007,500    
Convertible Promissory Note [Member]      
Short-Term Debt [Line Items]      
Term of notes 18 months 18 months  
Debt instrument, description The Notes were issued with and original issue discount (an “OID”) of 10%, and mature beginning April 2022 thru August 2022    
Debt converted into shares 141,635,524 37,818,154  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Nov. 16, 2021
Jan. 02, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaboration Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Annual royalty     $ 10,000 $ 5,000
debt common shares, value   $ 6,500    
Debt paid in cash   2,500    
Accrued expense     75,966 79,159
Debt description (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001.      
Collaboration Agreement [Member] | Common Stock [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
debt common shares, value   $ 4,000    
Debt percentage   20.00%    
Medical Advisory Board Agreements [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Debt paid in cash       45,000
Accrued expense     $ 209,836 105,438
Medical Advisory Board Agreements [Member] | Common Stock [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
debt common shares, value       $ 155,000
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Underlying Shares Beginning balance 28,693,368
Underlying Shares Granted 6,787,000 28,803,368
Weighted average exercise price, granted $ 0.01 $ 0.01
Weighted average remaining contractual Llfe (Years), granted 1 year 6 months 1 year 4 months 28 days
Underlying Shares Exercised (6,709,890) (110,000)
Weighted average exercise price, exercised $ 0.01 $ 0.01
Underlying Shares Forfeited
Weighted average exercise price, beginning balance $ 0.01  
Weighted average remaining contractual Llfe (Years), beginning balance 1 year 1 month 13 days  
Underlying Shares Ending balance 28,770,478 28,693,368
Weighted average exercise price, ending balance $ 0.01 $ 0.01
Weighted average remaining contractual Llfe (Years), ending balance 5 months 8 days  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Expected term, in years 1 year 6 months 2 years 9 months 29 days
Expected volatility 100.00% 162.24%
Risk-free interest rate 0.11% 0.44%
Dividend yield
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)
 12 Months Ended
Jan. 21, 2021
Jan. 19, 2021
Dec. 31, 2020
Sep. 15, 2020
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued           $ 26,250
Conversion of common stock shares         142,928,343 216,630,546
Conversion of common stock, value         $ 1,469,004 $ 378,182
Number of warrants exercised     100,909     100,909
Investment received         $ 1,502,000  
Investment received shares         22,682,142  
Shares issued upon exercise of warrants     28,693,368   28,770,458 28,693,368
General and administrative expenses         $ 6,681,261 $ 3,921,536
Dividend rate        
Risk-free interest rate         0.11% 0.44%
Expected volatility         100.00% 162.24%
Outstanding, intrinsic value, warrants         $ 3,288  
Benjamin Kaplan [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Shares issued upon exercise of warrants     3,358,498     3,358,498
Warrants issued during period, value           $ 720,695
General and administrative expenses           $ 720,695
Warrants exercise price     $ 0.01     $ 0.01
Benjamin Kaplan [Member] | Minimum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock price     0.37     $ 0.37
Risk-free interest rate           0.13%
Expected volatility           648.00%
Benjamin Kaplan [Member] | Maximum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock price     $ 0.12     $ 0.12
Dividend rate           0.00%
Risk-free interest rate           0.20%
Expected volatility           570.00%
Warrant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares         5,681,985  
Stock issued         $ 6,709,890  
Number of warrants exercised     110,000     110,000
Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares           1,050,000
Stock issued           $ 26,250
Conversion of common stock shares         141,635,524 37,818,154
Conversion of common stock, value         $ 1,469,004 $ 378,182
Common Stock [Member] | Consultant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock based compensation expense           $ 161,225
Number of stock issued for services           1,183,357
Convertible Promissory Note [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Conversion of common stock shares           37,818,154
Conversion of common stock, value           $ 378,182
Convertible Promissory Note And Accrued Interest [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares         141,635,524  
Stock issued         $ 1,469,004  
Ehave [Member] | Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock based compensation expense         $ 2,816,602  
Number of stock issued for services         7,354,312  
Mycotopia [Member] | Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock based compensation expense         $ 2,282,000  
Number of stock issued for services         534,602  
Strategic Alliance Agreement [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares       1,050,000    
Strategic Alliance Agreement [Member] | Psychedelitech Inc [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares       1,050,000    
Equity percentage       10.00%    
Stock issued       $ 26,250    
Cost of the investment     $ 26,250   $ 26,250 $ 26,250
Asset Sale And Purchase Agreement [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares 100,000   353,622      
Stock issued $ 40,000          
Asset Sale And Purchase Agreement [Member] | Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares 353,622          
Stock issued $ 60,000          
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable         $ 100,000  
Stock Purchase Agreement [Member] | Former And Current Directors [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Equity percentage   75.77%        
Purchase of shares, value   $ 350,000        
Purchase of shares   9,793,754        
Stock Purchase Agreement [Member] | Common Stock [Member] | Former And Current Directors [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Purchase of shares, value   $ 350,000        
Non controlling interest   $ 3,454        
Finder's Fee Agreement [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued, shares           1,250,000
Stock issued           $ 46,875
Compensation for services description           Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent.
Stock based compensation expense           $ 63,500
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Deferred tax asset, beginning $ 1,074,000 $ 741,000
Increase in valuation reserve 2,365,000 333,000
Deferred tax asset, ending 3,439,000 1,074,000
Valuation allowance (3,439,000) (1,074,000)
Net deferred tax assets
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Details Narrative) - CAD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Net operating, loss $ 15,715,067 $ 11,448,330
Net operating loss, description carried forward over 20 years.  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 5 Months Ended 12 Months Ended
May 18, 2022
Jan. 08, 2022
May 27, 2022
Dec. 31, 2021
Dec. 31, 2020
Subsequent Event [Line Items]          
Stock issued during period value new issues         $ 26,250
Common stock issued upon conversion of convertible promissory notes, shares       142,928,343 216,630,546
Stock issued during period value conversion of convertible securities       $ 1,469,004 $ 378,182
Common stock par value       $ 0 $ 0
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Common stock issued upon conversion of convertible promissory notes, shares     15,800,000    
Stock issued during period value conversion of convertible securities     $ 158,000    
Stock Issued During Period, Shares, Issued for Services     5,055,381    
Stock Issued During Period, Value, Issued for Services     $ 75,000    
Subsequent Event [Member] | Wesana Health Holdings Inc [Member]          
Subsequent Event [Line Items]          
Stock issued during period shares new issues     212,488    
Subsequent Event [Member] | Mycotopia Therapies Inc [Member]          
Subsequent Event [Line Items]          
Common stock par value $ 0.001        
Common stock conversion basic outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.        
Subsequent Event [Member] | E,i Ventures, Inc. [Member]          
Subsequent Event [Line Items]          
Common stock conversion basic At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).        
Subsequent Event [Member] | Purchase Agreement [Member]          
Subsequent Event [Line Items]          
Stock issued during period value new issues   $ 175,000      
Payment to acquire productive assets   $ 75,000      
Stock issued during period shares new issues   19,977,169      
Subsequent Event [Member] | RejuvIv Inc [Member] | Purchase Agreement [Member]          
Subsequent Event [Line Items]          
Issued and outstanding shares, percentage   100.00%      
Purchase price   $ 250,000      
Cash   $ 75,000      
Business acquisition percentage   100.00%      
XML 49 form20-f_htm.xml IDEA: XBRL DOCUMENT 0001653606 2021-01-01 2021-12-31 0001653606 2021-12-31 0001653606 2020-12-31 0001653606 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember 2019-12-31 0001653606 EHVVF:EquityPayableMember 2019-12-31 0001653606 us-gaap:RetainedEarningsMember 2019-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001653606 EHVVF:TotalEquityMember 2019-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2019-12-31 0001653606 2019-12-31 0001653606 us-gaap:CommonStockMember 2020-12-31 0001653606 EHVVF:EquityPayableMember 2020-12-31 0001653606 us-gaap:RetainedEarningsMember 2020-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001653606 EHVVF:TotalEquityMember 2020-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2020-12-31 0001653606 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001653606 EHVVF:EquityPayableMember 2020-01-01 2020-12-31 0001653606 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001653606 EHVVF:TotalEquityMember 2020-01-01 2020-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001653606 EHVVF:EquityPayableMember 2021-01-01 2021-12-31 0001653606 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001653606 EHVVF:TotalEquityMember 2021-01-01 2021-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001653606 us-gaap:CommonStockMember 2021-12-31 0001653606 EHVVF:EquityPayableMember 2021-12-31 0001653606 us-gaap:RetainedEarningsMember 2021-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001653606 EHVVF:TotalEquityMember 2021-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2021-12-31 0001653606 EHVVF:MycotopiaTherapiesIncMember 2021-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalEquipmentMember 2021-01-01 2021-12-31 0001653606 EHVVF:MedicalEquipmentMember 2021-12-31 0001653606 EHVVF:MedicalEquipmentMember 2020-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteThreeMember 2020-12-31 0001653606 EHVVF:RelatedPartyMember 2020-08-03 2020-08-04 0001653606 EHVVF:DirectorsMember 2020-08-03 2020-08-04 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2021-01-01 2021-01-02 0001653606 EHVVF:ExecutiveConsultingAgreementMember 2021-01-01 2021-12-31 0001653606 EHVVF:ExecutiveConsultingAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2019-06-23 2019-06-24 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2020-04-16 0001653606 EHVVF:BenjaminKaplanMember 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember 2020-01-01 2020-12-31 0001653606 srt:MinimumMember EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2020-01-01 2020-12-31 0001653606 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001653606 us-gaap:ServiceMember 2020-01-01 2020-01-02 0001653606 EHVVF:ChiefTechonologyOfficerMember 2021-01-01 2021-12-31 0001653606 EHVVF:ChiefTechonologyOfficerMember 2020-01-01 2020-12-31 0001653606 EHVVF:BonusOneMember 2021-12-31 0001653606 EHVVF:MilestonesOneMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusTwoMember 2021-12-31 0001653606 EHVVF:MilestonesTwoMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusThreeMember 2021-12-31 0001653606 EHVVF:MilestonesThreeMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusFourMember 2021-12-31 0001653606 EHVVF:MilestonesFourMember 2021-01-01 2021-12-31 0001653606 EHVVF:BonusFiveMember 2021-12-31 0001653606 EHVVF:MilestonesFiveMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesOneMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesTwoMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesThreeMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFourMember 2021-01-01 2021-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFiveMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001653606 EHVVF:MycotopiaCommonStocksMember 2021-12-31 0001653606 2021-12-20 0001653606 EHVVF:PromissoryNoteMember 2021-12-31 0001653606 EHVVF:PromissoryNoteMember 2021-01-01 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2021-01-01 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-01-01 2020-01-02 0001653606 us-gaap:CommonStockMember EHVVF:CollaborationAgreementMember 2020-01-01 2020-01-02 0001653606 us-gaap:CommonStockMember EHVVF:CollaborationAgreementMember 2020-01-02 0001653606 EHVVF:CollaborationAgreementMember 2021-12-31 0001653606 EHVVF:CollaborationAgreementMember 2020-12-31 0001653606 EHVVF:CollaborationAgreementMember 2021-11-15 2021-11-16 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2021-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-12-31 0001653606 EHVVF:StrategicAllianceAgreementMember 2020-09-14 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-09-14 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-09-15 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2021-12-31 0001653606 EHVVF:StrategicAllianceAgreementMember EHVVF:PsychedelitechIncMember 2020-12-31 0001653606 us-gaap:WarrantMember 2020-12-31 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember 2020-12-30 2020-12-31 0001653606 EHVVF:AssetSaleAndPurchaseAgreementMember 2021-01-20 2021-01-21 0001653606 us-gaap:CommonStockMember EHVVF:AssetSaleAndPurchaseAgreementMember 2021-01-20 2021-01-21 0001653606 us-gaap:CommonStockMember EHVVF:AssetSaleAndPurchaseAgreementMember 2021-01-01 2021-12-31 0001653606 EHVVF:FormerAndCurrentDirectorsMember EHVVF:StockPurchaseAgreementMember 2021-01-18 2021-01-19 0001653606 EHVVF:FormerAndCurrentDirectorsMember EHVVF:StockPurchaseAgreementMember 2021-01-19 0001653606 EHVVF:FormerAndCurrentDirectorsMember us-gaap:CommonStockMember EHVVF:StockPurchaseAgreementMember 2021-01-18 2021-01-19 0001653606 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteAndAccruedInterestMember 2021-01-01 2021-12-31 0001653606 EHVVF:FindersFeeAgreementMember 2020-01-01 2020-12-31 0001653606 srt:MinimumMember EHVVF:BenjaminKaplanMember 2020-12-31 0001653606 srt:MaximumMember EHVVF:BenjaminKaplanMember 2020-12-31 0001653606 srt:MaximumMember EHVVF:BenjaminKaplanMember 2020-01-01 2020-12-31 0001653606 srt:MinimumMember EHVVF:BenjaminKaplanMember 2020-01-01 2020-12-31 0001653606 EHVVF:ConsultantMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001653606 us-gaap:CommonStockMember EHVVF:EhaveMember 2021-01-01 2021-12-31 0001653606 us-gaap:CommonStockMember EHVVF:MycotopiaMember 2021-01-01 2021-12-31 0001653606 EHVVF:RejuvIvIncMember us-gaap:SubsequentEventMember EHVVF:PurchaseAgreementMember 2022-01-07 2022-01-08 0001653606 EHVVF:RejuvIvIncMember us-gaap:SubsequentEventMember EHVVF:PurchaseAgreementMember 2022-01-08 0001653606 us-gaap:SubsequentEventMember EHVVF:PurchaseAgreementMember 2022-01-07 2022-01-08 0001653606 us-gaap:SubsequentEventMember 2022-01-01 2022-05-27 0001653606 us-gaap:SubsequentEventMember EHVVF:WesanaHealthHoldingsIncMember 2022-01-01 2022-05-27 0001653606 us-gaap:SubsequentEventMember EHVVF:MycotopiaTherapiesIncMember 2022-05-18 0001653606 us-gaap:SubsequentEventMember EHVVF:MycotopiaTherapiesIncMember 2022-05-17 2022-05-18 0001653606 us-gaap:SubsequentEventMember EHVVF:EiVenturesIncMember 2022-05-17 2022-05-18 iso4217:USD shares iso4217:USD shares pure iso4217:CAD 0001653606 false FY Unlimited Unlimited 20-F false true 2021-12-31 --12-31 2021 false false 333-207107 EHAVE, INC Z4 100 SE 2nd St Suite 2000 Miami FL 33131 244523925 No No No Yes Yes Non-accelerated Filer true true false U.S. GAAP false 76 Turner, Stone & Company, LLP Dallas, Texas 2350741 1865110 24247 26250 26250 50000 40000 2426991 1955607 82185 2509176 1955607 1834742 1349866 349079 1067199 222493 2901941 1921438 130147 432578 3032088 2354016 0 0 244523925 244523925 67169962 67169962 24631466 17328406 3157789 1874963 -26316815 -19729562 114597 127784 1587037 -398409 -2109949 -522912 -398409 2509176 1955607 6681261 3921536 6681261 3921536 -6681261 -3921536 70953 141361 1941054 804356 -480 4179971 -3004387 176933 -8693748 -3514736 -8693748 -3514736 -2106495 -6587253 -3514736 -13187 -13853 -13187 -13853 -8706935 -3528589 -0.05 -0.11 140342653 32622248 25413920 13842414 -16214826 141637 -2230775 -2230775 2112765 2112765 2112765 37818154 378182 378182 378182 353622 40000 40000 40000 1050000 26250 26250 26250 100909 2433357 928795 928795 928795 1874963 1874963 1874963 -13853 -13853 -13853 -3514736 -3514736 -3514736 67169962 17328406 1874963 -19729562 127784 -398409 -398409 17328406 1874963 -19729562 127784 -398409 -398409 3454 3454 -3454 22682142 1502000 1502000 1502000 1512000 1512000 1512000 141635524 1469004 1469004 1469004 5681985 7354312 2816602 2816602 2816602 1282826 1282826 1282826 -13187 -13187 -13187 -6587253 -6587253 -2106495 -8693748 244523925 24631466 3157789 -26316815 114597 1587037 -2109949 -522912 24631466 3157789 -26316815 114597 1587037 -2109949 -522912 -8693748 -3514736 19899 2816602 928795 1939675 896348 18954 1282826 1874963 100000 -480 4179971 176933 3004387 -326885 -451550 224638 677576 -1963788 -38021 -212582 350000 350000 -212582 -349079 -138561 1512000 2238170 -141000 63500 -1502000 2664921 1895109 -2920 -9508 485631 1847580 1865110 17530 2350741 1865110 1469004 378182 40000 26250 <p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_ztTShNvL1bf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>1. <span id="xdx_825_zQw8xCSM9fab">ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_845_ecustom--OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock_zsyYnJ7Po2Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Organization and General Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mycotopia sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zCvKWwfRow19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Basis of Presentation and principles of consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia Therapies, Inc. (“Mycotopia”) of which the Company has a <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__dei--LegalEntityAxis__custom--MycotopiaTherapiesIncMember_zDEy4TeB9Uad" title="Ownership percentage">75.77</span>% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLPm9hvhkTGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Foreign Currency Translation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_840_ecustom--ForeignCurrencyRiskPolicyTextBlock_zdkhnU6AkKS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Foreign Currency Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3RUcqDrhUx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Cash and cash equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84D_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zDbzcIxCKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Software Products and Research and Development</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2021 and 2020, the Company recorded $<span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPjXJCgYBDqg" title="General and administrative expenses">101,633</span> and $<span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpuqdJ2bRUD5" title="General and administrative expenses">0</span>, respectively, as general and administrative expense for software development costs,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zN6HGkgVh4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Advertising Costs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company expenses advertising costs as incurred. Advertising expense totaled $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_z2sBgicAVeo8" title="Advertising expense">363,450</span> and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20200101__20201231_zwSg8hRnw1Id" title="Advertising expense">0</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9Jt6LLvEqUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Property and Equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $<span id="xdx_90D_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zcGEADENQWAc" title="Impairment of fixed assets">100,000</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BD_zfZIWxHw8kY7" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zMBKEWHm8L7j" title="Property, plant and equipment, useful life">5 years</span></span></td></tr> </table> <p id="xdx_8AF_zQxbKuUl5gkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2021 and 2020, property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_zo7nOYtNin0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zyeNnvwBNnG4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less, accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,899</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zMqGV4wGYhZi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zJtXUGEjJ498" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of approximately $<span id="xdx_903_eus-gaap--Depreciation_c20210101__20211231_zYhXuxAaKwY3" title="Depreciation">19,899</span> and $<span id="xdx_90D_eus-gaap--Depreciation_dxL_c20200101__20201231_z7on2cMpCXSe" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0584">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUsng7qo4wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Impairment of Long-lived Assets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which ar</span>e believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of property and equipment or intangible assets recognized during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zHuxoai4lCM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $<span id="xdx_908_eus-gaap--ProceedsFromLeasePayments_c20210101__20211231_zrLvvxODEsS6" title="Lease payments">4,000</span> per month. For the year ending December 31, 2021 and 2020, rent expense was $<span id="xdx_901_eus-gaap--PaymentsForRent_c20210101__20211231_zWpdEpbfSW8k" title="Rent expenses">48,000</span> and $<span id="xdx_902_eus-gaap--PaymentsForRent_c20200101__20201231_z8SWSgKinvE4" title="Rent expenses">0</span>. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zTTdaJpC1Rn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Income Taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zSRvKMgpcGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Net Loss per Common Share, basic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zTuY1I1PmNJf" title="Warrants purchased">28,770,458</span> common shares and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231_zCATv1nbq4wb" title="Common stock issued upon conversion securities">142,928,343</span> common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2020, the Company had outstanding warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231_zkCtU5vpeWGb" title="Warrants purchased">28,693,368 </span>common shares and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200101__20201231_z1VO0DzjxzOl" title="Common stock issued upon conversion securities">216,630,546</span> common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7YwpEm0Ibzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Recent Accounting Pronouncements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_845_ecustom--OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock_zsyYnJ7Po2Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Organization and General Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mycotopia sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zCvKWwfRow19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Basis of Presentation and principles of consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia Therapies, Inc. (“Mycotopia”) of which the Company has a <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__dei--LegalEntityAxis__custom--MycotopiaTherapiesIncMember_zDEy4TeB9Uad" title="Ownership percentage">75.77</span>% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 0.7577 <p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLPm9hvhkTGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Foreign Currency Translation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_840_ecustom--ForeignCurrencyRiskPolicyTextBlock_zdkhnU6AkKS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Foreign Currency Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3RUcqDrhUx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Cash and cash equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84D_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zDbzcIxCKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Software Products and Research and Development</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2021 and 2020, the Company recorded $<span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPjXJCgYBDqg" title="General and administrative expenses">101,633</span> and $<span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpuqdJ2bRUD5" title="General and administrative expenses">0</span>, respectively, as general and administrative expense for software development costs,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 101633 0 <p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zN6HGkgVh4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Advertising Costs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company expenses advertising costs as incurred. Advertising expense totaled $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_z2sBgicAVeo8" title="Advertising expense">363,450</span> and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20200101__20201231_zwSg8hRnw1Id" title="Advertising expense">0</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 363450 0 <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9Jt6LLvEqUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Property and Equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $<span id="xdx_90D_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zcGEADENQWAc" title="Impairment of fixed assets">100,000</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BD_zfZIWxHw8kY7" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zMBKEWHm8L7j" title="Property, plant and equipment, useful life">5 years</span></span></td></tr> </table> <p id="xdx_8AF_zQxbKuUl5gkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2021 and 2020, property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_zo7nOYtNin0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zyeNnvwBNnG4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less, accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,899</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zMqGV4wGYhZi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zJtXUGEjJ498" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of approximately $<span id="xdx_903_eus-gaap--Depreciation_c20210101__20211231_zYhXuxAaKwY3" title="Depreciation">19,899</span> and $<span id="xdx_90D_eus-gaap--Depreciation_dxL_c20200101__20201231_z7on2cMpCXSe" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0584">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 100000 <p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BD_zfZIWxHw8kY7" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zMBKEWHm8L7j" title="Property, plant and equipment, useful life">5 years</span></span></td></tr> </table> P5Y <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2021 and 2020, property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_zo7nOYtNin0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,084</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zyeNnvwBNnG4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less, accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,899</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zMqGV4wGYhZi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 102084 102084 19899 82185 19899 <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUsng7qo4wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Impairment of Long-lived Assets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which ar</span>e believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of property and equipment or intangible assets recognized during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zHuxoai4lCM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $<span id="xdx_908_eus-gaap--ProceedsFromLeasePayments_c20210101__20211231_zrLvvxODEsS6" title="Lease payments">4,000</span> per month. For the year ending December 31, 2021 and 2020, rent expense was $<span id="xdx_901_eus-gaap--PaymentsForRent_c20210101__20211231_zWpdEpbfSW8k" title="Rent expenses">48,000</span> and $<span id="xdx_902_eus-gaap--PaymentsForRent_c20200101__20201231_z8SWSgKinvE4" title="Rent expenses">0</span>. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 4000 48000 0 <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zTTdaJpC1Rn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Income Taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zSRvKMgpcGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Net Loss per Common Share, basic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zTuY1I1PmNJf" title="Warrants purchased">28,770,458</span> common shares and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231_zCATv1nbq4wb" title="Common stock issued upon conversion securities">142,928,343</span> common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2020, the Company had outstanding warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231_zkCtU5vpeWGb" title="Warrants purchased">28,693,368 </span>common shares and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200101__20201231_z1VO0DzjxzOl" title="Common stock issued upon conversion securities">216,630,546</span> common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 28770458 142928343 28693368 216630546 <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7YwpEm0Ibzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Recent Accounting Pronouncements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zqsTKmn9uLFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>2. <span id="xdx_822_z60LLl0ThxRg">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Through December 31, 2021, the Company has incurred an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zsrLifsyzrta" title="Accumulated deficit">26,316,815</span>, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $<span id="xdx_903_eus-gaap--ProfitLoss_iN_pp0p0_di_c20210101__20211231_zytkZ2mB0nek" title="Net loss">8,693,748</span> for the year ended December 31, 2021. Our total cash balance as of December 31, 2021 was $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_z2n23ah0JTy3" title="Cash">2,350,741</span>. At December 31, 2021, we had a working capital deficit of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20211231_zqwu8nNfVt5" title="Working capital deficit">474,950</span>. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> -26316815 -8693748 2350741 474950 <p id="xdx_801_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zjA5ihXZILP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>3. <span id="xdx_827_zWlp7XQZJKVg">FAIR VALUE MEASUREMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Other current assets, accounts payable and accrued expenses, and convertible notes are all stated at book value due to the term and nature of such items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zH7mzfCdAVL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>4. <span id="xdx_82D_zXmL0W3U7PUf">RELATED PARTY TRANSACTIONS </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the period ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_pp0p0" title="Debt instrument, principal amount">11,000</span>, in the aggregate, including $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_pp0p0" title="Debt original issue discount">1,000</span> of original issue discount and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_zZcnuXrhbbOf" title="Aggregate of warrants">110,000</span> warrants, in the aggregate, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_zuvv0uSvFRQ3" title="Warrants exercise price">0.01</span> per share. During the year ended December 31, 2021, this note was converted into <span id="xdx_907_eus-gaap--CommonStockDividendsShares_pid_c20210101__20211231_zi32McH4iHOi" title="Convertion of common stock">110,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On August 4, 2020, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200803__20200804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_z9yCxzAFsXgg" title="Number of shares issued for services, shares"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200803__20200804__srt--TitleOfIndividualAxis__custom--DirectorsMember_zxZ53FRD8tO9" title="Number of shares issued for services, shares">775,194</span></span> shares of common stock, in the aggregate, to two individuals who are a related party and directors of the Company for services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="text-decoration: underline">Consulting Agreement with the CEO</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with Benjamin Kaplan to serve as the Company’s CEO for an initial term of <span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zHoxzQ0IrxX" title="Term of notes">36</span> months. As of December 31, 2021 and 2020, the Company has recorded $<span id="xdx_900_eus-gaap--InterestExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zY3K9xJKevI" title="Interest expenses">210,900</span> and $<span id="xdx_900_eus-gaap--InterestExpense_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zINIrCrcDdF7" title="Interest expenses">320,000</span>, respectively, as accrued expense in relation to the Executive Consulting Agreement. As of December 31, 2021 and 2020, the Company has accrued $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zDjlJSTdnXO" title="Interest expenses on debt">3,157,789</span> and $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zzMXYOZrAGWg" title="Interest expenses on debt">1,874,963</span>, respectively, as equity payable in relation to the Executive Consulting Agreement. During the years ending December 31, 2021 and 2020, the Company has recorded $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zmvv3pwf2ANc" title="Repayments to related party debt">1,691,226</span> and $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_pp0p0" title="Repayments to related party debt">2,194,963</span> as general and administrative expense in relation to the executive consulting agreement. During the year ending December 31, 2021, the Company paid $<span id="xdx_904_eus-gaap--PaymentsToEmployees_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z6GzxRIzdVAk" title="Payments to CEO">517,500</span> to the CEO in relation to the Executive Consulting Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of <span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20190623__20190624__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_znkWl0co1so9" title="Term of notes">24</span> months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On June 29, 2019, the Company and BK amended the Agreement as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zQgjBpQzTuh9" title="Warrants exercise price">0.01</span> USD per share and shall expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z3Rg9HSsfur" title="Warrant expiry date">April 16, 2022</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company issued <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zCoqWTic4KZc" title="Shares issued upon exercise of warrants">3,358,498</span> vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $<span id="xdx_90A_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_pdp0_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zmWQ3ccprVf6" title="Warrants issued during period, value">720,695</span> (see Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Upon the closing of a Significant Transaction (defined as the closing of financing for at least $<span id="xdx_905_eus-gaap--PaymentForContingentConsiderationLiabilityFinancingActivities_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Payment for contingent consideration">500,000</span> or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $<span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Payment of consideration for rendered services">1,000,000</span> USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 1, 2021, the Company entered into a new consulting agreement with the CEO for a term of <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtM_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zN67zSY8xV46">36</span> months and will automatically renew for an additional 12 months. Compensation under the January 1, 2021 agreement is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Annual Salary Compensation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company shall pay the CEO a fee of $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zyuMb19qwj7h" title="Annual salary compensation">24,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">per month as annual salary compensation. During the year ended December 31, 2021, the Company recorded $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuCvDfZl8ag1" title="General and administrative expense">288,000</span> as general and administrative expense for the CEO fee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Bonus</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zjkKxneFkRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B7_zJJp43T5yRu7" style="display: none">SCHEDULE OF BONUS AND MILESTONES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus (Canadian Dollars)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA Milestones (Canadian Dollars)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 40%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zyqifyjtB7T5" title="Bonus">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1<sup>st </sup>$<span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember_zERmxAD2OCwh" title="Milestones">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zxPo2QkPlvVc">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2<sup>nd </sup>$<span id="xdx_90E_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember_zH6FBzSbrnJg">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zBh1b2i6K0Qj">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3<sup>rd </sup>$<span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember_ziiK0GmQG0R1">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zeUUPl0HJ957">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4<sup>th </sup>$<span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember_ziWQA0jQI0u4">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zN5PmOdmdYz5">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5<sup>th </sup>$<span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember_zoSKPsJIyTpe" title="EBITDA Milestones">1,000,000</span></span></td></tr> </table> <p id="xdx_8AA_zbeLJ2RudWlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_893_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zdyOOOaagc74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BC_zQsWSfHCx7Zc" style="display: none">SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus (Shares)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Capitalization Milestone (Canadian Dollars)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98F_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zTC7LBZqvwg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 41%; color: Black; text-align: left" title="Bonus"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 54%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zB0dHHGPhmza">20,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zkZpGnShiQoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zVg1AZCKd2Fk">40,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98D_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zbpj6AEICy8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zzEFuBc87UU5">60,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zc53F3qNrRWb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_z8qFHZ405hmi" title="Market Capitalization Milestone">80,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zkpS9cN0kXdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zBmtO8Xcxibk" title="Market Capitalization Milestone">100,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_zAC6YgbAoDWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock Grants – Significant Transactions</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Upon the Company closing of a Significant Transaction, the CEO shall be granted shares of common stock or new series of preferred shares of the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt of such completed transaction. The CEO shall earn this grant for each Significant Transaction closed by the Company. A “Significant Transaction” shall mean a licensing transaction, merger with or acquisition of an operating company in a strategic or synergistic line of business, and a financing or direct or indirect share issuance transaction involving the Company, which as a whole, provides cash flow or equivalent value in excess of $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zIV09zjVr8U6" title="Payments cashflows">250,000</span>. For the years ending December 31, 2021 and 2020, the Company accrued $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z1pm0M8vzlza" title="General and administrative expenses">1,282,826</span> and $<span id="xdx_903_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z2uOQyj66Rrk">1,874,963</span>, respectively, as equity payable in relation to the Significant Transaction milestones being met. These amounts were recorded as general and administrative expense in the Company’s consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Equity Payable to Chief Executive Officer</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2021 and 2020, the Company recorded $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zFMnspTUbmrk">3,157,789</span> and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zEMY0SzKo559">1,874,963</span>, respectively, as equity payable for Significant Transactions. During the years ended December 31, 2021 and 2020, the Company recorded $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z0suVJUGVN98">1,282,826</span> and $<span id="xdx_909_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z0Jny0Gz7dkd">1,874,963</span>, respectively, as general and administrative expense for Significant Transactions entered into during the periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Other Expenses</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will reimburse the CEO for other expenses of $<span id="xdx_902_eus-gaap--OtherGeneralExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zAixx6VE8nYc" title="Other expenses">3,000</span> per month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Assistant</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will reimburse the CEO up to $<span id="xdx_909_eus-gaap--InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zs9ONAI6wpKh" title="Reimbursement">700</span> per weeks to hire an assistant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Rent</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will reimburse the CEO up to $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zPxzWe82HH44" title="Rent payments">4,000</span> per month to lease office space to be used for Company matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Consulting Agreement with CFO</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On October 1, 2020, the Company entered into a consulting agreement with the Company’s CFO, James Cardwell for an initial term of one year, which was extended for an additional year upon its anniversary. Compensation pursuant to the agreement shall be a minimum of $<span id="xdx_909_eus-gaap--CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1_iI_c20211231_zMd3saVbJnSc" title="Minimum payments">1,500</span> per month. As of December 31, 2021 and 2020, the Company has accrued $<span id="xdx_907_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20211231_zYvprCw2kVY2" title="Accrued expense">16,500</span> and $<span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20201231_zUgbq7PQfzQg">4,500</span>, respectively, as accrued expense in relations to this agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Consulting Agreement with Chief Technology Officer</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 1, 2020, the Company entered into an executive employment agreement with the Chief Technology Officer. The Company shall pay the executive $<span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20200102__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zeyCaAP55WGh" title="Annual service">120,000</span> annually for services rendered. During the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231_zUEzRmakBhyc" title="Issuance of common stock">2,033,016</span> shares of common stock with a fair value of $<span id="xdx_90F_eus-gaap--AdvancesFairValueDisclosure_iI_c20211231_zJLOjQ2DGTTf" title="Common stock fair value">130,113</span>. As of December 31, 2021 and 2020, the Company recorded $<span id="xdx_901_eus-gaap--CostsAndExpenses_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChiefTechonologyOfficerMember_zTSIzKLxBPf" title="Accrued expenses">138,360</span> and $<span id="xdx_909_eus-gaap--CostsAndExpenses_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ChiefTechonologyOfficerMember_zHIjZF001oxh">129,180</span> as accrued expenses related to this agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 11000 1000 110000 0.01 110000 775194 775194 P36M 210900 320000 3157789 1874963 1691226 2194963 517500 P24M 0.01 2022-04-16 3358498 720695 500000 1000000 P36M 24000 288000 <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zjkKxneFkRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B7_zJJp43T5yRu7" style="display: none">SCHEDULE OF BONUS AND MILESTONES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus (Canadian Dollars)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBITDA Milestones (Canadian Dollars)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 40%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zyqifyjtB7T5" title="Bonus">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1<sup>st </sup>$<span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember_zERmxAD2OCwh" title="Milestones">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zxPo2QkPlvVc">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2<sup>nd </sup>$<span id="xdx_90E_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember_zH6FBzSbrnJg">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zBh1b2i6K0Qj">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3<sup>rd </sup>$<span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember_ziiK0GmQG0R1">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zeUUPl0HJ957">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4<sup>th </sup>$<span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember_ziWQA0jQI0u4">1,000,000</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zN5PmOdmdYz5">100,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5<sup>th </sup>$<span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember_zoSKPsJIyTpe" title="EBITDA Milestones">1,000,000</span></span></td></tr> </table> 100000 1000000 100000 1000000 100000 1000000 100000 1000000 100000 1000000 <p id="xdx_893_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zdyOOOaagc74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BC_zQsWSfHCx7Zc" style="display: none">SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus (Shares)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Capitalization Milestone (Canadian Dollars)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98F_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zTC7LBZqvwg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 41%; color: Black; text-align: left" title="Bonus"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 54%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zB0dHHGPhmza">20,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zkZpGnShiQoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zVg1AZCKd2Fk">40,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_98D_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zbpj6AEICy8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zzEFuBc87UU5">60,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zc53F3qNrRWb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_z8qFHZ405hmi" title="Market Capitalization Milestone">80,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zkpS9cN0kXdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zBmtO8Xcxibk" title="Market Capitalization Milestone">100,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5000000 20000000 5000000 40000000 5000000 60000000 5000000 80000000 5000000 100000000 250000 1282826 1874963 3157789 1874963 1282826 1874963 3000 700 4000 1500 16500 4500 120000 2033016 130113 138360 129180 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zEFbCBoqK4N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>5. <span id="xdx_822_zUffHR9c4Mx7">PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Convertible Notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the years ended December 31, 2021 and 2020, the Company issued convertible promissory notes (the “Notes”) with a term <span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtM_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zvCrZhxA9of2" title="Term of notes"><span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zS8VZCMRuXr8" title="Term of notes">18</span></span> months upon issuance. <span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember" title="Debt instrument, description">The Notes were issued with and original issue discount (an “OID”) of 10%, and mature beginning April 2022 thru August 2022</span>. At December 31, 2021 the Notes are convertible into <span id="xdx_90C_eus-gaap--ExcessStockSharesIssued_iI_pid_c20211231_zaD5ulnuihA6" title="Common stocks shares issued">142,928,343</span> shares of the Company’ common stock and <span id="xdx_90F_eus-gaap--ExcessStockSharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--MycotopiaCommonStocksMember_zJDnAUy9UBxe">1,007,500</span> shares of Mycotopia common stock. During the years ended December 31, 2021 and 2020, the Company issued <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zmMJYRAWApHl" title="Debt converted into shares">141,635,524</span> and <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zB7nsshFXK22" title="Debt converted into shares">37,818,154</span>, respectively, shares of common stock upon conversion of the Notes and accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_zjxEjYiPKoQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B7_zHIaVpXMzXXl" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of <br/> December 31,2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zmf5czgGQtoh" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20200101__20201231_zaQ9rh85dANb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; color: Black; text-align: right" title="Issuances"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,544,487</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversions</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_ecustom--ConversionsOfNotesPayable_c20200101__20201231_zdXQbz1rIH5c" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Conversions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(378,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20201231_zPqKabgSVcQf" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Debt discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,407,582</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of original issue discount (interest expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_ztFab3vAtdq5" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of original issue discount (interest expense)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">804,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of BCF and warrants (amortization expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20200101__20201231_zBuq7PHefDU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of BCF and warrants (amortization expense)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_zrf4uyY8dyNa" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">655,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20210101__20211231_zn5MWLcRM5Id" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,713,700</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversions (not inclusive of accrued interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zQN4XiTGIYpj" title="Accrued interest">44,104</span>)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--ConversionsOfNotesPayable_c20210101__20211231_zXhBO6vRf4Ie" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,424,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20211231_zLpnfGkdIQPj" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,686,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of original issue discount (interest expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_zao7B0NOSS89" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,047</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of BCF and warrants (amortization expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231_zq49cI9TI148" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,584,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zVRDsuxIK7kk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,197,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zPfAOUYNYGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Promissory Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 20, 2021, the Company entered into a settlement agreement to apply the $<span id="xdx_90D_eus-gaap--ContractWithCustomerRefundLiability_iI_c20211220_zM3L5O2bbM45" title="Tax refund">302,637</span> tax refund from OIDMTC as payment for the promissory note recorded in the amount of $<span id="xdx_90E_eus-gaap--NotesPayableCurrent_iI_c20201231_zhY9x6WKTCQ8" title="Promissory notes">349,079</span> as of December 31, 2020. In connection with the settlement, previous amounts of principal and accrued interest due under the promissory note were forgiven in the aggregate amount of $<span id="xdx_900_eus-gaap--NotesPayable_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zKrTS7tZbXa4" title="Promissory notes payable">350,739</span>. As part of the settlement, the Company agreed to compensate the lenders and issued $<span id="xdx_90A_eus-gaap--StockIssued1_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zy80EtMVWTtb" title="Lenders and issued">50,569</span> worth of common stock. For the year ended December 31, 2021, the Company recorded in its consolidated statements of operations a loss on settlement of debt in the amount of $<span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20210101__20211231_zm8KCAzZlv5a" title="Operations loss on debt settlements">480</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> P18M P18M The Notes were issued with and original issue discount (an “OID”) of 10%, and mature beginning April 2022 thru August 2022 142928343 1007500 141635524 37818154 <p id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_zjxEjYiPKoQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8B7_zHIaVpXMzXXl" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of <br/> December 31,2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zmf5czgGQtoh" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20200101__20201231_zaQ9rh85dANb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; color: Black; text-align: right" title="Issuances"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,544,487</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversions</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_ecustom--ConversionsOfNotesPayable_c20200101__20201231_zdXQbz1rIH5c" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Conversions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(378,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20201231_zPqKabgSVcQf" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Debt discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,407,582</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of original issue discount (interest expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_ztFab3vAtdq5" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of original issue discount (interest expense)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">804,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of BCF and warrants (amortization expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20200101__20201231_zBuq7PHefDU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of BCF and warrants (amortization expense)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_zrf4uyY8dyNa" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">655,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20210101__20211231_zn5MWLcRM5Id" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,713,700</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversions (not inclusive of accrued interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zQN4XiTGIYpj" title="Accrued interest">44,104</span>)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--ConversionsOfNotesPayable_c20210101__20211231_zXhBO6vRf4Ie" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,424,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20211231_zLpnfGkdIQPj" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,686,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of original issue discount (interest expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_zao7B0NOSS89" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,047</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of BCF and warrants (amortization expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231_zq49cI9TI148" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,584,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, balance at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zVRDsuxIK7kk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,197,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2544487 -378182 2407582 804356 91992 655071 1713700 44104 -1424900 1686200 355047 1584628 1197346 302637 349079 350739 50569 480 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmN8yrCVdPN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>6. <span id="xdx_823_zHLoWLV3Jl41">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="text-decoration: underline">Collaboration Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2021 and 2020, the Company recorded $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zKKC01E9kzt5" title="Annual royalty">10,000</span> and $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z8weR8EACvhd" title="Annual royalty">5,000</span>, respectively, for the annual royalty due under the terms of the collaboration agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="text-decoration: underline">Agreements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant $<span id="xdx_900_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqch94Fy5uW2" title="Payment for consultants">6,500</span> per month for services rendered to be paid $<span id="xdx_900_eus-gaap--RepaymentsOfOtherDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zULfZQpqsnP" title="Debt paid in cash">2,500</span> in cash and $<span id="xdx_905_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmAB3YIZyxb7" title="debt common shares, value">4,000</span> in common shares of the Company to be valued at a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJRjzuQg0wF5" title="Debt percentage">20</span>% discount to the lowest trading price for the five trading days prior to date upon which payment is due. As of December 31 2021 and 2020, the Company recorded $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z8FytkTamZw1" title="Accrued expense">75,966</span> and $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqpLCrvV1Ho6" title="Accrued expense">79,159</span> as accrued expenses related to this agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On November 16, 2021, the Company entered into a consulting agreement for a term of three years to advise the Company and its Ketadash Subsidiary (see “Subsequent Events”) in establishing services to be provided in California. The Company will pay the consultant a percentage of gross profits as follows: <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20211115__20211116__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zGjGjPnX5Fsi" title="Debt description">(i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001.</span> As of December 31, 2021 and the date of this filing, no amounts have been earned under this contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Medical Advisory Board Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the period ended December 31, 2020, the Company entered into medical advisory board agreements with four members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $<span id="xdx_906_eus-gaap--RepaymentsOfOtherDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zxINacV1yvJb" title="Debt paid in cash">45,000</span> in cash and $<span id="xdx_907_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwRiRIclaUul">155,000</span> worth of stock in common stock. As of December 31, 2021 and 2020, the Company has accrued $<span id="xdx_907_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zto7lbZ5pthb" title="Accrued expense">209,836</span> and $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zU1CmkqFG8lj" title="Accrued expense">105,438</span> in relation to these agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 10000 5000 6500 2500 4000 0.20 75966 79159 (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001. 45000 155000 209836 105438 <p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgmzX1AyQ7c4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>7. <span id="xdx_82E_zvr8oPqoIfKc">STOCKHOLDERS’ EQUITY (DEFICIT)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On September 15, 2020, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember_zGnisc7rGsIj" title="Common stock issued, shares">1,050,000</span> shares of common stock in accordance with a strategic alliance agreement and as consideration for the purchase of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zfAndyFoFgGj" title="Common stock purchase, shares">1,050,000</span> share of Psychedelitech, Inc. (“Psychedelitech”) (a private Ontario corporation). As a result of the transaction, the Company purchased <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zQ1457Q2B0ce" style="font: 10pt Times New Roman, Times, Serif" title="Equity percentage">10</span>% of Psychedelitech. The shares were recorded at fair value on the date of issuance of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zrBYU3CBwha" title="Common stock fair value issued">26,250</span>. As of December 31, 2021 and 2020, the investment in Psychedelitech is recorded at cost in the amount of $<span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_z4EWDXcRziCd" title="Cost of the investment"><span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zzd3UMJOkAR1">26,250</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zW92W1JbrEr" title="Conversion of common stock shares">37,818,154</span> shares of common stock, in the aggregate, upon conversion of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z6FGh0cB3Wjj" title="Conversion of common stock, value">378,182</span> of convertible promissory notes (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company issued <span id="xdx_904_ecustom--ClassOfWarrantOrRightExercised_iI_c20201231_zkKxIAZW7gI4" title="Number of warrants exercised">100,909</span> shares of common stock upon the cashless exercise of <span id="xdx_909_ecustom--ClassOfWarrantOrRightExercised_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6oL2Agyz3K2" title="Number of warrants exercised">110,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2020, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201230__20201231__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z3LLWTfuOHCb">353,622 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of common stock in relation to an asset sale and purchase agreement entered into on January 21, 2021 with CureDash, Inc. (a Deleware Corporation) (“CureDash” or the “Seller”). The shares were recorded at fair value on the date of issuance of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z7sMo612LQ5">40,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">. As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet. On January 21, 2021, the Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase price of the assets was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z8CnjFB7yLik">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">payable with the issuance of the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb11h3d8rlOb">353,622 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of common stock and $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYCdDXB72Sd4">60,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">in cash which was paid upon closing on January 21, 2021. As of December 31, 2021, the Company recorded the purchase as an asset acquisition and recorded $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgvyBZajC1c">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">as fixed assets where were impaired during the year ended December 31, 2021 (see Note 1, Property and Equipment).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (“20/20 Global”) that provide for: (i) 20/20 Global’s purchase for $<span id="xdx_90C_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zM9OinbzzIxg" title="Purchase of shares, value">350,000</span> in cash of all of the outstanding stock of Mycotopioa Therapies, Inc. (“MYC”), the Company’s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management. In a related transaction, Ehave agreed to purchase <span id="xdx_90C_ecustom--PaymentsToAcquireEquitySecuritiesShares_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zf7669AZabL1" title="Purchase of shares">9,793,754</span> shares of 20/20 Global common stock from third parties, which constitutes approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z62R4qe9oKu5" title="Equity percentage">75.77</span>% of the issued and outstanding shares of 20/20 Global’s common stock, for $<span id="xdx_901_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhJVSFf4TXv8" title="Purchase of shares, value">350,000</span> in cash. There was a change in control of 20/20 Global’s board of directors and the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer. The Company acquired a controlling interest in 20/20 Global, changed its name to Mycotopia Therapies, Inc. (“Mycotopia”), and consolidated Mycotopia as of December 31, 2021. The Company recorded a non-controlling interest in the amount of negative $<span id="xdx_908_eus-gaap--NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqORO7pDR9F8" title="Non controlling interest">3,454</span> for the disposal of MYC and re-acquisition of Mycotopia. The purpose of this transaction was to monetize the Company’s subsidiary into a publicly traded company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2021, the Company received aggregate investments of $<span id="xdx_90B_ecustom--InvestmentReceived_c20210101__20211231_zyZrXh9AHOEc" title="Investment received">1,502,000</span> and issued <span id="xdx_901_ecustom--InvestmentReceivedShares_c20210101__20211231_zyZj8RyziDba" title="Investment received shares">22,682,142</span> shares of common stock, in the aggregate, from Regulation A Offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6u8fU1qOo4g" title="Common stock issued, shares">5,681,985</span> shares of common stock upon the cashless exercise of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z24MXcH38Tc1" title="Common stock issued warrant, shares">6,709,890</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteAndAccruedInterestMember_zGlGmNzxDEOj" title="Common stock issued, shares">141,635,524</span> shares of common stock, in the aggregate, upon the conversion of convertible promissory notes and accrued interest in the amount of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteAndAccruedInterestMember_z6MDOaCTXZvb" title="Common stock issued, value">1,469,004</span>, in the aggreage. (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>STOCK BASED COMPENSATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company entered into a finder’s fee agreement with a consultant to assist the Company in procuring sources of financing such as equity, debt, or a merger or sale of the Company. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_z6Oq543aD7ll" title="Compensation for services description">Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent.</span> During the year ending December 31, 2020, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zjvrHjve6oW5" title="Stock issued, shares">1,250,000</span> shares of common stock which was recorded at fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zRFWMxfNRfn7" title="Stock issued">46,875</span> and paid $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zyV7UO60qKBh" title="Stock based compensation expense">63,500</span> in relation to the finder’s fee agreement. The Company recognized these amounts as interest expense in the Company’s consolidated statements of operations and other comprehensive loss during the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company issued <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zZgCT2NgyYl4" title="Shares issued upon exercise of warrants">3,358,498</span> vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $<span id="xdx_90D_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z0p0lih1ZPN9" title="Warrants issued during period, value">720,695</span>. The Company expensed $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z9K47AzlUPHd" title="General and administrative expenses">720,695</span> as general and administrative expense in relation to this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock prices of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zkn23SGTrM37" title="Stock price">0.37</span> and $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zPSfGAttRPC5" title="Stock price">0.12</span>, b) exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zBqBYMwu8sZ2" title="Warrants exercise price">0.01</span>, c) dividend rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zEQJM1BOKdhi" title="Dividend rate">0</span>%, d) risk free rates of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zUAEKCVD7DAl" title="Risk-free interest rate">0.20</span>% and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zTq8XPRoOhp9" title="Risk-free interest rate">0.13</span>%, and e) expected volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zxxRV9eDHc0e" title="Expected volatility">570</span>% and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zylceUgHbaY7" title="Expected volatility">648</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2020, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zb6vk9IGSVAk" title="Number of stock issued for services">1,183,357</span> shares of common stock, in the aggregate to consultants for services rendered. The Company expensed $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zlgZsEzu3LX5" title="Stock based compensation expense">161,225</span>, in the aggregate, in relation to this issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ending December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EhaveMember_z0MPP0HMWHpd" title="Number of stock issued for services">7,354,312</span> shares of Ehave common stock for services rendered. The Company recorded stock based compensation of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EhaveMember_zhvwqnVIZ2Yd" title="Stock based compensation expense">2,816,602</span> for the fair value of the shares issued of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MycotopiaMember_zhKdJFdOIGw7" title="Number of stock issued for services">534,602</span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MycotopiaMember_z5KJXHf0Ttzb" title="Stock based compensation expense">2,282,000</span> as equity for services rendered to Mycotopia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Warrants Issued</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_znstxQtlpet" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zomrxm5uHCk6" style="display: none">SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying <br/>Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Term (Years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zPvx7tzY2k23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_zAoPVYxy0sq1" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Underlying Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,803,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zWlqJ5YrXFth" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zAqp2FQv0Ag7" title="Weighted average remaining contractual Llfe (Years), granted">1.41</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20200101__20201231_zCOn8XLsK783" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20200101__20201231_zXVvuLOYhOBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_zDRHQoXcmFca" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zoPtixTnwqX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,693,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zFbo1uifNyL3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5Yje2NBvRWd" title="Weighted average remaining contractual Llfe (Years), beginning balance">1.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zQPqF9mFTqxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,787,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGcZ4RermwPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z7csjRGBvGJj" title="Weighted average remaining contractual Llfe (Years), granted">1.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zQxjwRBR2oVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,709,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210101__20211231_zH94SJYCq237" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zLKR9WkOpsoh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_zXENby9aH0Ml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,770,478</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zFe1I4xuYop2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231_zy8MeWaGJ9ed" title="Weighted average remaining contractual Llfe (Years), ending balance">0.44</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zP7Kcb661PK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The intrinsic value of warrants outstanding as of December 31, 2021 was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zFjJKkxPN2Q" title="Outstanding, intrinsic value, warrants">3,288</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_z6c677kY2hp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BA_zX0FAp6E6b05" style="display: none">SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term, in years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zbFtCQFfc98" title="Expected term, in years">1.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1DeD6o9wjS9" title="Expected term, in years">2.83</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zabF38jn0oll" title="Expected volatility">100</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zlvvIatxWoP5" title="Expected volatility">162.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zTi9Kelhj1mb" title="Risk-free interest rate">0.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zO685fyGsQH9" title="Risk-free interest rate">0.44</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_z0aZbH3aQKf8" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231_pdd" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zKlsyQ6LCJyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 1050000 1050000 0.10 26250 26250 26250 37818154 378182 100909 110000 353622 40000 100000 353622 60000 100000 350000 9793754 0.7577 350000 3454 1502000 22682142 5681985 6709890 141635524 1469004 Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. 1250000 46875 63500 3358498 720695 720695 0.37 0.12 0.01 0 0.0020 0.0013 5.70 6.48 1183357 161225 7354312 2816602 534602 2282000 <p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_znstxQtlpet" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zomrxm5uHCk6" style="display: none">SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying <br/>Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Term (Years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zPvx7tzY2k23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_zAoPVYxy0sq1" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Underlying Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,803,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zWlqJ5YrXFth" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zAqp2FQv0Ag7" title="Weighted average remaining contractual Llfe (Years), granted">1.41</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20200101__20201231_zCOn8XLsK783" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20200101__20201231_zXVvuLOYhOBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_zDRHQoXcmFca" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zoPtixTnwqX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,693,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zFbo1uifNyL3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5Yje2NBvRWd" title="Weighted average remaining contractual Llfe (Years), beginning balance">1.12</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zQPqF9mFTqxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,787,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGcZ4RermwPb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z7csjRGBvGJj" title="Weighted average remaining contractual Llfe (Years), granted">1.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zQxjwRBR2oVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,709,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210101__20211231_zH94SJYCq237" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zLKR9WkOpsoh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_zXENby9aH0Ml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,770,478</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zFe1I4xuYop2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231_zy8MeWaGJ9ed" title="Weighted average remaining contractual Llfe (Years), ending balance">0.44</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 28803368 0.01 P1Y4M28D 110000 -0.01 28693368 0.01 P1Y1M13D 6787000 0.01 P1Y6M 6709890 -0.01 28770478 0.01 P0Y5M8D 3288 <p id="xdx_89F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_z6c677kY2hp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> <span id="xdx_8BA_zX0FAp6E6b05" style="display: none">SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term, in years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zbFtCQFfc98" title="Expected term, in years">1.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1DeD6o9wjS9" title="Expected term, in years">2.83</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zabF38jn0oll" title="Expected volatility">100</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zlvvIatxWoP5" title="Expected volatility">162.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zTi9Kelhj1mb" title="Risk-free interest rate">0.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zO685fyGsQH9" title="Risk-free interest rate">0.44</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_z0aZbH3aQKf8" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231_pdd" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> P1Y6M P2Y9M29D 1 1.6224 0.0011 0.0044 <p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_z594lxVfwa7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>8. <span id="xdx_820_zupYrNLBlFHg">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2021 and December 31, 2020 due to the Company’s operating losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2021, the Company has a net operating loss for tax purposes of CAD $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_uCAD_c20211231_z0gZzdrmQ2i2" title="Net operating, loss">15,715,067</span> (2020 – CAD $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_uCAD_c20201231_zfbx2sRDrKTh" title="Net operating, loss">11,448,330</span>) that can be <span id="xdx_90C_ecustom--NetOperatingLossDescription_c20210101__20211231_ziz1czM5eEA1" title="Net operating loss, description">carried forward over 20 years.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Deferred Income Taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9jVIeZSsXxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B5_zt7f7Vh1Fqv8" style="display: none">SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 97%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_490_20210101__20211231_z22wN7altAFi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49E_20200101__20201231_zV1psAqFMBZ7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets (liabilities):</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iS_zARrTEoond2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax asset, beginning</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetIncreaseInValuationReserve_zB5V2PEEHz9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,365,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iE_zH9IFCturMT7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax asset, ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,439,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_zbm3h2QNqi0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,439,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iE_zBjAtVkuuxyf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_zef0vh2O4dd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>EHAVE, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(Expressed in U.S. Dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> 15715067 11448330 carried forward over 20 years. <p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9jVIeZSsXxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B5_zt7f7Vh1Fqv8" style="display: none">SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 97%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_490_20210101__20211231_z22wN7altAFi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_49E_20200101__20201231_zV1psAqFMBZ7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets (liabilities):</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iS_zARrTEoond2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax asset, beginning</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetIncreaseInValuationReserve_zB5V2PEEHz9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,365,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iE_zH9IFCturMT7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax asset, ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,439,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_zbm3h2QNqi0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,439,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,074,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iE_zBjAtVkuuxyf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1074000 741000 2365000 333000 3439000 1074000 3439000 1074000 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zJpXs63ASSKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>9. <span id="xdx_821_zj2QRE6qJZmg">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On January 8, 2022, the Company entered into a stock purchase agreement to acquire <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zriYokBYYyXl" title="Issued and outstanding shares, percentage">100</span>% of the issued and outstanding shares of Rejuv IV, Inc., a California company, (or “Ketadash”) from the seller (the “Seller”). The purchase price of the shares is $<span id="xdx_901_eus-gaap--BusinessCombinationConsiderationTransferred1_c20220107__20220108__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSl5JJQvJ648" title="Purchase price">250,000</span> payable as follows: (i) $<span id="xdx_90C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_c20220108__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlgm1UyGaxF9" title="Cash">75,000</span> in cash, and (ii) $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlYHaEtmmJu5" title="Stock issued during period value new issues">175,000</span> of common stock valued at the average closing price for the five trading days preceding January 8, 2022. As of the date of this filing, the Company paid <span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8SJlZESOfMd" title="Business acquisition percentage">100</span>% of the purchase price, paid the $<span id="xdx_905_eus-gaap--PaymentsToAcquireProductiveAssets_c20220107__20220108__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1fqj4DD58l4" title="Payment to acquire productive assets">75,000</span> in cash and issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlJyp3WD2Doe" title="Stock issued during period shares new issues">19,977,169</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Subsequent to year end, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3IBCIkttgqi" title="Stock issued during period conversion of convertible securities">15,800,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of common stock upon the conversion of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9ho4KKCG9la" title="Stock issued during period value conversion of convertible securities">158,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">of convertible debt in accordance with the terms of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Subsequent to year end, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCS7AeASP4Ka">5,055,381 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">to a consultant for services rendered at a fair value of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwYysIooVEe3">75,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Subsequent to year end, the Company received <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--WesanaHealthHoldingsIncMember_zpF7XNjk2wIj" title="Stock issued during period shares new issues">212,488</span> shares of Wesana Health Holdings, Inc. in exchange for all of the Company’s Psytech shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mycotopia Merger</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2022, Mycotopia entered into an Agreement and Plan of Merger (the “Agreement” whereby Mycotopia will merge with a wholly owned subsidiary of PSLY.com. Simultaneously E,iVentures, Inc. (“E.i”) will merge with a separate wholly owned subsidiary of PSLY.com.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At closing each share of common stock of Mycotopia, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20220518__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--MycotopiaTherapiesIncMember_pdd" title="Common stock par value">.001</span> per share (the “Mycotopia Common Stock”), issued and <span id="xdx_908_eus-gaap--CommonStockConversionBasis_c20220517__20220518__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--MycotopiaTherapiesIncMember_zBXskYT9iTpl" title="Common stock conversion basic">outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--CommonStockConversionBasis_c20220517__20220518__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--EiVenturesIncMember_zXQFsOUL0SG2" title="Common stock conversion basic">At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The closing of the Merger will take place as soon as practicable (and, in any event, within two (2) Business Days) after satisfaction of all conditions to the Merger.</span></p> 1 250000 75000 175000 1 75000 19977169 15800000 158000 5055381 75000 212488 0.001 outstanding immediately prior to the effective time of the merger shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock. At Closing each share of common stock of E.i will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4). EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 120 245 1 false 55 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ehave.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://ehave.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://ehave.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Deficit Sheet http://ehave.com/role/StatementOfChangesInStockholdersDeficit Consolidated Statement of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://ehave.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPolicies ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN Sheet http://ehave.com/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - FAIR VALUE MEASUREMENT Sheet http://ehave.com/role/FairValueMeasurement FAIR VALUE MEASUREMENT Notes 9 false false R10.htm 00000010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://ehave.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES Notes http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotes PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES Notes 11 false false R12.htm 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://ehave.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://ehave.com/role/StockholdersEquityDeficit STOCKHOLDERS??? EQUITY (DEFICIT) Notes 13 false false R14.htm 00000014 - Disclosure - INCOME TAXES Sheet http://ehave.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://ehave.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesTables ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://ehave.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://ehave.com/role/RelatedPartyTransactions 18 false false R19.htm 00000019 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables) Notes http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesTables PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables) Tables http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotes 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Sheet http://ehave.com/role/StockholdersEquityDeficitTables STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Tables http://ehave.com/role/StockholdersEquityDeficit 20 false false R21.htm 00000021 - Disclosure - INCOME TAXES (Tables) Sheet http://ehave.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://ehave.com/role/IncomeTaxes 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) Sheet http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 23 false false R24.htm 00000024 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://ehave.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://ehave.com/role/GoingConcern 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF BONUS AND MILESTONES (Details) Sheet http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails SCHEDULE OF BONUS AND MILESTONES (Details) Details 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details) Sheet http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details) Details 27 false false R28.htm 00000028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://ehave.com/role/RelatedPartyTransactionsTables 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://ehave.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Notes http://ehave.com/role/ScheduleOfNotesPayableDetailsParenthetical SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Details 30 false false R31.htm 00000031 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative) Notes http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative) Details http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesTables 31 false false R32.htm 00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://ehave.com/role/CommitmentsAndContingencies 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details) Sheet http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details) Sheet http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details) Details 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Sheet http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Details http://ehave.com/role/StockholdersEquityDeficitTables 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) Sheet http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) Details 36 false false R37.htm 00000037 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://ehave.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://ehave.com/role/IncomeTaxesTables 37 false false R38.htm 00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://ehave.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://ehave.com/role/SubsequentEvents 38 false false All Reports Book All Reports form20-f.htm ehvvf-20211231.xsd ehvvf-20211231_cal.xml ehvvf-20211231_def.xml ehvvf-20211231_lab.xml ehvvf-20211231_pre.xml ex12-1.htm ex12-2.htm ex13-1.htm ex13-2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form20-f.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 120, "dts": { "calculationLink": { "local": [ "ehvvf-20211231_cal.xml" ] }, "definitionLink": { "local": [ "ehvvf-20211231_def.xml" ] }, "inline": { "local": [ "form20-f.htm" ] }, "labelLink": { "local": [ "ehvvf-20211231_lab.xml" ] }, "presentationLink": { "local": [ "ehvvf-20211231_pre.xml" ] }, "schema": { "local": [ "ehvvf-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 399, "entityCount": 1, "hidden": { "http://ehave.com/20211231": 29, "http://fasb.org/us-gaap/2022": 89, "http://xbrl.sec.gov/dei/2022": 3, "total": 121 }, "keyCustom": 36, "keyStandard": 209, "memberCustom": 44, "memberStandard": 11, "nsprefix": "EHVVF", "nsuri": "http://ehave.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ehave.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://ehave.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES", "role": "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotes", "shortName": "PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://ehave.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "role": "http://ehave.com/role/StockholdersEquityDeficit", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - INCOME TAXES", "role": "http://ehave.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUBSEQUENT EVENTS", "role": "http://ehave.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "EHVVF:OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "EHVVF:OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://ehave.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables)", "role": "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesTables", "shortName": "PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://ehave.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "role": "http://ehave.com/role/StockholdersEquityDeficitTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - INCOME TAXES (Tables)", "role": "http://ehave.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-012021-12-31_custom_MedicalEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)", "role": "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-012021-12-31_custom_MedicalEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "role": "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://ehave.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "EHVVF:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31_custom_BonusOneMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF BONUS AND MILESTONES (Details)", "role": "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails", "shortName": "SCHEDULE OF BONUS AND MILESTONES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31_custom_BonusOneMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31_custom_BonusOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details)", "role": "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "shortName": "SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31_custom_BonusOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "role": "http://ehave.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfMediumTermNotes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://ehave.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "role": "http://ehave.com/role/ScheduleOfNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "role": "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "shortName": "PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-012021-12-31_custom_CollaborationAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-012021-12-31_custom_CollaborationAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details)", "role": "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails", "shortName": "SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details)", "role": "http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails", "shortName": "SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "role": "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "EHVVF:InvestmentReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details)", "role": "http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2019-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://ehave.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://ehave.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2022-01-012022-05-27_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss", "role": "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Changes in Stockholders' Deficit", "role": "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "shortName": "Consolidated Statement of Changes in Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "role": "http://ehave.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN", "role": "http://ehave.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - FAIR VALUE MEASUREMENT", "role": "http://ehave.com/role/FairValueMeasurement", "shortName": "FAIR VALUE MEASUREMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form20-f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "EHVVF_AssetSaleAndPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Sale And Purchase Agreement [Member]", "label": "Asset Sale And Purchase Agreement [Member]" } } }, "localname": "AssetSaleAndPurchaseAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_BenjaminKaplanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Benjamin Kaplan [Member]", "label": "Benjamin Kaplan [Member]" } } }, "localname": "BenjaminKaplanMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_BonusFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus Five [Member]", "label": "Bonus Five [Member]" } } }, "localname": "BonusFiveMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_BonusFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus Four [Member]", "label": "Bonus Four [Member]" } } }, "localname": "BonusFourMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_BonusOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus One [Member]", "label": "Bonus One [Member]" } } }, "localname": "BonusOneMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_BonusThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus Three [Member]", "label": "Bonus Three [Member]" } } }, "localname": "BonusThreeMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_BonusTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus Two [Member]", "label": "Bonus Two [Member]" } } }, "localname": "BonusTwoMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_ChangeInFairValueOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of derivative liability.", "label": "ChangeInFairValueOfDerivativeLiability", "verboseLabel": "Change in fair value of derivative liability" } } }, "localname": "ChangeInFairValueOfDerivativeLiability", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_ChiefTechonologyOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Techonology Officer [Member]", "label": "Chief Techonology Officer [Member]" } } }, "localname": "ChiefTechonologyOfficerMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_ClassOfWarrantOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercised.", "label": "Number of warrants exercised" } } }, "localname": "ClassOfWarrantOrRightExercised", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EHVVF_CollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement [Member]", "label": "Collaboration Agreement [Member]" } } }, "localname": "CollaborationAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_CommonStockIssuedForConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for conversion of debt.", "label": "Common stock issued for conversion of debt" } } }, "localname": "CommonStockIssuedForConversionOfDebt", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_CommonStockIssuedForCuredash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for curedash.", "label": "Common stock issued for CureDash" } } }, "localname": "CommonStockIssuedForCuredash", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_CommonStockIssuedForPsytech": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for psytech.", "label": "CommonStockIssuedForPsytech", "verboseLabel": "Common stock issued for Psytech" } } }, "localname": "CommonStockIssuedForPsytech", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_ConversionsOfNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversions of notes payable.", "label": "Conversions" } } }, "localname": "ConversionsOfNotesPayable", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "EHVVF_ConvertiblePromissoryNoteAndAccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note And Accrued Interest [Member]", "label": "Convertible Promissory Note And Accrued Interest [Member]" } } }, "localname": "ConvertiblePromissoryNoteAndAccruedInterestMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note [Member]", "label": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_ConvertiblePromissoryNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note Three [Member]", "label": "Convertible Promissory Note Three [Member]" } } }, "localname": "ConvertiblePromissoryNoteThreeMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_DeferredTaxAssetIncreaseInValuationReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax asset increase in valuation reserve.", "label": "Increase in valuation reserve" } } }, "localname": "DeferredTaxAssetIncreaseInValuationReserve", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "EHVVF_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors [Member]", "label": "Directors [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_EhaveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ehave [Member]", "label": "Ehave [Member]" } } }, "localname": "EhaveMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_EiVenturesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "E,i Ventures, Inc. [Member]", "label": "E,i Ventures, Inc. [Member]" } } }, "localname": "EiVenturesIncMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_EquityPayable": { "auth_ref": [], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity payable.", "label": "Equity payable" } } }, "localname": "EquityPayable", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "EHVVF_EquityPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Payable [Member]", "label": "Equity Payable [Member]" } } }, "localname": "EquityPayableMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "EHVVF_EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity payable to chief executive officer recorded as operating expense.", "label": "Equity payable to Chief Executive Officer recorded as operating expense" } } }, "localname": "EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_ExecutiveConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Consulting Agreement [Member]", "label": "Executive Consulting Agreement [Member]" } } }, "localname": "ExecutiveConsultingAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_FindersFeeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finder&#8217;s fee agreement [Member]", "label": "Finder's Fee Agreement [Member]" } } }, "localname": "FindersFeeAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_ForeignCurrencyRiskPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Currency Risk [Policy Text Block]", "label": "Foreign Currency Risk" } } }, "localname": "ForeignCurrencyRiskPolicyTextBlock", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "EHVVF_FormerAndCurrentDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former And Current Directors [Member]", "label": "Former And Current Directors [Member]" } } }, "localname": "FormerAndCurrentDirectorsMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_GainLossOnSettlementOfDebt": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on settlement of debt.", "label": "(Loss) gain on settlement of debt", "negatedLabel": "Loss (gain) on settlement of debt" } } }, "localname": "GainLossOnSettlementOfDebt", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows", "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "EHVVF_GainOnForgivenessOfDevelopmentGrant": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on forgiveness of development grant.", "label": "GainOnForgivenessOfDevelopmentGrant", "negatedLabel": "Gain on forgiveness of development grant" } } }, "localname": "GainOnForgivenessOfDevelopmentGrant", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_ImpairmentOfFixedAssets": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment of fixed assets.", "label": "Impairment of fixed assets" } } }, "localname": "ImpairmentOfFixedAssets", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_InvestmentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment received.", "label": "Investment received" } } }, "localname": "InvestmentReceived", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EHVVF_InvestmentReceivedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment received shares.", "label": "Investment received shares" } } }, "localname": "InvestmentReceivedShares", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EHVVF_MarketCapitalizationMilestonesFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Capitalization Milestones Five [Member]", "label": "Market Capitalization Milestones Five [Member]" } } }, "localname": "MarketCapitalizationMilestonesFiveMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MarketCapitalizationMilestonesFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Capitalization Milestones Four [Member]", "label": "Market Capitalization Milestones Four [Member]" } } }, "localname": "MarketCapitalizationMilestonesFourMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MarketCapitalizationMilestonesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Capitalization Milestones One [Member]", "label": "Market Capitalization Milestones One [Member]" } } }, "localname": "MarketCapitalizationMilestonesOneMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MarketCapitalizationMilestonesThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Capitalization Milestones Three [Member]", "label": "Market Capitalization Milestones Three [Member]" } } }, "localname": "MarketCapitalizationMilestonesThreeMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MarketCapitalizationMilestonesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Capitalization Milestones Two [Member]", "label": "Market Capitalization Milestones Two [Member]" } } }, "localname": "MarketCapitalizationMilestonesTwoMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MedicalAdvisoryBoardAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Advisory Board Agreements [Member]", "label": "Medical Advisory Board Agreements [Member]" } } }, "localname": "MedicalAdvisoryBoardAgreementsMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_MedicalEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Equipment [Member]", "label": "Medical Equipment [Member]" } } }, "localname": "MedicalEquipmentMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MilestonesFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Five [Member]", "label": "Milestones Five [Member]" } } }, "localname": "MilestonesFiveMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MilestonesFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Four [Member]", "label": "Milestones Four [Member]" } } }, "localname": "MilestonesFourMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MilestonesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones One [Member]", "label": "Milestones One [Member]" } } }, "localname": "MilestonesOneMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MilestonesThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Three [Member]", "label": "Milestones Three [Member]" } } }, "localname": "MilestonesThreeMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MilestonesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Two [Member]", "label": "Milestones Two [Member]" } } }, "localname": "MilestonesTwoMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "EHVVF_MycotopiaCommonStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mycotopia Common Stocks [Member]", "label": "Mycotopia Common Stocks [Member]" } } }, "localname": "MycotopiaCommonStocksMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_MycotopiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mycotopia [Member]", "label": "Mycotopia [Member]" } } }, "localname": "MycotopiaMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_MycotopiaTherapiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mycotopia Therapies Inc [Member]", "label": "Mycotopia Therapies Inc [Member]" } } }, "localname": "MycotopiaTherapiesIncMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_NetOperatingLossDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss description.", "label": "Net operating loss, description" } } }, "localname": "NetOperatingLossDescription", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "EHVVF_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash interest expense.", "label": "Non-cash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization And General Description Of Business [Policy Text Block]", "label": "Organization and General Description of Business" } } }, "localname": "OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "EHVVF_PaymentOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of convertible notes.", "label": "Payment of convertible notes" } } }, "localname": "PaymentOfConvertibleNotes", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_PaymentOfPromissoryNotes": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of promissory notes.", "label": "Payment of promissory notes" } } }, "localname": "PaymentOfPromissoryNotes", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_PaymentsToAcquireEquitySecuritiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments to acquire equity securities shares.", "label": "Purchase of shares" } } }, "localname": "PaymentsToAcquireEquitySecuritiesShares", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EHVVF_ProceedsFromRegInvestment": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from reg investment.", "label": "ProceedsFromRegInvestment", "negatedLabel": "Proceeds from Reg A investment" } } }, "localname": "ProceedsFromRegInvestment", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_PsychedelitechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Psychedelitech Inc [Member]", "label": "Psychedelitech Inc [Member]" } } }, "localname": "PsychedelitechIncMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement [Member]", "label": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_PurchaseOfFixedAssets": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of fixed assets.", "label": "Purchase of fixed assets" } } }, "localname": "PurchaseOfFixedAssets", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EHVVF_RejuvIvIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RejuvIv Inc [Member]", "label": "RejuvIv Inc [Member]" } } }, "localname": "RejuvIvIncMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party [Member]", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_RevenueRecognitionMilestoneMethod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration recognized during the period for the milestone or milestones.", "label": "EBITDA Milestones", "verboseLabel": "Market Capitalization Milestone" } } }, "localname": "RevenueRecognitionMilestoneMethod", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "monetaryItemType" }, "EHVVF_ScheduleOfEstimatedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Estimated Useful Life [Table Text Block]", "label": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT" } } }, "localname": "ScheduleOfEstimatedUsefulLifeTableTextBlock", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "EHVVF_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, Beginning balance.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted average exercise price, ending balance", "periodStartLabel": "Weighted average exercise price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "EHVVF_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants in Period Weighted Average Grant Date Fair Value [Table Text Block]", "label": "SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "EHVVF_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, Exercised.", "label": "Weighted average exercise price, Exercised", "negatedLabel": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "EHVVF_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, Granted.", "label": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "EHVVF_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award non-options granted weighted average remaining contractual term", "label": "Weighted average remaining contractual Llfe (Years), granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "durationItemType" }, "EHVVF_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life (Years), Beginning Balance.", "label": "Weighted average remaining contractual Llfe (Years), beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "durationItemType" }, "EHVVF_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Life (Years), Ending Balance.", "label": "Weighted average remaining contractual Llfe (Years), ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "durationItemType" }, "EHVVF_StockIssuedDuringEquityPayableToChiefExecutiveOfficer": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during equity payable to chief executive officer.", "label": "Equity payable to Chief Executive Officer" } } }, "localname": "StockIssuedDuringEquityPayableToChiefExecutiveOfficer", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EHVVF_StockIssuedDuringPeriodSharesCashlessWarrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued upon cashless warrant exercise,shares.", "label": "Common stock issued upon cashless warrant exercise, shares" } } }, "localname": "StockIssuedDuringPeriodSharesCashlessWarrantExercised", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EHVVF_StockIssuedDuringPeriodValueCashlessWarrantExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued upon cashless warrant exercise.", "label": "Common stock issued upon cashless warrant exercise" } } }, "localname": "StockIssuedDuringPeriodValueCashlessWarrantExercised", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EHVVF_StockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreement [Member]", "label": "Stock Purchase Agreement [Member]" } } }, "localname": "StockPurchaseAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_StrategicAllianceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Alliance Agreement [Member]", "label": "Strategic Alliance Agreement [Member]" } } }, "localname": "StrategicAllianceAgreementMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_TotalEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Equity [Member]", "label": "Total Equity [Member]" } } }, "localname": "TotalEquityMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "EHVVF_WesanaHealthHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wesana Health Holdings Inc [Member]", "label": "Wesana Health Holdings Inc [Member]" } } }, "localname": "WesanaHealthHoldingsIncMember", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EHVVF_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ehave.com/20211231", "presentation": [ "http://ehave.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ehave.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r154", "r155", "r156", "r157", "r174", "r206", "r231", "r233", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r427", "r429", "r443", "r444" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r154", "r155", "r156", "r157", "r174", "r206", "r231", "r233", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r427", "r429", "r443", "r444" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r131", "r155", "r156", "r225", "r227", "r380", "r426", "r428" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r131", "r155", "r156", "r225", "r227", "r380", "r426", "r428" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r150", "r154", "r155", "r156", "r157", "r174", "r206", "r228", "r231", "r233", "r263", "r264", "r265", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r427", "r429", "r443", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r150", "r154", "r155", "r156", "r157", "r174", "r206", "r228", "r231", "r233", "r263", "r264", "r265", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r427", "r429", "r443", "r444" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r132", "r363" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued expense" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expense" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r11", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less, accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r39", "r40", "r41", "r415", "r434", "r435" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r49", "r50", "r336", "r337", "r338", "r339", "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r41", "r49", "r50", "r51", "r97", "r98", "r99", "r320", "r357", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r170", "r218", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "verboseLabel": "Fair value of warrants and beneficial conversion feature issued in connection with convertible debt" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of Federal Home Loan Bank (FHLBank) advances carried under the fair value option.", "label": "Common stock fair value" } } }, "localname": "AdvancesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r65", "r81", "r194", "r346" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r59", "r81", "r194", "r348" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "negatedLabel": "Amortization expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r81", "r194", "r202", "r203", "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of BCF and warrants (amortization expense)" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r81", "r140", "r141" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of original issue discount (interest expense)" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "auth_ref": [ "r303", "r304", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r93", "r123", "r125", "r129", "r136", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r313", "r321", "r334", "r367", "r369", "r393", "r412" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r25", "r93", "r136", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r313", "r321", "r334", "r367", "r369" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation and principles of consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r230", "r232", "r297" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r230", "r232", "r294", "r295", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business acquisition percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r299", "r300", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r298", "r299", "r300", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Payment of consideration for rendered services" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "verboseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum lease payments for capital leases net of executory costs, which include amounts paid by the lessee to the lessor for insurance, maintenance and taxes.", "label": "Minimum payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r9", "r83" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets", "http://ehave.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r76", "r83", "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r76", "r335" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r327" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in fair value of derivative liability" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants purchased", "verboseLabel": "Shares issued upon exercise of warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Aggregate of warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r401", "r420" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES (NOTE 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r151", "r152", "r153", "r158", "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Issuance of common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common stock conversion basic" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Convertion of common stock" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r97", "r98", "r329" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Ordinary shares, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheetsParenthetical", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".", "label": "Ordinary shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorizedUnlimited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheetsParenthetical" ], "xbrltype": "authorizedUnlimitedItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Ordinary shares, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Ordinary shares, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r369" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, no par value, unlimited shares authorized, 244,523,925 and 67,169,962 shares issued and outstanding, respecively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r46", "r47", "r56", "r404", "r424" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiability": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.", "label": "Tax refund" } } }, "localname": "ContractWithCustomerRefundLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Current portion of convertible notes, net of debt discount" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Long-term portion of convertible notes, net of debt discount" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r15", "r395", "r413", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "periodEndLabel": "Convertible promissory notes, ending balance", "periodStartLabel": "Convertible promissory notes, beginning balance" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Accrued expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r86", "r88" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt converted into shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r90", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r188", "r195", "r196", "r197", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r92", "r95", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r200", "r201", "r202", "r203", "r349", "r394", "r395", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Fair value of warrants and beneficial conversion feature issued in connection with convertible debt" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r13", "r15", "r219", "r394", "r395", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt instrument, description", "verboseLabel": "Debt description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r171", "r200", "r201", "r347", "r349", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r31", "r198", "r347", "r349" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r32", "r92", "r95", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r200", "r201", "r202", "r203", "r349" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term of notes" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r184", "r346", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r346", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "negatedLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "periodEndLabel": "Deferred tax asset, ending", "periodStartLabel": "Deferred tax asset, beginning" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "periodEndLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedPeriodEndLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r145" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense", "verboseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE ATTRIBUTABLE TO EHAVE, INC. STOCKHOLDERS" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r102", "r103", "r104", "r105", "r106", "r110", "r111", "r113", "r114", "r115", "r118", "r119", "r330", "r331", "r405", "r425" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE SHARES OUTSTANDING:" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Common Share, basic" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r335" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r97", "r98", "r99", "r101", "r107", "r109", "r120", "r137", "r218", "r221", "r269", "r270", "r271", "r286", "r287", "r329", "r336", "r337", "r338", "r339", "r340", "r342", "r357", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage", "verboseLabel": "Equity percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Common stocks shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "FAIR VALUE MEASUREMENT" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative", "terseLabel": "Annual service", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r144", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r61", "r82", "r102", "r103", "r104", "r105", "r112", "r115", "r309" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r94", "r276", "r277", "r283", "r288", "r289", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r48", "r274", "r275", "r277", "r278", "r282", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r77", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and other payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r80" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r53", "r122", "r345", "r348", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expenses" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r65", "r192", "r199", "r202", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expenses on debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r400", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation": { "auth_ref": [ "r436", "r437" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to fund for payment received from affiliate to reimburse fund for loss on investment transaction, and realized and unrealized gain (loss) on investment not meeting guidelines of fund.", "label": "Reimbursement" } } }, "localname": "InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "SCHEDULE OF BONUS AND MARKET CAPITALIZATION MILESTONES" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Cost of the investment" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r93", "r126", "r136", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r314", "r321", "r322", "r334", "r367", "r368" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r93", "r136", "r334", "r369", "r397", "r418" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r30", "r93", "r136", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r314", "r321", "r322", "r334", "r367", "r368", "r369" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r37", "r93", "r136", "r159", "r163", "r164", "r165", "r168", "r169", "r334", "r396", "r417" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r76", "r79", "r82" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r42", "r45", "r51", "r54", "r82", "r93", "r100", "r102", "r103", "r104", "r105", "r108", "r109", "r112", "r123", "r124", "r127", "r128", "r130", "r136", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r331", "r334", "r402", "r422" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Ehave, Inc. stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r42", "r45", "r51", "r108", "r109", "r316", "r324" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: loss attributable to the noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r222", "r312", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Non controlling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r97", "r98", "r99", "r221", "r307" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r15", "r395", "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Promissory notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Promissory note", "verboseLabel": "Promissory notes" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets", "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r124", "r127", "r128", "r130" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "OPERATING LOSS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r352", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Payments cashflows" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating, loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r4", "r96", "r121", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r24", "r369" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r310", "r311", "r319" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign exchange translation adjustment", "verboseLabel": "Foreign exchange translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r46", "r49", "r50", "r52", "r55", "r218", "r336", "r341", "r342", "r403", "r423" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other expenses" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r58" ], "calculation": { "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Operations loss on debt settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expenses", "verboseLabel": "Rent payments" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r72" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Financing fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "auth_ref": [ "r74", "r134" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Purchase of shares, value" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r67" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "negatedLabel": "Purchase of subsidiary" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r68", "r303", "r304", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payment to acquire productive assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToEmployees": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of cash to employees, including wages and salaries, during the current period.", "label": "Payments to CEO" } } }, "localname": "PaymentsToEmployees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r23", "r138", "r139" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r69" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Net proceeds from convertible notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r66" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.", "label": "Proceeds from sale of subsidiary" } } }, "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.", "label": "Issuances" } } }, "localname": "ProceedsFromIssuanceOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePayments": { "auth_ref": [ "r355", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from lease payment, classified as operating activity.", "label": "Lease payments" } } }, "localname": "ProceedsFromLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "debt common shares, value" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r42", "r45", "r51", "r75", "r93", "r100", "r108", "r109", "r123", "r124", "r127", "r128", "r130", "r136", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r310", "r315", "r317", "r324", "r325", "r331", "r334", "r407" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/GoingConcernDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StatementsOfCashFlows", "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r10", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r148", "r369", "r408", "r419" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment", "verboseLabel": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r148", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r229", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r229", "r360", "r364", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r358", "r359", "r361", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Debt paid in cash" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments to related party debt" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r142", "r143", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Software Products and Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r221", "r369", "r416", "r433", "r435" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets", "http://ehave.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r97", "r98", "r99", "r101", "r107", "r109", "r137", "r269", "r270", "r271", "r286", "r287", "r329", "r430", "r432" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Annual royalty" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Annual salary compensation" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Stock price" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF BONUS AND MILESTONES" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails", "http://ehave.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r362", "r364" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r223", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://ehave.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Compensation for services description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield", "verboseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Underlying Shares Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Underlying Shares Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Underlying Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Underlying Shares Ending balance", "periodStartLabel": "Underlying Shares Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfOutstandingStockWarrantsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, intrinsic value, warrants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails", "http://ehave.com/role/ScheduleOfBonusAndMilestonesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfWeightedAverageAssumptionsOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Issued and outstanding shares, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "verboseLabel": "Bonus" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/ScheduleOfBonusAndMarketCapitalizationMilestonesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r24", "r398", "r399", "r411" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r49", "r50", "r51", "r97", "r98", "r99", "r101", "r107", "r109", "r120", "r137", "r218", "r221", "r269", "r270", "r271", "r286", "r287", "r329", "r336", "r337", "r338", "r339", "r340", "r342", "r357", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r97", "r98", "r99", "r120", "r380" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Warrants issued during period, value" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r86", "r87", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Lenders and issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r16", "r17", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Common stock issued for CureDash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r35", "r189", "r218", "r219", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued upon conversion of convertible promissory notes, shares", "terseLabel": "Conversion of common stock shares", "verboseLabel": "Common stock issued upon conversion securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/OrganzationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued for services, shares", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Number of stock issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r218", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for Psytech,shares", "terseLabel": "Stock issued during period shares new issues", "verboseLabel": "Stock issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "common stock issued for regulation A offerrings, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r36", "r218", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Disposal and re-acquisition of Mycotopia Therapies, Inc." } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r36", "r218", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued upon conversion of convertible promissory notes", "terseLabel": "Stock issued during period value conversion of convertible securities", "verboseLabel": "Conversion of common stock, value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r218", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for Psytech", "terseLabel": "Stock issued during period value new issues", "verboseLabel": "Stock issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for regulation A offerings" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r93", "r133", "r136", "r334", "r369" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "TOTAL EHAVE, INC. STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r50", "r93", "r97", "r98", "r99", "r101", "r107", "r136", "r137", "r221", "r269", "r270", "r271", "r286", "r287", "r307", "r308", "r323", "r329", "r334", "r336", "r337", "r342", "r357", "r431", "r432" ], "calculation": { "http://ehave.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/BalanceSheets", "http://ehave.com/role/StatementOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r91", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r221", "r224", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r343", "r371" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r343", "r371" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r343", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r343", "r371" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ehave.com/role/PromissoryNoteAndConvertiblePromissoryNotesDetailsNarrative", "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative", "http://ehave.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrant expiry date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r110", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ehave.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919320-209978" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919327-209978" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r372": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=6488101&loc=d3e8658-115831" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=d3e8909-115832" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r446": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r448": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r449": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r450": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r451": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r452": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r454": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r457": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r458": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r459": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r460": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r461": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r462": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r463": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r464": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r465": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" } }, "version": "2.1" } ZIP 57 0001493152-22-015363-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-015363-xbrl.zip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